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Abstract  
 
 The aggregation of the human brain protein alpha-synuclein is associated with Parkinson’s 
disease and a host of other neurodegenerative diseases termed the synucleinopathies. In this thesis 
is described aspects of the pathophysiology of alpha-synuclein and that of six point mutants 
associated with familial Parkinson’s disease, as well as strategies aimed at impeding the aggregation 
process.  
 A novel ten-residue peptide – KDGIVNGVKA – was identified using NMR spectroscopy as 
binding to aggregated forms of alpha-synuclein and preventing fibril elongation. Through the use 
of multiple alanine-scanning variants of the peptide it was determined that a critical three-residue 
stretch – IVN – was essential for binding to alpha-synuclein aggregates. Through the use of cell 
viability and NMR metabolomics experiments the impact of these shortened amyloid fibrils formed 
in the presence of the peptide on SH-SY5Y cells was assessed. The shortened fibrils did not result in 
an increase in toxicity and the cellular metabolome of the challenged cells was more similar to those 
of the control samples than of those cells challenged with the fibrils formed without the peptide 
inhibitor.  
 In this thesis a hitherto uncharacterized interaction between alpha-synuclein and the 
peptidyl-prolyl isomerase cyclophilin-D was described. Through a combination of NMR and 
isothermal titration calorimetry it was shown that cyclophilin-D binds to alpha-synuclein at its acidic 
C-terminus, and through ThT fluorescence assays that this was sufficient to prevent alpha-synuclein 
aggregation. The incubation of pre-formed alpha-synuclein fibrils with cyclophilin-D resulted in their 
dramatic shortening, as seen by TEM, and the restoration of peaks associated with the monomeric 
protein in the HSQC NMR spectra. These are evidence that cyclophilin-D disaggregates alpha-
synuclein fibrils. This disaggregation activity was dependent on the cis-trans isomerase activity of 
cyclophilin-D and was not observed using the catalytically compromised mutants R55K and R82K.  
 Through the use of circular dichroism spectroscopy, the lipid-binding affinity of alpha-
synuclein, its point mutants, and nitrated forms was probed. Nitration, a post-translational 
modification identified in Lewy bodies, was found to impair lipid-binding, which may be of 
importance given recent reports in the literature of large levels of membranes present in Lewy 
bodies. The rates of alpha-synuclein aggregation were compared using ThT fluorescence, and it was 
found that nitrated alpha-synuclein was incapable of forming amyloid fibrils. Additionally, through 
the use of TEM the length and morphology of the fibrils formed by the different mutants was 
observed, and a lengths analysis was conducted. This revealed that A30P formed extremely long 
fibrils, whilst G51D and A53E formed particularly short fibrils. Together these experiments shed 
light on the pathophysiology of alpha-synuclein, with novel findings not shown previously for the 
six disease-linked mutants.  
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1 Introduction 
1.1 Definition of amyloid 
  
The International Society of Amyloidosis defines amyloid as a protein that has misfolded to 
form insoluble fibrils which are largely deposited extracellularly (1). To be deemed amyloid the 
fibrils must bind to Congo red dye (Figure 1-1) and exhibit green, yellow or orange birefringence 
when observed under polarized light, and when isolated should exhibit a cross-β X-ray diffraction 
pattern (1). Amyloid itself is often associated with disease, but functional amyloids have also been 
discovered (e.g. biofilms) (2). It is also common to use the benzathiazole dyes thioflavin-S (ThS) and 
thioflavin-T (ThT) (Figure 1-1) to monitor amyloid formation, although neither are considered 
definitive indicators of amyloid. ThS is maximally excited at 389nm with an emission maxima at 
426nm; this fluorescence is dramatically enhanced when the dye is bound to β-sheets. ThT operates 
in the same way but has a characteristic shift in fluorescence excitation and emission maxima upon 
binding (from 385 to 450nm and 445 to 482nm, respectively). 
 
Figure 1-1 - Structure of the amyloid-binding dyes Congo red, ThS, and ThT.  Top) Structure of the dye Congo red. The 
binding of Congo red is a requirement for aggregates to be deemed true amyloid. Bottom) The structure of the 
benzothiazole dyes ThS (left) and ThT (right).  
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Well-known examples of amyloid include the peptide amyloid-beta (Aβ) – associated with 
Alzheimer’s disease – in which it forms extracellular plaques in the central nervous system (CNS) 
(3), and also islet amyloid polypeptide (IAPP) – associated with diabetes mellitus type II – in the 
Islets of Langerhans in the pancreas (4).  The proteins alpha synuclein (aSyn) and the microtubule-
associated protein tau have traditionally been considered “amyloid-like” or “intracellular amyloid” 
given the fact that the deposits of these aggregated proteins are found intracellularly within the 
neurons. However, they have recently been officiated by the International Society of Amyloidosis 
as true amyloids given the fact that after cell death these deposits may be found extracellularly (1).  
1.2 Protein mis-folding and aggregation  
 
In the case of pathological amyloids, life begins as a native protein with a physiological 
function. These proteins then undergo some sort of change that allows for their aggregation; the 
cause of this is not always clear. For example, in the case of the amyloid-β precursor protein (APP) 
the protein is proteolytically processed by beta secretase-I (BACE-I), and subsequently a γ-
secretase, to form the Aβ peptide (5–7). In others, off-pathway species are formed during folding 
which can serve as nucleation points or “seeds”, or the protein structure is disturbed in some way 
by mutations or by changes in the local environment that result in the exposure of normally buried 
residues that can act as interfaces for aberrant protein-protein interactions (PPIs). This new 
aggregation-capable species is the “nucleus”. The formation of the nucleus is usually a slow and 
rare event. The length of time needed for the emergence of this nucleus species is termed the “lag-
phase”, and this is the time-limiting step. This nucleus provides a platform for further mis-folding 
and aggregation to form higher-order oligomeric species: dimers, trimers, tetramers and onward 
(Figure 1-2). These oligomers are structurally ambiguous. Some have appeared as: spheres, beads-
on-a-string, annular structures or ‘tubes’, and more (8,9). Their characterization is difficult due to 
their heterogeneity and that isolation may alter the chemical kinetics enabling their existence. The 
oligomers begin to take on more and more of a cross-β character, at which point they begin to be 
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termed “protofibrils” and “protofilaments”. Protofibrils consist of stacks of individual monomeric 
units that each form β-strands of an overall β-sheet architecture growing in the direction of the 
fibril axis. Each sheet is held together by hydrogen bonds formed from the backbone amides (and 
also any sidechain amides) to those above and below the β-strand. The monomeric units may form 
quite complex motifs (e.g. Greek key) with multiple strand-forming regions (10). Complementary β-
strands within the same monomer may interact via electrostatic interactions to form so-called 
“zippers” that repeat throughout the sheet. These zippers usually exclude water and thus 
hydrophobics, as well as electrostatics, play an important role in maintaining the stability of the 
protofilament.  The cross-β X-ray fibre diffraction images reveal sharp reflections at 4.7Å and 10Å, 
corresponding to the inter-strand and inter-sheet spacings respectively (Figure 1-3). Multiple 
protofilaments ultimately align or twine around each other, depending on local conditions, to form 
the final fibril. This fibril will be approximately 10nm in diameter and can be considered to be a 
highly energetically stable, off-pathway form of the protein (11).  
 
Figure 1-2 - Schematic showing the process of amyloid formation. A folded monomeric unit misfolds in such a way as to 
enable aberrant interactions with other misfolded units. These multimeric units grow and take on increasing levels of β-
structure. These β-strands ultimately stack to form vast β-sheets, becoming protofibrils and later protofilaments. Multiple 
protofilaments may associate or intertwine forming a fibril. 
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Figure 1-3 - Schematic showing how the inter-strand and inter-sheet spacings of amyloid fibrils give rise to a cross-ß X-
ray diffraction pattern.  The image is the diffraction pattern from fibrils of Aβ(1-42). Adapted from (12). 
It is to be noted that a single peptide or protein can form different types of fibril; so-called 
“strains”. These strains may have different structures and toxicities, and as a result are of interest 
with regards to disease. For example, aSyn has been implicated in a host of neurodegenerative 
diseases. It remains an open question as to whether and to what extent different strains correspond 
to different pathologies. Two distinct strains of aSyn with different structures, levels of toxicity and 
seeding capacities have recently been reported and this may influence pathology, through differing 
rates of elongation and capacity for seeding (13,14). Different strains seem to be formed under 
different environmental conditions in vitro such as: ionic strength, pH,  and the number of ‘seeding 
generations’ (14). This is perhaps unsurprising as these factors influence the interactions holding 
fibrils together dramatically; changes will result in differences in interaction and result in the 
stabilization of different species. 
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1.3 Will the toxic species please stand up? 
 
Many neurodegenerative diseases are associated with amyloid. This includes aSyn with 
Parkinson’s disease (PD) and the other synucleinopathies, Aβ with Alzheimer’s disease (AD), tau 
with AD and the tauopathies, and huntingtin with Huntington’s disease (HD) (3,15–17). The 
question of how the amyloids are associated with neuronal cell death is an open one. Disease onset 
and progression appears to be linked with protein aggregation and it has historically been thought 
that the amyloid fibrils must be toxic. It was thought that extracellular fibrils could disrupt the cell 
membrane whilst intracellular fibrils may disrupt axonal transport (18). This view has been 
challenged in recent years by the discovery that the severity of AD does not correlate with 
deposition of Aβ fibrils, as shown in patients immunized against Aβ42 (19).  This has led to the 
consensus moving in another direction; that it is the prefibrillar oligomeric species that are the 
arbiters of toxicity (20). Oligomers have been observed to form a variety of different structures and 
have been shown to be able to interact with, and disrupt, lipid membranes (21). If oligomers are 
truly the toxic species responsible for mediating cell death then the fibrils may be thought of 
repositories that sequester the oligomers away, and thus may be protective. Alternatively, the 
fibrils could be seen as a source of potentially toxic material if the equilibrium were to shift in favour 
of fibril disassembly. 
1.4 Intrinsically disordered proteins 
 
ASyn and the other members of the synuclein family are all intrinsically disordered proteins 
(IDPs), which is to say that they lack any stable fold or tertiary structure in solution. Recent 
estimates suggest that ≥30% of all eukaryotic proteins are either IDPs or contain intrinsically 
disordered regions (IDRs) (22). IDPs and IDRs generally contain very few hydrophobic residues to 
form any kind of “hydrophobic core” around which the protein could fold. Instead they are rich in 
polar and charged residues, and display a lack of any defined structure (23). These proteins fly in 
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the face of the traditional structure-function relationship that has historically underpinned the field 
of structural biology.  As a direct result of this, IDPs and IDRs represent a particular challenge as 
structural biology has been largely built around the determination of stable tertiary structures using 
X-ray crystallography and, recently, cryo-electron microscopy (cryo-EM). Nuclear magnetic 
resonance (NMR) spectroscopy and other “softer” solution-based biophysical techniques, such as 
circular dichroism (CD) spectroscopy and small angle X-ray scattering (SAXS), have proven to be the 
most successful techniques with regard to gaining a real understanding of the behaviour of aSyn 
and other IDPs as they recognize the key role that dynamics plays alongside structure in protein 
functionality. The structural plasticity of IDPs means that they are capable of a wide-array of 
different functions. These can be in protein-protein interactions, chaperone activity, lipid-protein 
interactions, ligand-scavenging, and linker regions. Many reviews have been written on this class of 
proteins which can go into far greater detail than myself here (24). The role of aSyn, tau and other 
IDPs in neurodegenerative disease represent something of a clarion call for a field that needs to 
take IDPs seriously and push for a greater understanding of their physiological and 
pathophysiological roles. 
1.5 The synuclein family 
 
ASyn is a 140-residue protein expressed primarily within the neurons, where it is localized 
at the presynaptic terminals (25).  ASyn belongs to the synuclein family of proteins consisting of: 
aSyn (14.5kDa), beta synuclein (bSyn) (14.3kDa), and gamma synuclein (gSyn) (13.3kDa), the 
physiological functions of which all remain obscure. Of the three, aSyn is by far the most intensely 
studied and over the past two decades a picture has gradually been emerging suggesting a role in 
vesicle docking/replenishment at the synaptic membrane through the promotion of soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex formation (26). 
BSyn and gSyn exhibit 61.6% and 48.3% sequence identity to aSyn, respectively (Figure 1-4). BSyn 
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is also found in the presynaptic terminals of the brain and CNS, whilst gSyn appears to be found 
predominantly in the peripheral nervous system (PNS) (27,28). 
 
 
Figure 1-4 - Multiple sequence alignment of aSyn, bSyn, and gSyn. Those residues highlighted in blue are conserved 
across all three proteins, whilst lighter blue indicates that the residue is conserved across two of the three proteins. The 
dashed red box indicates the residues Val73-Glu83 found in the NAC region of aSyn that are absent in bSyn. The alignment 
was produced in Jalview (29).  
 
1.5.1 The structure of α-synuclein 
 
ASyn is a 140-residue IDP which is classically divided into three domains:  the N-terminal 
domain (NTD) (1 – 60), the non-Aβ component (NAC) domain (61 – 95), and the C-terminal domain 
(CTD) (96 – 140) (see Figure 1-5). The NTD is largely positively charged due to the high prevalence 
of lysine residues. This is because the NTD mediates the interactions with the lipid membranes of 
synaptic vesicles, which are rich in negatively charged lipid head groups (30–32). The NTD contains 
seven 11-residue imperfect repeats containing the key KTKEGV motif. The repeats enable the NTD 
to form a helix that sits across the top of lipid membranes which is thought to be related to aSyn’s 
function. Solution structures of aSyn bound to detergent micelles have been solved using NMR to 
reveal a broken helix conformation, wherein there is a slight break in the helix between residues 
38-45 (see Figure 1-6) (30). It is thought that in contact with synaptic vesicles aSyn forms an 
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unbroken helix (33). It is also known that N-terminal acetylation, which is a native modification in 
vivo, results in an increase in the helix-forming propensity of aSyn (34). The NAC region has 
historically been thought to be the main fibril-forming region of aSyn, although the fibril core has 
since been shown to extend beyond the confines of the NAC domain (10,35). This region is the most 
hydrophobic part of aSyn and appears to act as a secondary site of lipid interaction (36,37). The CTD 
is the most dynamic region of aSyn and contains a preponderance of negatively charged aspartic 
and glutamic acid residues. The function of this domain is unclear, although there have been reports 
of it transiently “folding over” the hydrophobic NAC domain as a “shield” and of binding to 
components of the SNARE complex (38,39). C-terminally truncated aSyn (residues 1-123 or 1-120) 
aggregates more rapidly than the full-length protein and is commonly found in deposits of the 
protein (40). This may be a result of the loss of a highly soluble portion of the protein and the 
concomitant loss of “shielding” provided to the NAC region, allowing for aberrant hydrophobic 
interactions.   
 
 
Figure 1-5 - Schematic of aSyn domain organization and mutation/modification sites. The NTD (1-60), NAC domain (61-
95), and the CTD (96-140) are shown. The full length amino acid sequence is written underneath. PD-linked point mutation 
sites are underlined and highlighted in blue, whilst those sites shown to undergo either nitration or phosphorylation are 
underlined and highlighted in red.  
   
Until recently, aSyn has been exclusively reported to exist as a monomer within the cytosol. 
However this view was challenged in 2011 by Bartels et al who reported the discovery of aSyn in a 
tetrameric form that they believed was the primary and functional form of the protein (41). Indeed, 
they claimed that the “native” tetrameric form of aSyn was aggregation-resistant and it was the 
disruption of the tetramer that allowed aSyn to aggregate and ultimately trigger the death of 
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neurons. The authors claimed that the tetramer had escaped notice due to the extremely harsh 
purification procedures (e.g. boiling, acidification etc) used in protein preparation. These findings 
were the target of a wide-degree of suspicion in the scientific community, for a host of reasons. 
These included criticisms that the aSyn used in the experiment was isolated from erythrocytes 
rather than brain tissue and the inability of the community to replicate their results. Indeed, after 
a series of tit-for-tat publications rebutting each other the issue seems to have been put to rest in 
a publication by Theillet et al in which in-cell NMR was used to study aSyn in a more physiologically 
representative environment; within mammalian neuronal cells (42–44). This study showed that 
aSyn existed predominantly as an acetylated monomer within the cytosol. 
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Figure 1-6 - Different structures adopted by aSyn, as solved by solution-state and solid-state NMR. Top) The structure 
of monomeric micelle-bound aSyn solved by solution-state NMR. Note the broken helix formed between residues 1-92 that 
would lie across the surface of the micelle. Bottom) The ssNMR structure of a single aSyn protofilament exhibiting a striking 
“Greek-key” β-architecture. The N-terminal residues 1-38 and C-terminal residues 97-140 are disordered and have been 
removed from the image. The leftmost image shows the fibril at a sideways angle, whilst the rightmost image shows a 
“birdseye view” of the fibril coming out of the page. 
As an amyloid protein aSyn’s monomeric form will begin to oligomerize and eventually form 
fibrils. There has been no successful characterization of aSyn oligomers in high-resolution as they 
are very heterogenous and extremely condition-dependent, although SAXS has recently been used 
to obtain low-resolution models over the time course of aggregation (45). Moreover any attempt 
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to isolate these oligomers will disrupt the delicate equilibrium in which they exist, and thus they 
could change. Until very recently the fibrils of aSyn were also very poorly characterized. However, 
with the latest advances in solid-state NMR (ssNMR) and cryo-EM the mystery has begun to be 
picked apart. Tuttle et al showed in a landmark paper that the aSyn protofilament adopts a  “Greek-
key” motif (Figure 1-6) (10). This structure was solved by ssNMR and has since been validated by 
cryo-EM (46). Impressively, the N- and C-termini of the protein remain completely disordered even 
in the fibril structure. Cryo-EM has been particularly helpful in probing the structure of whole fibrils 
and different polymorphs. The paper by Li et al, for example, looked at so-called “rod” and “twister” 
polymorphs (46). They showed that each fibril was composed of two protofilaments and that in the 
rod fibrils those protofilaments adopted the Greek-key conformation identified by ssNMR. 
However, in the twister polymorph the Greek-key was incompletely formed and was instead a “β-
arch”. This also meant that fewer residues were involved in the actual fibril and it was suggested by 
the authors that this is what contributed to the “twister” morphology, as there were more residues 
extending out into space (46).  
1.5.2 The function of α-synuclein 
 
 Despite intense study for 30 years, aSyn remains something of an enigma. This is especially 
so with regards to its physiological function which is still poorly understood. ASyn is predominantly 
expressed in the brain and localized to presynaptic terminals (25). Here it is thought to play a role 
in the regulation of the docking of synaptic vesicles to the presynaptic membrane (26,47). Despite 
being a widely conserved protein, the deletion of aSyn in mice was not lethal. Instead these mice 
displayed a vastly reduced synaptic response to a prolonged train of stimulation (47). Examination 
by transmission electron microscopy (TEM) revealed a stark reduction in the number of vesicles in 
the “reserve pool” – those vesicles standing by to dock to the presynaptic membrane after those 
already docked fuse when the synapse fires (47). Headway has been made recently with several 
high-profile publications. It was described by Burré et al that aSyn at the presynaptic membrane 
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binds to the N-terminal of synaptobrevin-2 via its CTD and that this instigated the formation of  
SNARE complexes, which themselves promote vesicle fusion (39) .  The same group later showed 
that aSyn at the membrane multimerizes and that it was this form of the protein – not cytosolic 
monomeric aSyn – that promoted SNARE formation (26).  
1.5.3 The structure and function of β- and γ-synuclein 
 
BSyn and gSyn are both poorly characterized. Neither protein is aggregation prone. GSyn is 
the most substantially different from the others, but the main difference between aSyn and bSyn 
lies in the fact that bSyn lacks the Val73-Glu83 portion of the NAC domain (Figure 1-4). Intriguingly, 
the addition of these residues to bSyn does not result in it becoming amyloidogenic and the 
formation of fibrils as may have been expected (48). It is thought that the role of this 11-residue 
patch in aSyn aggregation is as much a feature of its location in the sequence as its relative 
hydrophobicity and simply inserting this into the corresponding region in bSyn is not enough. This 
case emphasizes the point that comparatively simple changes made to IDPs don’t always have the 
expected consequence, despite the lack of any 3D structure that may be distorted. This point is also 
evident with respect to point mutations in aSyn. As stated earlier, there are six known pathogenic 
mutations in aSyn that are associated with PD. Despite these only being single point mutations and 
the mutation sites all being very close together (five of the six mutation sites are within seven 
residues of each other – see Figure 1-5) the effects are quite different. For example H50Q reportedly 
results in a late-onset form of PD, whilst G51D leads to an early-onset form (49,50). It is clearly of 
great importance to have a comprehensive and complete understanding of aSyn and how minor 
changes affect it – as they can clearly have quite radically different clinical effects. 
1.6 Lewy bodies, Lewy neurites, and glial cytoplasmic inclusions 
 
Lewy bodies (LBs) are named after Fritz Heinrich Lewy who studied them in detail in the early 
20th century. LBs are intracellular proteinaceous inclusions found within neurons and are the 
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pathological hallmark of PD and some other synucleinopathies (Figure 1-7 A). They are composed 
primarily of misfolded forms of aSyn and are immuno-reactive to the protein. 
Immunohistochemistry reveals a dense “core” region and a lighter “halo” surrounding it (51). 
Approximately 90% of the aSyn deposited within LBs is phosphorylated at S129, whilst only 5% of 
protein is phosphorylated at the residue outside of the LBs (52). Nitrated and C-terminally truncated 
forms of aSyn have also been identified in LBs (53,54). It is unclear whether these modifications 
encourage the protein’s deposition into LBs – hence their enrichment over homeostatic levels – or 
whether they occur post-deposition. Ubiquitin colocalizes with aSyn in LBs. This suggests that aSyn 
within LBs has been marked for degradation, but that perhaps the cellular degradation machinery 
is overwhelmed or incapable of removing the fibrillar aSyn (55).  
 
Figure 1-7 - Lewy bodies, Lewy neurites and glial cytoplasmic inclusions. A) Lewy bodies immunostained for aSyn in 
neurons of the subtantia nigra. B) Lewy neurite immunostained for aSyn in neurons of the substantia nigra. C) Glial 
cytoplasmic inclusions immunostained for aSyn in the frontal cortex. Images taken from (17,56). 
 
Neurites are projections from neuronal cells and Lewy neurites (LNs) are those projections 
that contain aggregated aSyn (Figure 1-7 B). In this sense they are similar to LBs and are also found 
in the synucleinopathies. 
Glial cytoplasmic inclusions (GCIs), also known as Papp-Lantos bodies, are a distinct 
pathological feature from LBs and LNs (Figure 1-7 C). GCIs are also composed of aggregated aSyn, 
but unlike LBs and LNs which are found within the neurons GCIs are found within oligodendrocytes, 
a type of glial cell (56). GCIs are generally crescent or cone-shaped, but some have a flame-like 
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shape similar to neurofibrillary (NFTs) in AD. GCIs are not found in PD or AD, and are a hallmark of 
the brutal disease multiple system atrophy (MSA) (57).  
1.7 The synucleinopathies 
 
The huge level of interest in aSyn stems not from the mystery of its physiological function, 
but rather from its pathophysiology. The discoveries in 1997 by Spillantini et al and Polymeropoulos 
et al that aSyn was the main component of LBs and that mutations in the SNCA gene were found in 
rare familial forms of PD together acted as a starting gun to research into the ties between aSyn 
and neurodegeneration (17,58). Since this time a total of six point mutations in the protein 
sequence (A30P, E46K, H50Q, G51D, A53T, and A53E) have been linked to familial PD. The 
involvement of aSyn aggregation has now been tied to a whole host of fatal, progressive and 
currently incurable neurodegenerative diseases, collectively termed the “synucleinopathies” 
(Figure 1-8). These diseases include, but are not limited to: PD, Parkinson’s disease dementia (PDD), 
dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer’s disease (LBVAD), and MSA. 
MSA is not a Lewy pathology, instead forming GCIs, and thus is not part of the continuum shown in 
Figure 1-8. 
 
Figure 1-8 - Alzheimer's and Parkinson's exist on a spectrum. There is a high-degree of overlap between Lewy and Aβ 
pathology, and which of these predominates determines the course and type of the disease. 
  
1.7.1 Parkinson’s disease 
 
PD – named after James Parkinson who first described the disease in his 1817 piece An 
Essay on the Shaking Palsy – is a progressive and fatal neurodegenerative disease afflicting 1% of 
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the population over the age of 60 (59). This makes it the second most common neurodegenerative 
disease after AD. It is characterized by a number of symptoms referred to under the umbrella term 
“parkinsonism” (60). These symptoms include: a resting tremor, a stooped gait, difficulty walking, 
bradykinesia, and muscular rigidity. There are also varying levels of non-motor symptoms including: 
loss of sense of smell, constipation, sleep disorders, and psychiatric issues. The symptoms become 
more severe as the disease progresses and are caused by the progressive loss of neurons in the 
brain. The motor symptoms are caused specifically by the loss of dopaminergic neurons in the 
substantia nigra pars compacta in the midbrain (60). The degree and movement of the Lewy 
pathology throughout the brain is classified by the Braak stages (see Figure 1-9 and Table 1-1) (61). 
The Braak stage and the extent of Lewy pathology is correlated with disease severity. The only 
treatment is the administration of the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA), 
which rescues motor symptoms but has no impact on disease progression (62). 
 
Figure 1-9 - Schematic showing the progression of Lewy pathology throughout the brain at different Braak stages. The 
shading indicates the pattern and degree of Lewy pathology. Image taken from (63). 
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Table 1-1: The Braak stages of Lewy pathology. Stages defined by Braak et al (61). 
Braak stage Location of Lewy pathology 
1 Medulla oblongata 
2 Stage 1 plus pontine tegmentum 
3 Stage 2 plus emergence into the midbrain, including notably the substantia nigra pars 
compacta 
4 Stage 3 plus basal prosencephalon and mesocortex 
5 Stage 4 plus neocortex (high order sensory association areas) 
6 Stage 5 plus neocortex (first order sensory association areas and premotor areas) 
 
1.7.1.1 Sporadic, environmental, and familial Parkinson’s disease 
 
The majority (~90%) of cases of PD are sporadic in nature. This is to say that patients do not 
have any family history of the disease and onset is as a result of factors that are as yet not well 
understood. Approximately one in ten patients, however, have genetic mutations that result in the 
development of PD (64). This is so-called familial PD. Despite its comparative rarity, the ability to tie 
disease onset to specific genetic defects has been used as an opportunity to study the wider disease 
mechanisms in more detail. Mutations in multiple genes have been identified and some of these 
are listed in Table 1-2 (64,65). 
Table 1-2 - The different familial PD-linked loci and the associated genes involved. Loci beyond PARK9 have not been 
included due to their poor characterization.  
Locus Chromosome Protein (Gene) Protein function Autosomal 
Dominant
/Recessive 
PARK1 4q21.3 α-synuclein (SNCA) Precise role unknown. Involvement in 
synaptic vesicle docking to presynaptic 
membrane 
Dominant 
PARK2 6q25.2-27 Parkin (PRKN) E3 ubiquitin ligase Recessive 
PARK3 2p13 Unknown Unknown Dominant 
PARK4 4q21.3 α-synuclein (SNCA) See PARK1 Dominant 
PARK5 4p14 UCHL1 (UCHL1) Ubiquitin carboxyl terminal hydrolase Dominant 
PARK6 1p35-p36 PINK1 (PINK1) Serine/threonine kinase Recessive 
PARK7 1p36 DJ-1 (PARK7) Unknown Recessive 
PARK8 12p11q13.1 LRRK2 (LRRK2) Serine/threonine kinase Dominant 
PARK9 1p36 ATP13A2 (ATP13A2) Cation transport Recessive 
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It is thought that mutations in LRRK2 are the most common cause of familial PD (66), whilst 
the others are much rarer. Intriguingly, many of the proteins identified in familial PD are associated 
with ubiquitin-mediated protein degradation (parkin, UCHL1 and PINK1) and mitochondrial quality 
control (ATP13A2, LRRK2 and DJ-1) and may operate on the same biochemical pathways (67–72). 
However, such mutations can have wildly different effects on the age of onset of PD, disease 
severity and pathology. 
Also, a few cases of PD are environmental in origin. Exposure to pesticides such as 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and paraquat has been linked to oxidative 
stress and the development of PD (73,74). 
1.7.1.2 Parkinson’s disease-linked point mutations in α-synuclein 
 
Polymeropoulos et al identified that point mutations in the SNCA gene encoding aSyn were 
found in an Italian family – “the Contursi kindred” – with a history of Parkinson’s disease (58). In 
members of this family there was a single nucleotide substitution (G209A) in SNCA that resulted in 
the substitution of the alanine at position 53 of the protein being replaced with a threonine (A53T). 
Since then the total number of known PD-linked point mutations in aSyn has reached six. These are: 
A30P, E46K, H50Q, G51D, A53T, and A53E (49,50,58,75–77). These point mutations are rare, but 
represent a powerful opportunity for studying the mechanisms of PD. Despite all being located in 
close proximity to each other they have quite wildly differing effects. For example, H50Q and G51D 
are changes in immediately adjacent residues and yet H50Q is associated with accelerated 
fibrillation and late disease onset, whilst G51D is associated with a greater tendency for 
oligomerization and an earlier age of onset. The effects of these mutations are particularly difficult 
to understand as aSyn itself is an unstructured protein and thus lacks a native structure that can be 
perturbed. Understanding how these mutations result in the onset of PD is important in 
understanding how PD arises sporadically and for a wider understanding of the underlying disease 
mechanisms.  
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It is known that some of the mutations in particular (e.g. A53T) enhance the rate of aSyn 
aggregation (78). It is also known that some of the mutations have an impact on the protein’s 
intrinsic ability to associate with lipid bilayers (e.g. A30P) (79). What the work in this thesis provides 
is a comprehensive study of the different PD-linked mutants that have been analysed under 
identical conditions and at the same time. The hope is that this will fill in some of the gaps in the 
literature regarding the mutants, particularly those for those only discovered recently, and help 
resolve any contradictions. I also hope that this information will provide insight into how these 
different mutants result in remarkably different disease phenotypes. 
 
1.7.2 Dementia with Lewy bodies, Parkinson’s disease dementia, and 
the Lewy body variant of Alzheimer’s disease 
 
DLB is a disease closely related to PD and is one of the most common dementias. Due to its 
similarity with AD it is thought to be significantly under-diagnosed. According to official figures it 
makes up 4% of all cases of dementia, but according to the Alzheimer’s Society may make up as 
much as 15% of all dementia based upon studies of brain tissue of patients taken post mortem (80). 
Like PD it is characterized by the appearance of LBs in the brain. Dementia is most commonly the 
presenting feature and patients will commonly exhibit powerful hallucinations, sleep disorders, and 
also the classic parkinsonian symptoms (e.g. stooped gait, rigidity, resting tremors etc) (80).  
 PDD and DLB are extremely similar; the diagnosis of a patient is dependent on which 
symptoms present first (81). A presentation of motor symptoms associated with parkinsonism 
before the onset of the dementia-like symptoms results in a PDD diagnosis. If the reverse happens 
then a DLB diagnosis is more likely.  
 There is some confusion as to whether LBVAD is a separate disease, as some sources use it 
as an alternative name for DLB (82,83). The synucleinopathies exist on a spectrum with AD on one 
end and PD at the other (Figure 1-8). The position on the spectrum relates to the extent of Lewy or 
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Aβ pathology. Those diseases with greater Lewy pathology, or in which Lewy pathology is 
predominant, are more Parkinson’s-like in presentation (e.g. PDD). Others with a greater 
prevalence of Aβ plaques will be more Alzheimer’s-like. LBVAD may exist somewhere on this 
spectrum, but it must be remembered that each patient and case is unique and trying to pigeonhole 
every case may prove to be impossible. 
1.7.3 Multiple system atrophy 
 
MSA is a fatal and progressive neurodegenerative disease characterized by the pathological 
hallmark GCIs. These proteinaceous inclusions composed of aggregated aSyn are found within 
oligodendrocytes and are distinct from the LBs and LNs found in the neurons in patients with PD or 
DLB. MSA is a rare disease and there are thought to be 3,300 patients in the UK and Ireland; the 
incidence is generally thought to be around 5 patients in every 100,000 over 50 years of age (84). 
Symptoms can include parkinsonism – resulting in many cases being initially diagnosed as PD – and 
cerebellar ataxia (problems with balance and coordination of movement) (85). Despite its similarity 
to PD it is a faster moving disease and death typically occurs within about 9 years of diagnosis (85). 
MSA is relatively “new” disease as it has historically been considered as three separate diseases: 
striatonigral degeneration, sporadic olivopontocerebellar atrophy, and Shy-Drager syndrome. MSA 
is an umbrella that is subdivided into MSA-P, the Parkinson’s-like subtype historically known as 
striatonigral degeneration, and MSA-C, the subtype associated with cerebellar dysfunction and 
historically known as sporadic olivopontocerebellar atrophy (86,87). Shy-Drager syndrome is now 
considered a slightly archaic name, but is sometimes used as an alternative name for MSA as a 
whole. It is noteworthy to acknowledge that the strain of aSyn found in MSA is distinct from those 
found in patients with PD and that it is a prion (88). This makes aSyn the second identified human 
prion in history, subsequent only to the prion protein (PrP) in Creutzfeldt-Jakob disease (CJD).  
1.8 Therapeutic strategies against the synucleinopathies 
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In the fight against neurodegeneration and the synucleinopathies there are a number of 
therapeutic strategies that are under active investigation and development. Currently, there are no 
cures and all treatments target symptoms rather than the underlying pathology.  
1.8.1 Symptomatic treatments 
 
1.8.1.1 L-DOPA 
 
L-DOPA is a precursor to the neurotransmitter dopamine and is itself formed from the 
amino acid tyrosine (Figure 1-10) (89,90). L-DOPA is commonly administered to patients with PD in 
order to alleviate the typical parkinsonian motor symptoms, such as resting tremors. Dopamine 
cannot be administered itself due to its poor penetrance across the blood-brain barrier. L-DOPA, on 
the other hand, can cross the blood-brain barrier and its movement is facilitated by the 4F2hc/LAT1 
amino acid transport system (91). The recognizable symptoms of PD are caused by the loss of 
dopaminergic signalling neurons in the substantia nigra pars compacta of the brain. L-DOPA offsets 
this loss by increasing the supply of dopamine available (62). It should be noted that not all patients 
are receptive to treatment by L-DOPA and in those that are the benefits of the treatment decline 
over time as the disease progresses. 
 
 
Figure 1-10 - L-DOPA is the precursor to dopamine. L-DOPA is given to patients with Parkinson’s disease in order to ease 
its associated motor symptoms, which arise as a result of the loss of dopamine signalling neurons in the substantia nigra. 
The administration of L-DOPA can temporarily make up for the shortfall in dopaminergic signalling in some patients. 
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1.8.1.2 Dopamine agonists 
 
Dopamine agonists (e.g. pramipexole) are another form of symptomatic treatment of PD, 
which may be administered alongside L-DOPA or alone (92). As their name suggests this is a class 
of compounds that serve to bind to and activate dopamine receptors, and in this way mimic the 
action of dopamine (93,94). Pramipexole was discovered to significantly improve symptoms in early 
cases of PD (92) however there are notable side-effects and withdrawal symptoms, especially 
regarding impulse control (e.g. gambling) (95,96). Like L-DOPA, the aim of these compounds is to 
mitigate against the loss of overall dopaminergic signalling caused by the death of neurons in the 
substantia nigra pars compacta. However, also like L-DOPA, this form of treatment appears to 
become less effective over time – this is because the scale of neuronal loss can no longer be 
compensated for by the administration of greater levels of dopamine mimics. 
1.8.2 Non-symptomatic treatments 
 
Non-symptomatic treatments are those that are not aimed at targeting the obvious 
parkinsonian symptoms of PD, but those that are actually targeting the underlying pathology. This 
means they are aimed at either preventing the accumulation of aSyn aggregates, or somehow 
reversing the process. None of these treatments currently exist, yet there are numerous ideas and 
several of these are currently undergoing clinical trials. 
1.8.2.1 Peptide inhibitors of α-synuclein aggregation 
 
The majority of drugs on the market currently are small molecules (<1kDa), however there 
is an increasing level of interest in the use of peptides as pharmaceuticals. Peptides are generally 
far more specific to a given target than small molecules and thus are less likely to have prohibitive 
side-effects. Also, many of the issues that have historically proved an impediment to their clinical 
use (e.g. proteolytic degradation and localization) are better understood and can now be 
circumvented (97). Peptides are particularly attractive to neurodegenerative research due to their 
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specificity and their potential to impede fibril elongation. Some peptides, for example, have been 
shown to form β-hairpin structures that “cap” fibrils to prevent the addition of further monomeric 
units and thus blocking their elongation. This has been shown for amylin and aSyn (98). This can be 
particularly facilitated in N-methylated peptides (i.e. the backbone amides are methylated) as it 
prevents the formation of hydrogen bonds by one side of the peptide (99).  
1.8.2.2 Monoclonal antibodies targeting α-synuclein  
 
Pathological forms of aSyn are now known to move from cell-to-cell in a prion-like manner. 
Virginia Lee and colleagues very elegantly showed this in mice in 2012, and that aSyn pathology 
spread from an initial point of injection to anatomically connected regions (100). The same group 
then showed the potential of antibodies specific to mis-folded aSyn to assuage the spread of the 
pathology and the consequent cell death and motor symptoms. This is presumably by binding to 
the pathological species and preventing their movement from one neuron to another in which they 
could seed the mis-folding of native protein (101). The effectiveness of the antibody-driven 
approach was also shown by Masliah et al who used the passive immunization of a mouse model 
of PD with the 9E4 (anti aSyn 118-126) antibody to promote aSyn clearance and improved cognitive 
performance (102). This idea has been picked up by Roche and Prothena who are operating in 
partnership to develop monoclonal antibodies targeting aSyn with the aim of preventing the spread 
of aSyn pathology and preventing further loss of neurons. Their anti-synuclein antibody 
Prasinezumab (PRX002/RG7935) is currently in Phase II clinical trials having just passed through 
Phase Ib trials in which it was found to be safe and well tolerated (103).  
 
1.8.2.3 Chaperone-mediated disaggregation of aggregates 
 
A number of publications have emerged in recent years describing the ability of different 
proteins, or a collection of proteins, to either inhibit fibril formation or to actively break-up pre-
existing fibrils (104–106). These processes are either passive, requiring no energy input (e.g. 
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cyclophilin-40), or active and require the hydrolysis of ATP to drive the process (e.g. Hsp70) (105). 
The viability of these approaches clinically has not been shown. Energy-driven approaches, such as 
that of the disaggregase formed by Hsp70, DNAJB1 and an Hsp110 nucleotide exchange factor, may 
place an unacceptable energetic burden on the neurons. The spontaneous processes observed with 
members of the cyclophilin family may not be realistic either, given that they themselves are big 
players in cell death and their precise involvement remains poorly understood and controversial 
(106).  
1.8.3 Challenges 
 
The development of therapeutics to be used in the treatment of neurodegenerative disease 
is fraught with difficulties. These challenges go above and beyond those normally encountered on 
the bumpy road of drug development. First and foremost is a lack of knowledge. The mechanisms 
that underlie neuronal cell death are not well understood, and in the case of AD there is even 
argument as to whether focus should be placed on Aβ pathology or tau pathology. Billions of dollars 
have been spent by pharmaceutical companies on failed clinical trials (e.g. bapineuzumab) (107) to 
interrupt pathways that are not understood; as a direct result of this Pfizer announced in early 2018 
its departure from research into new therapeutics for AD and PD. This highlights the need for 
further basic research into neurodegeneration. Additionally, there are problems with a lack of 
biomarkers. Neurodegenerative disease generally only becomes noticeable after pathology is 
widespread throughout the patient’s brain. This makes a preventative approach difficult.  
From the point-of-view of designing clinical trials neurodegenerative disease is difficult 
because they typically move very slowly. AD and PD, for example, are mostly diagnosed in people 
over the age of 60. By this stage the pathology may be already well established throughout the 
brain, yet patients can live with AD or PD for decades. To continuously monitor sufficient numbers 
of people for such durations to see the impact of a drug candidate is a herculean challenge.  
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1.9 Project aims 
 
The work here is best considered as several separate projects unified by a common protein of 
interest, aSyn. The experimental chapters are chapters 4, 5, 6, and 7. Chapter 4 relates to the 
inhibition of aSyn aggregation using a peptide inhibitor (KDGIVNGVKA) of aSyn aggregation. The 
inhibition of aSyn aggregation is a strategy of therapeutic interest, and whilst implicit evidence for 
the interaction between KDGIVNGVKA and aSyn is available in the initial publication by Cheruvara 
et al there is no explicit evidence (108). It was an aim of this project to obtain concrete evidence of 
an interaction between aSyn and KDGIVNGVKA, and if possible identify the residues (if any) which 
mediate the interaction. This would primarily be elucidated using NMR and TEM, and would allow 
the further development of peptide-based inhibitors, which in the long-term could hold therapeutic 
potential.  
Chapter 5 overlaps with and complements the work from chapter 4. The work conducted in 
this chapter was aimed at identifying the metabolic pathways affected as a result of challenging SH-
SY5Y neuroblastoma cells with aSyn. It was hypothesized that differences could be observed in the 
metabolic profile of cells which had been exposed to aSyn monomers versus fibrils, and fibrils versus 
aSyn that had been incubated with KDGIVNGVKA. Previous work from the group had shown 
statistically significant differences in the metabolic profile of cells that had been exposed to 
different species of aSyn (109), and it was my hypothesiss that the incubation of aSyn with 
KDGIVNGVKA would result in the formation of alternative species that would result in similarly 
significant differences. Any information that could be withdrawn regarding metabolic pathways 
involved could be used to infer the mechanisms of aSyn toxicity (e.g. mitochondrial dysfunction) 
and if/how the peptide inhibitor mitigates that toxicity.  
Chapter 6 explores the properties of the PD-linked aSyn point mutants and the effects of 
tyrosine nitration via peroxynitrite. The information surrounding the PD-linked mutants in the 
literature is often patchy or even contradictory. It was my aim to express and purify all of these PD-
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linked mutants such that I could conduct experiments investigating their properties at the same 
time and under identical conditions. This would allow for a comprehensive comparison of the 
effects of these mutations on the rate of aggregation, lipid interactions, and cell toxicity. Given that 
some of these mutations have quite different effects on the onset and progression of PD it is 
important to have clarity on their fundamental properties. The effect of nitration on aggregation 
and lipid-binding is also of importance as this is a pathologically relevant modification found in LBs 
(53), and gaining an understanding of whether this is a cause or a consequence of aggregation 
would potentially help resolve some of the questions regarding causality in PD.  
Chapter 7 covers work that was aimed at probing the relationship between aSyn, cyclophilin-
D (CypD), and the mitochondria. This came about as a result of work (for which I supplied aSyn) in 
which it was shown by NMR that CypD and aSyn interact. CypD is a big target and regulator of 
mitochondrial permeability transition pore (mPTP) opening, whilst there is also evidence that aSyn 
localizes to the mitochondria and may open the MPTP (110–112).  This raises a lot of questions. It 
is my hypothesis that aSyn aggregates localize to the mitochondria where they interact with CypD, 
which then initiates the opening of the mPTP to result in cell death. This was probed primarily 
through NMR spectroscopy and TEM, carried out in conjunction with Prof Lu-Yun Lian. 
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2 NMR theory 
 
Much of the information and figures in this chapter are adapted from the Second Edition of 
“Understanding NMR Spectroscopy” by James Keeler (113). 
2.1 Chemical shift and spins 
 
NMR spectroscopy is a technique used to study atomic nuclei, and is widely used in chemistry 
and biophysics/structural biology. It may be used to observe nuclei with a quantum property called 
“spin”. The majority of nuclei observed in NMR have a spin state (S) of  +
1
2
 or −
1
2
. This includes 1H 
(a proton), 15N, 31P and 13C. The most commonly observed in biophysics are 1H, 15N and 13C. 1H is 
present in everything, whilst recombinantly produced proteins may be enriched in the isotopes 15N 
and 13C using supplemented bacterial growth media. These nuclei, when placed in a magnetic field, 
will begin to precess about the magnetic field. It is often said that the individual spins align “with” 
or “against” the magnetic field – spin up (α) or spin down (β). This is a slightly incomplete picture. 
It is energetically favourable for spins to align with the magnetic field, however due to thermal 
fluctuations spins are constantly rearranging. There is only a very slight excess of spins aligned with 
the magnetic field, but this is sufficient to provide the sample as whole with a net alignment with 
the field. Thus, the magnetization can be considered across the whole sample rather than just for 
individual spins in individual molecules. 
The spins precess about the applied magnetic field (B0) at a particular frequency, the Larmor 
frequency (ω0 in rad s-1 or ν0 in Hz). The Larmor frequency of the nucleus is given by: 
𝜔0 =  −𝛾𝐵0  or  𝜈0 =  −𝛾𝐵0/2𝜋 
The gyromagnetic ratio (γ) is specific to each type of nucleus (e.g. 1H) and describes the relationship 
between its angular momentum and its magnetic moment. An NMR experiment reports in ppm the 
degree to which the spins in a sample diverge from the Larmor frequency of a defined standard 
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(e.g. 1H in the reference compound tetramethylsilane (TMS)). This quantity is the chemical shift (δ). 
The chemical shift relates to the frequency in Hz as follows: 
𝛿(𝑝𝑝𝑚) = 106  × 
𝜈 −  𝜈𝑟𝑒𝑓
𝜈𝑟𝑒𝑓
 
The reference frequency is often used in NMR as a synonym for magnetic field strength (e.g. an 
800MHz magnet). The 106 makes the maths come out more simply (hence parts per million). The 
chemical shift is reported rather than the frequency in Hz because the frequency value is dependent 
on the magnetic field strength, whereas the chemical shift has removed the field dependence. Thus 
the chemical shift allows for the comparison of data collected on spectrometers with different 
magnetic field strengths. 
 The Larmor frequency of spins is affected by the local chemical environment and it is this 
feature that makes NMR so powerful. The rate of precession about the magnetic field is dependent 
on how much magnetic field the spins “see”. Nuclei surrounded by large clouds of electrons are 
somewhat protected by a countering magnetic field generated by the electrons. For example, the 
1H nuclei within methyl groups (CH3) are relatively shielded, whilst 1H nuclei adjacent to an 
electronegative atom such as oxygen or nitrogen will “feel” the magnetic field to a greater extent. 
Thus the nuclei of these groups will exhibit a different chemical shift on an NMR spectrum. The 
NMR spectrum shows peaks for each different chemical environment in a sample for a given 
nucleus. 
2.2 Pulses and the free induction decay 
 
The actual output of an NMR experiment is called the FID. This is a signal that arises as a 
result of the sample magnetization vector being placed in the transverse (x, y) plane and passing 
through the receiver coils. This induces an electric current within the coils that can be measured. It 
is an analogue signal, but is recorded as digitized points that are reconstructed into the FID signal 
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during data processing. As the name suggests, the signal is decaying. The transverse magnetization 
in the x,y plane relaxes over time into nothing, and this means that the initial part of the FID contains 
the most signal whilst the latter parts decay into noise. This has implications for data processing. 
Data processing employs a mathematical operation called a Fourier transform, developed by Joseph 
Fourier in 1822, which converts the rather uninterpretable time-domain FID signal into a frequency-
domain spectrum comprising peaks at all of the different frequencies that make up the FID (Figure 
2-1).  
 
 
Figure 2-1 - The conversion of the free induction decay into an NMR spectrum. The free induction decay (left) is the time-
domain data collected in an NMR experiment. The majority of the signal is present at the beginning and gradually fades 
away into the noise due to T2 relaxation. The data is then made time-independent and converted into the frequency 
domain via a Fourier transformation. This results in a typical NMR peak (right). 
 
The magnetization vector is placed into the transverse plane by a radiofrequency (RF) pulse. 
RF pulses are used due to them having frequencies within a similar range as the Larmor frequencies 
of the spins in NMR samples. Radio waves are a form of electromagnetic radiation, which is to say 
that they are composed of an electric component and a magnetic component. This applied 
magnetic field is generally termed B1 and is much weaker than the Bo field of the magnet, but at a 
frequency equal to the Larmor frequency of the spins it achieves resonance which enables it to push 
the spin magnetization vector into the transverse x,y plane. The duration and power of the pulse 
affect the degree to which the magnetization is flipped. Most pulses used in pulse sequences are 
so-called 90° or 180° pulses; meaning that they flip the magnetization vector by 90° or 180°. Before 
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an experiment is started the parameters to achieve a 90° for the nuclei in the sample must be 
calibrated. This is done by pulsing until the signal reaches zero (indicating a flip of 180°). A pulse of 
half this length is then used as the 90°. 
Strictly speaking, pulses that are equal in frequency to the Larmor precession are on-
resonance pulses. Also utilized in pulse sequences are off-resonance pulses, which do not exactly 
match the Larmor frequency. Instead, these pulses are useful for targeting multiple spins at once.  
2.3  Models of NMR 
 
There are several models used to describe how NMR operates. These are the energy level 
model, the vector model, and the product operator model. Here is described the energy level model 
as it is easier to visualize and is a useful teaching tool. However it is an incomplete model and for a 
more complete understanding of NMR both the vector model and the product operator model are 
used. However, these are not discussed here as this level of understanding is not necessary to 
comprehend the work described in this thesis. 
2.3.1 Energy level model 
 
When the sample is placed into the magnetic field two energy levels emerge, spin up (α) 
and spin down (β) mentioned earlier. There is a difference in energy (ΔE) between these energy 
levels given by:  
∆𝐸 = 𝐸𝛽 − 𝐸𝛼 
The energy needed to move the spins from one energy level to the other is related through Planck’s 
constant (h) to the frequency of an incoming photon (ν) as given by:  
∆𝐸 = ℎ𝜈 
As described in 2.1 the Larmor frequency is dependent on the gyromagnetic ratio of the nucleus (as 
this determines whether spin state α or β is lower in energy) and the magnetic field strength B0 (as 
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a stronger magnetic field will increase the separation between the two energy levels). This means 
that by applying a pulse of radiation with the same frequency as the Larmor frequency of the spins 
– the rate of precession – you will induce an energy level transition in the spins and observe a peak 
in the NMR spectrum (Figure 2-2). Peaks will appear at points corresponding to the Larmor 
frequency of every spin in the sample. This corresponds to every different chemical environment in 
the sample. 
 
Figure 2-2 - The energy level model of NMR and spin states. After the sample is placed into the magnetic field spins are 
separated into α and β spin states. The spins can move between the energy levels through the application of an RF pulse 
of a frequency matching the difference in energy between them. This will be represented in an NMR spectrum by a peak 
at the corresponding frequency. 
2.4 1D NMR 
 
2.4.1 1D Proton experiments 
 
1D proton experiments are the simplest type of NMR experiment, but also one of the most 
valuable. 1D proton experiments (Figure 2-3) consist of a pre-scan delay (d1) to allow the 
magnetization to reach equilibrium followed by a single pulse and acquisition. One would expect 
the pulse to be 90° for maximum magnetization, however it is often the case that pulses that rotate 
the magnetization by just 30° are used. This is because the time it takes for the magnetization to 
return to equilibrium from 90° is such that by pulsing the sample more frequently with just 30° 
pulses results in “more bang for your buck” (better signal-to-noise). The pulse sequence shown in 
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Figure 2-3 is the basic pulse sequence, but it may be modified with additional pulses that fulfil roles 
such as water suppression (to hide the large water peak at 4.7ppm in aqueous samples). 
It is best practice to run a 1D proton experiment on every sample, especially before longer 
two- and three-dimensional experiments. This allows one to check that various parameters (e.g. 
spectral-width) are optimized. It also provides a quick-and-easy check of the state of the sample, 
such as whether it is folded or whether there are any contaminants present.  
 
 
Figure 2-3 - The pulse sequence for a 1D proton experiment. It consists of an initial delay (d1) that allows the 
magnetization to reach equilibrium prior to a 30° pulse, followed immediately by the acquisition period. 
 
2.4.2 WaterLOGSYs 
 
WaterLOGSY experiments are a type of one-dimensional NMR experiment that were 
designed and are used to study the interaction of weakly-binding ligands to protein molecules. The 
basic principle of the experiment is that the sample contains a large excess of ligand to protein (e.g. 
10µM protein to 200µM ligand). The pulse sequence applies the magnetization to the water of the 
sample, which is then transferred through a variety of mechanisms to the ligand and protein. These 
mechanisms include: saturation of Hα resonances; saturation of NH and OH protons in fast exchange 
with water; and magnetization that has been transferred to bound water trapped in cavities on the 
surface of the protein and/or at the protein:ligand interface. For these mechanisms to successfully 
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transfer magnetization to the ligand efficiently it requires the interaction of the ligand with the 
protein as they are based on nuclear Overhauser effects (NOEs) and spin diffusion, both of which 
require close proximity between the spins. Additionally, this experiment works best for weakly 
binding systems, as it means that there is a regular and rapid exchange of bound and unbound 
ligand. This allows a larger proportion of the total ligand present to acquire magnetization, as 
opposed to in more tightly binding systems. This is also the reason why the large excess of ligand to 
protein is used; because the ligand is not being saturated directly. A characteristic of the experiment 
is that “binders” and “non-binders” will have signals of opposite sign due to their different tumbling 
rates, resulting in either a positive or negative NOE. The sign change, however, may not be seen if 
there is a high degree of exchange with the solvent. WaterLOGSYs were used in this thesis to probe 
the interaction between aSyn and a peptide inhibitor of its aggregation given their widespread 
usage in the pharmaceutical industry and their increased sensitivity compared to saturation transfer 
difference (STD) experiments (114). 
2.5 Multidimensional NMR 
 
Some spectra, especially for larger molecules like proteins, become very crowded due to the 
large number of different chemical environments. In these situations it can be difficult to interpret 
the spectra and it is instead helpful to increase the dimensionality of the experiment. Most 
commonly two-dimensional experiments (e.g. correlation spectrscopy (COSY), total correlation 
spectroscopy (TOCSY), heteronuclear single quantum coherence (HSQC)) are used, however higher-
dimensional experiments are possible. Multidimensional experiments may be homonuclear (e.g. 
the 2D COSY) or heteronuclear (e.g. the 2D HSQC). Here the intensity is plotted as a function of 
more than one frequency; in other words a peak represents two or more nuclei that are coupled 
together (via bonds or through space).  
Two-dimensional experiments are broken down into four parts: preparation, evolution (t1), 
mixing, and acquisition (t2) (Figure 2-4). Preparation refers to the initial step where magnetization 
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is placed into the transverse plane where it can be manipulated further. During the evolution period 
the magnetization is allowed to evolve so couplings and chemical shifts may develop. Following this 
is the mixing time during which the magnetization is primed for acquisition; this may include steps 
to transfer magnetization onto a more sensitive nucleus (e.g. 1H).  
In two-dimensional spectra the first scan is recorded with an evolution time (t1) of zero. This 
then gets incrementally increased with every scan. This means that the evolution time (t1) gets 
recorded as a function of the acquisition time (t2). In this way following Fourier transformation the 
data corresponds to two frequency domains – t1 and t2. The Fourier transformation of the data is 
slightly more involved than that for the one-dimensional NMR spectra as it needs to be processed 
“both ways” (i.e for t1 and t2).  
 
Figure 2-4 - The pulse sequence of a decoupled HSQC experiment. The preparation part of the HSQC is an INEPT block 
that transfers magnetization to the X nucleus. During the evolution period there is a single 180° for decoupling of the S 
nucleus. During the mixing period a second INEPT block is used to transfer magnetization back to the 1H nucleus, for 
detection. During the detection period a rapid series of pulses is used to remove couplings. This is the decoupling block.  
 
2.5.1 Heteronuclear Single Quantum Coherence 
 
The HSQC is a heteronuclear NMR experiment commonly used in biomolecular NMR. 1H-15N 
HSQCs are most common, but 1H-13C HSQCs are also possible. These experiments can be thought of 
as providing a “fingerprint” of a protein. There are peaks from the backbone amides of every amino 
acid present in the protein in 1H-15N HSQC spectrum, with the exception of prolines and the N-
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terminal residue. Peaks from amide-bearing sidechains may also be present, but these lie away 
from the backbone peaks. The chemical environment of the backbone amides is heavily dependent 
on protein conformation and this makes HSQC experiments very useful for observing PPIs and 
ligand-binding (115–117).  
Both 15N and 13C are far less sensitive than 1H due to their gyromagnetic ratios being smaller 
in magnitude (15N has a negative gyromagnetic ratio, unlike 1H and 13C) and thus the size of the 
magnetization they produce is much lower. It is thus more common – in biomolecular NMR – to 
transfer magnetization from the “insensitive” 15N and 13C nuclei onto 1H. This is the principle used 
in the HSQC experiment and it works through INEPT blocks (Figure 2-5).  
 
Figure 2-5 - The pulse sequence of the INEPT block, a key component of many multi-dimensional NMR experiments. The 
initial 90° pulse places the magnetization into the transverse plane, whilst the two 180° pulses remove the effect of the 1H 
chemical shift evolution. The final two 90° pulses result in the transfer of the magnetization to the X nucleus and the 
formation of the antiphase state.  
 
The INEPT block begins with a 90°(x) pulse on the 1H nucleus to move the magnetization into 
the transverse plane. This is followed by a delay during which the chemical shift evolves. The issue 
with this is that it results in a state called “multiple quantum coherence”; in other words that both 
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the 1H and X nuclear magnetization is in the transverse plane. To rectify this two 180° pulses are 
applied simultaneously onto the 1H and X nuclei. This removes the effect of the 1H nucleus chemical 
shift evolution whilst leaving the X nucleus unaffected. The second delay followed by the 
simultaneous 90° pulses mean that the magnetization is fully transferred to the less sensitive X 
nucleus, whilst the 1H magnetization is in the transverse plane – this is a state called antiphase.  
The remainder of the HSQC pulse sequence (Figure 2-4) is essentially a second INEPT block in 
reverse to allow the transfer of the magnetization back from the X nucleus to the more sensitive 1H 
nucleus where it is detected. During the detection period there is also a “decoupling block”. This is 
a train of rapid pulses that are used to remove unwanted 1H-X couplings. This results in the peaks 
appearing as singlets rather than exhibiting a confusing degree of splitting.   
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3 Preparation and characterization of alpha-synuclein 
 
3.1 Outline of chapter 
 
In this chapter is described the expression and purification of wild-type (WT) aSyn and each 
of the point mutations associated with PD. In addition to this is described the process by which the 
backbone NMR assignment of the WT protein was obtained. In validation of the successful 
preparation of the PD-linked mutations HSQCs and mass spectra of each were obtained. These 
confirmed the ability to prepare significant quantities of each of the proteins to high purity, which 
was essential to carry out the work in this thesis. 
3.2 Methods 
 
The procedure used in the expression and purification of WT aSyn is also used for A30P, E46K, 
H50Q, G51D, A53T, and A53E aSyn. 
3.2.1 Expression of α-synuclein 
 
The pRK172 aSyn expression construct (kindly gifted by Michel Goedert) was freshly 
transformed into E.coli BL21 cells, using the heat-shock method. These cells were used to inoculate 
1mL of super optimal broth with catabolite repression (SOC) (100ug/mL ampicillin), which was 
grown at 37°C with shaking at 200rpm for 8 hours. 150μL of this culture was then used to inoculate 
50mL of minimal medium (Solution A: 12.5g/L Na2HPO4, 7.5g/L KH2PO4 pH 7.2; Solution B (for 1L): 
4g (13C) glucose, 1g (15N) NH4Cl, 240mg MgSO4•7H2O, 20mg CaCl2•2H2O, 10mg thiamine), which was 
grown at 37°C overnight. This starter culture was used to inoculate 1L of minimal medium such that 
the starting optical density at 600nm (OD600) was 0.1. This culture was then grown at 37°C at 180rpm 
until the OD600 reached 0.8. At this point isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added 
to the culture to a final concentration of 0.5mM and the culture was then incubated shaking 
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overnight at 18°C. The next day cells were harvested by centrifugation at 4,000g for 20mins at 4°C. 
The cell pellets were snap frozen in liquid nitrogen (LN2) prior to storage at -80°C. 
3.2.2 Site-directed mutagenesis of α-synuclein 
 
The QuikChange II kit (Agilent Technologies) was used according to the manufacturer’s 
instructions to prepare the six PD-linked aSyn mutants (A30P, E46K, H50Q, G51D, A53T, and A53E). 
The WT aSyn pRK172 expression construct was used as the template. The reaction was carried out 
according to the manufacturer’s instructions with the primer sequences shown in Table 3-1. 
Table 3-1 - The forward and reverse primers used to generate the PD-linked mutants of aSyn 
Mutation Primer Sequences 
A30P  
5'-ctcttttgtctttcctggtgcttctgctacaccct-3' 
5'-agggtgtagcagaagcaccaggaaagacaaaagag-3' 
 
E46K  
5'-catgcaccactcccttcttggttttggagcc-3' 
5'-ggctccaaaaccaagaagggagtggtgcatg-3' 
 
H50Q  
5'-ctgttgccacaccctgcaccactccctcc-3' 
5'-ggagggagtggtgcagggtgtggcaacag-3' 
 
G51D  
5'-ccactgttgccacatcatgcaccactccc-3' 
5'-gggagtggtgcatgatgtggcaacagtgg-3' 
 
A53T  
5'-gtcttctcagccactgtcgtcacaccatgcaccactc-3' 
5'-gagtggtgcatggtgtgacgacagtggctgagaagac-3' 
 
A53E  
5'-cttctcagccactgtttccacaccatgcaccac-3' 
5'-gtggtgcatggtgtggaaacagtggctgagaag-3' 
 
 
The mutant constructs were subsequently transformed into TOP10 chemically competent 
cells. Single colonies were used to inoculate 5mL SOC, which were then grown at 37°C overnight 
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with shaking. The DNA was extracted and amplified using the QIAprep Spin Miniprep Kit (Qiagen), 
and then sent off for DNA sequencing (Source Bioscience) to confirm successful mutagenesis. 
3.2.3 Purification of α-synuclein 
 
 The cell pellets were thawed and resuspended in 20mL Buffer A (20mM Tris-HCl pH 8.0, 
1mM ethylenediaminetetraacetic acid (EDTA)). Cells were lysed by pressure homogenization, 
followed by a single cycle of ultra-sonication (30s at 23KHz) to shear DNA. The lysate was incubated 
at 85°C for 10mins and then clarified by centrifugation at 18,000g for 30mins at 4°C. The clarified 
lysate was applied directly to a 5mL Q HiTrap anion exchange chromatography column (GE 
Healthcare Life Sciences) that had been pre-equilibrated with the Buffer A. Protein was eluted from 
the column via gradient elution with Buffer B (Buffer A + 1M NaCl). Fractions were analysed by SDS-
PAGE using a 15% acrylamide gel and the standard Coomassie Brilliant Blue R-250 staining 
procedure. ASyn is found to elute from the column at approximately 300mM NaCl. The fractions 
were pooled and filtered through an Amicon Ultra-15 centrifugal filter with a 30kDa molecular 
weight cut-off (MWCO) (EMD Millipore). The flow-through was collected and applied to a 10kDa 
MWCO centrifugal filter, and was concentrated to 10mg/mL. The protein concentration was 
determined using UV absorbance at 280nm (ε = 5600 M-1cm-1 and MW = 14.5kDa). Protein purity 
was assessed by SDS-PAGE and mass spectrometry (MS) was used to verify that the protein was of 
the expected mass. 
3.2.4 Monomerization of α-synuclein 
 
Prior to all experiments, unless explicitly stated, aSyn was buffer exchanged into double-
distilled water using a PD-10 desalting column (GE Healthcare Life Sciences). The protein was then 
snap frozen in liquid nitrogen and transferred to a freeze-drier for lyophilisation. The lyophilised 
protein was resuspended in 2mL hexafluoroisopropanol (HFIP) (Sigma Aldrich) and thoroughly 
vortexed until transparent. The HFIP was then evaporated under a stream of nitrogen to leave a 
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thin “film” of protein lining the sample tube. This film was then resuspended in the buffer of choice 
for subsequent experiments with the protein in a monomeric-state. 
3.2.5 Standard NMR collection procedure 
 
Unless otherwise explicitly stated all NMR spectra were collected on a Bruker Avance III 
800MHz spectrometer equipped with a TCI CryoProbe (Bruker) at 298K. Samples were prepared in 
5mm glass tubes in “NMR buffer” (10mM sodium phosphate pH 7.0, 100mM KF, 0.05% NaN3) with 
a final concentration of 5% D2O (v/v) for the signal lock. Tuning and matching was carried out as 
appropriate. The “topshim” automated shimming procedure was used to ensure homogeneity of 
the magnetic field across the sample. The duration of the 90° pulse was recorded and set for each 
experiment using the automated “pulsecal” routine. Water suppression was optimized by varying 
the offset and the pulse power level until the water signal was at a minimum. Samples were left in 
the magnet for at least 5mins prior to shimming and data collection to allow magnetization to reach 
equilibrium. 
3.2.6 Standard NMR data processing and analysis 
 
NMR data were processed and phased in TopSpin version 3.5 pl 7 (Bruker). Analysis of peak 
intensities and shifts of 1D spectra was carried out in TopSpin, whilst 2D and 3D NMR spectral 
analysis was carried out using CcpNmr Analysis version 2.4.2 (CCPN). 
3.2.7 Backbone assignment of wild-type α-synuclein 
 
15N/13C-labelled aSyn was resuspended in NMR buffer such that the final concentration of 
protein was 180μM. HNCO, HN(CA)CO, CBCA(CO)NH and HNCACB experiments were recorded for 
the backbone assignment. 1D proton and 1H-15N HSQC spectra were collected before and after 
every 3D experiment to monitor the condition of the sample. Backbone resonance assignment was 
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carried out using CCPN Analysis. To validate the assignment the resonances were followed 
independently through the carbonyl-amide and the Cα/Cβ-amide linkages. 
3.3 Results & Discussion 
 
3.3.1 Expression and purification of α-synuclein 
 
ASyn (WT, A30P, E46K, H50Q, G51D, A53T, and A53E) was successfully expressed in minimal 
growth media and purified using ion-exchange chromatography. Bands of ≥95% purity could be 
seen for each by SDS-PAGE (Figure 3-1). Additionally, intact masses matching the predicted mass 
were obtained for each by MS. Unlabelled, 15N-labelled, and 13C/15N double-labelled protein was 
prepared as necessary for the different experiments.  
 
Figure 3-1 - SDS-PAGE gel of purified WT aSyn and the PD-linked mutants and intact MS measurements. Each of the 
forms is >95% pure with a single strong band at 14.5kDa, as shown by SDS page gel (left). The intact masses of each were 
measured by intact MS to confirm that the actual mass of the proteins matched with what was expected. The MS 
instrument had a 4Da miscalibration, hence each measurement is consistently about 4Da out from the expected value. 
 
3.3.2 Backbone assignment of wild-type α-synuclein 
 
A reliable backbone assignment is an essential resource because peak shifts are a visible 
sign of peptide-protein interactions, binding events, and protein conformational changes. By 
mapping the identity of the different peaks it should therefore be possible to identify the residues 
involved in these events. For example, in the event of a titration to investigate ligand-binding it 
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should be possible to identify those residues involved in the binding event (117). There are several 
previously published assignments of aSyn, however these have often been of samples in different 
buffers and at different temperatures. These factors can result in peak shifts and thus a new 
backbone assignment of aSyn in the NMR buffer that would be used in later experiments was 
desirable. To this end, four different 3D NMR experiments (HNCO, HN(CA)CO, CBCA(CO)NH and 
HNCACB) were collected. These were interspersed with HSQCs to confirm the state of the protein 
did not change during the timeframe of the experiments. Through the HNCO and HN(CA)CO it was 
possible to follow amino acid linkages through the carbonyl groups, whilst through the CBCA(CO)NH 
and HNCACB spectra linkages through the Cα and Cβ peaks could be followed (Figure 3-2). Having 
the two separate sets of experiments facilitated the assignment process by allowing for validation 
of assignments made using one set of experiments. Additionally, it was often the case that regions 
that were difficult to assign in one set of experiments, due to poorly resolved peaks, were better 
resolved in the other spectra enabling their assignment. Through this process, 122 residues out of 
a total of 134 assignable residues (140 – (5 prolines + 1 N-terminal residue)) were successfully 
assigned (Figure 3-3).  
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Figure 3-2 - Schematic showing the process of backbone residue assignment of WT aSyn. Top) Overlaid CBCA(CO)NH 
(blue) and HNCACB (cyan and brown, positive and negative phasing respectively) spectra showing how the amino acid 
chain can be followed via the Cα and Cβ peaks. Bottom) Overlaid HNCO (purple) and HN(CA)CO (green) spectra showing 
how the linkages can be independently followed using the carbonyl groups. 
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Figure 3-3 - An assigned HSQC spectrum of WT aSyn, and HSQCs of each of the PD-linked mutants. Left) An assigned 
HSQC spectrum of WT aSyn. Right) HSQCs of each of the PD-linked aSyn mutants superimposed with the spectrum for WT. 
Shifts are evident at the mutation site itself and in those residues adjacent to it. 
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4 The inhibition of α-synuclein aggregation using a 
novel peptide-based inhibitor 
 
4.1 Introduction 
 
4.1.1 The plodding advance of neurodegenerative disease 
 
Neurodegenerative diseases, such as PD and AD, arguably represent the most significant 
challenge to modern medicine. This is in the sense that they are both prevalent and, as yet, remain 
entirely unconquered. Unlike cancers, with their opportunities for surgical intervention, various 
chemotherapies or radiotherapy, there are no tools currently available that allow us to fight back 
against the gradual yet relentless progression of neurodegeneration. In the 21st century, with its 
vast and ever-growing human population and increased life spans, the impact of 
neurodegeneration is felt like never before. In the UK 850,000 people are thought to live with 
dementia to the tune of £26billion per annum (118).  
4.1.2 The peptide inhibitor 
 
As discussed previously in 1.8.2.1 there is great interest in the development of new peptide-
based inhibitors to combat the toxicity of aggregation-prone proteins, such as aSyn.  Collaborators 
at the University of Bath recently published a paper describing a peptide designed to inhibit the 
aggregation of aSyn (108). They identified this peptide using a novel intracellular library-screening 
technique based upon the recombination of dihydrofolate reductase in the event of binding 
between a peptide candidate and the protein target. Peptides targeting aSyn aggregation have been 
trialled before (99,119), but Cheruvara et al built a library of peptide sequences specifically aimed 
at the 45-54 region of aSyn in which the majority of the PD-linked point mutations are found. The 
only criteria needed to be fulfilled by a successful candidate in this screening assay is that it: a) bind 
to aSyn and b) reduce cytotoxicity. The successful peptide candidate identified was the 10-residue 
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peptide KDGIVNGVKA, which is acetylated at the N-terminus and amidated at the C-terminus 
(Figure 4-1). In the publication the group showed via ThT fluorescence assays and atomic force 
microscopy (AFM) that KDGIVNGVKA abrogated aSyn fibril formation in vitro. They also showed that 
the exposure of cells to aSyn plus peptide reduced cytotoxicity compared to aSyn alone using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.  
 
Figure 4-1 – Skeletal formula of the KDGIVNGVKA peptide inhibitor. This structure was prepared using the PepDraw 
server (120).   
4.1.3 Aims 
 
The aim in this work was to use NMR to test the hypothesis that KDGIVNGVKA was binding 
to aSyn, and if possible identify the binding site(s). This was based on the initial observations of 
Cheruvara et al who produced indirect evidence of binding and abrogation of aSyn aggregation 
(108). To assist in the identification of those residues involved in binding two alanine variants of 
KDGIVNGVKA were also utilized: KDGIVAGVKA and KAGIVNGVKA. 
4.2 Methods 
 
The peptides KDGIVNGVKA, KDGIVAGVKA, and KAGIVNGVKA used in these experiments were 
either kindly provided by Jody Mason (University of Bath) or purchased from China Peptides 
(Shanghai, China). All peptides were N-terminally acetylated and C-terminally amidated. 
4.2.1 NMR experiments 
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All NMR experiments were prepared, run and analysed as outlined in sections 3.2.5 and 
3.2.6. 
4.2.1.1 Peptide-binding NMR titrations 
 
15N-labelled WT aSyn was resuspended in NMR buffer such that the final concentration was 
180μM. Initial 1D and 1H-15N HSQC spectra were collected and subsequently KDGIVNGVKA peptide 
was added to the sample, such that the peptide:protein ratio was 0.25:1. 1D and 1H-15N HSQC 
experiments were repeated for this molar ratio. This process was repeated and 1D and 1H-15N 
HSQCs were collected for each of the following peptide:protein ratios: (0.25:1), (0.5:1), (0.75:1), 
(1:1), (2:1), (6:1), (15:1) and (20:1). 1D proton spectra were collected with 32 scans, 8 dummy scans, 
0.557s acquisition time, and sweep width 9.1877ppm. 1H-15N HSQCs were collected with 4 scans, 
32 dummy scans, an acquisition time of 0.109s (1H) and 0.061s (15N), and a sweep width of 
9.1877ppm (1H) and 26.0000ppm (15N). Spectra were analysed in CCPN Analysis and compared to 
the assigned WT aSyn spectrum to check for peak shifts or line-broadening. Chemical shift 
perturbations were expressed as: 
∆𝛿 = {(∆𝐻)2 + (0.15∆𝑁)2}1/2 
 
4.2.1.2 Timecourse HSQCs of peptide and α-synuclein 
 
ASyn was resuspended in NMR buffer to a final concentration of 200µM; one sample was 
of aSyn alone whilst the other contained an equimolar concentration of KDGIVNGVKA peptide. 1D 
proton spectra and a 1H-15N HSQC were collected on each sample. The samples were then incubated 
at 37°C with agitation. A further 1D and 1H-15N HSQC spectrum were collected on the samples every 
24hours for two weeks. 1D proton spectra were collected with 32 scans, 8 dummy scans, 0.557s 
acquisition time, and a sweep width of 9.1877ppm. 1H-15N HSQC spectra were collected with 8 
scans, 100 dummy scans, an acquisition time of 0.120s (1H) and 0.061s (15N), and a sweep width of 
8.3080ppm (1H) and 26.0000ppm (15N). CCPN Analysis was used for data analysis. 
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4.2.1.3 WaterLOGSY peptide-binding experiments 
 
This experiment was carried out for the following peptides: KDGIVNGVKA, KAGIVNGVKA, 
KDGIVAGVKA, KDGAVNGVKA, KDGIANGVKA, KDGIVNAVKA, and KDGIVNGAKA. Lyophilized WT aSyn 
and peptide were reconstituted in NMR buffer with 5% D2O to a final concentration of 50μM and 
1mM respectively. Each experiment required multiple samples: 1mM peptide alone, 50μM WT aSyn 
alone, 50μM WT aSyn + 1mM peptide. 1D proton and WaterLOGSY spectra were collected on each 
sample every day for 7 days. The 1D proton spectra were collected with 128 scans, 20 dummy scans, 
an acquisition time of 0.734s, and a sweep width of 13.9456ppm. WaterLOGSY spectra were 
collected with 256 scans, 16 dummy scans, an acquisition time of 0.729s, and a sweep width of 
14.0396ppm. 1D and WaterLOGSY spectra were compared in TopSpin with the control spectra to 
check for signs of binding. 
4.2.1.4 Natural abundance 1H-13C HSQCs of peptides 
 
The peptides KDGIVNGVKA, KDGIVAGVKA and KAGIVNGVKA were dissolved in D2O such 
that the final concentration was 1mM. 1D proton and 1H-13C HSQC spectra were collected for each 
peptide, and then the samples were incubated at 37°C with agitation for 1 week. Then a further 1D 
proton and 1H-13C HSQC spectrum was collected for each. 1D proton spectra were collected with 
128 scans, 100 dummy scans, an acquisition time of 0.557s, and a sweep width of 9.1877ppm. 1H-
13C HSQC spectra were collected with 16 scans, 16 dummy scans, an acquisition time of 0.100s (1H) 
and 0.014s (13C0, and a sweep width of 10.0122ppm (1H) and 65.0005ppm (13C). Spectra were 
processed in TopSpin and analysed in CCPN Analysis. 
4.2.2  “Ageing” of peptides 
 
Stocks of 4mM “aged” KDGIVNGVKA, KDGIVAGVKA, and KAGIVNGVKA were prepared by 
resuspending the lyophilized peptide into either NMR buffer for NMR studies or PBS pH 7.4 for 
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aggregation assays and TEM. The peptides were then incubated at 37°C with agitation for 1 week. 
The stock was then available for use in downstream experiments and assays. 
4.2.3 ThT analysis of α-synuclein incubated with KDGIVNGVKA, 
KDGIVAGVKA, or KAGIVNGVKA 
 
Three samples of 500μL aSyn (WT, A30P, E46K, H50Q, G51D, A53T and A53E) were prepared 
in PBS pH 7.4 at a concentration of 100μM. One sample was protein alone, whilst the second 
contained “fresh” KDGIVNGVKA peptide at a final concentration of 100μM. The third sample 
contained “aged” KDGIVNGVKA at a concentration of 100μM. Each of these tubes was incubated at 
37°C with agitation for 1 week. 100μL aliquots were taken and snap frozen in LN2 on day 0, 1, 3 and 
7. These aliquots were then thawed and transferred to a 96-well black-walled, clear bottom plate 
(Nunc) for endpoint fluorescence measurements on a Flexstation 3 microplate reader (Molecular 
Devices). Identical samples were simultaneously prepared and measured for the peptides 
KDGIVAGVKA and KAGIVNGVKA. Each sample was measured in triplicate and the final volume in 
each well was 50μL. The 50μL was made up using 25μL of sample and 25μL of buffer with 2μM ThT. 
λex = 440nm and λem = 490nm. Data was processed and analysed using OriginLab. Statistical 
significance of the differences was assessed using analysis of variance (ANOVA) with the Bonferroni 
post hoc test. 
4.2.4 TEM analysis of α-synuclein incubated with KDGIVNGVKA, 
KDGIVAGVKA, or KAGIVNGVKA 
 
5μL of each sample as used for the ThT assay was mounted onto a carbon-coated copper 
grid for 2mins. The grid was then gently blotted onto a piece of filter paper to remove excess liquid 
before applying 4% (w/v) uranyl acetate for 30s. Uranyl acetate was removed and the grid dried by 
blotting onto a piece of filter paper. Images were collected on a 120kV Tecnai G2 Spirit BioTWIN 
electron microscope (FEI) with a SIS Megaview III camera. Image and fibril length analysis was 
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carried out using ImageJ and OriginLab, with the scale bar on each image used as the length 
reference. 
4.2.5 Mass spectrometry analysis of KDGIVNGVKA, KDGIVAGVKA, and 
KAGIVNGVKA 
 
All MS analysis was carried out by Philip Brownridge and the Centre for Proteome Research 
at the University of Liverpool. Fresh and aged peptide samples were diluted to a concentration of 
1pmol/µL in 50% acetonitrile, 0.1% formic acid and infused at 5µL/min onto the electrospray 
ionization (ESI) source of an Orbitrap Fusion. Comparison of theoretical and experimental m/z 
values showed that measurements were accurate to 3ppm. Asn deamidation in KDGIVNGVKA was 
probed using the corresponding 1Da mass shift and the proportion of Asn deamidated was 
determined through deconvolution of the isotope (13C) cluster peaks. This was further confirmed 
through higher-energy C-trap dissociation (HCD) MS-MS. The formation of iso-Asp in the peptides 
over time was monitored using the KDGIVAGVKA peptide, due to the lack of Asn. KDGIVAGVKA 
peptide was diluted in 50mM ammonium bicarbonate to a concentration of 0.211µg/µL in 40µL. 
0.12µg Asp-N (Roche, Switzerland) was then added to provide an enzyme:substrate ratio of 1:50. 
The sample was incubated at 37°C and 2µL aliquots of the digest were taken at different timepoints 
(0hr, 1hr, 3.5hr, 6hr, overnight). Each sample was analysed by ESI on the Q-Exactive HF between 
300 and 1500 m/z at 60,000 resolution. The ratio of Ac-KDGIVAGVKA-Amid ions to DGIVAGVKA-
Amid ions was used to infer the degree of iso-Asp formation for samples of fresh and aged peptide. 
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4.3 Results 
 
4.3.1 Peptide-binding NMR titrations 
 
The titration of increasing levels of the KDGIVNGVKA peptide against monomeric aSyn did 
not result in the expected changes in aSyn’s HSQC profile. This was true at a 1:1 peptide:protein 
molar ratio, and was consistent up to a 20:1 ratio. Using the prepared backbone resonance 
assignment (Figure 3-3) it had been determined which peak corresponded to which amino acid 
within the protein. Any changes in the chemical environments of these amino acids induced by, for 
example, the binding of a peptide to the protein would be clearly visible. With the exception of a 
shift in the resonance corresponding to His50 no significant changes were seen (Figure 4-2). The 
change in His50 is likely a result of a minor buffer mis-match between the peptide and protein, 
especially given the proximity of the buffer pH to the histidine pKa and the lack of any peak shifts at 
neighbouring residues. These findings ran marginally contrary to the suggestions of the paper by 
Cheruvara et al (108). In this paper the KDGIVNGVKA peptide was identified using a novel 
intracellular screening assay on the basis that it bound to monomeric aSyn – specifically the 45-54 
region of the protein – and reduced cytotoxicity. In the original publication the peptide was 
described as being powerfully inhibitory of aSyn aggregation at even 1:1 concentration. The lack of 
peak shifts seen here at even 20:1 molar ratio strongly suggest that there is no binding between 
monomeric aSyn and KDGIVNGVKA. 
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Figure 4-2 - Bar chart showing the HSQC peak shifts of WT aSyn upon addition of KDGIVNGVKA. The peak shift distances 
were measured following the addition of KDGIVNGVKA peptide to a 20-fold molar excess of the peptide versus the protein. 
Gaps indicate those residues that are either unassigned or for which the chemical shift perturbation could not be accurately 
determined due to overlapping peaks. 
 
 There are several possible explanations for this apparent lack of peptide-protein 
interaction:  
1) There is no interaction. 
2)  They interact on a timescale that is not conducive to NMR. 
3) The interaction takes place between the peptide and an aSyn species that is “NMR-
invisible”. 
Of the three options it is the possibility of an interaction between the peptide and an NMR-
invisible species (e.g. oligomers or fibrils) that seemed the most likely and most probe-able. 
Oligomers and fibrils both exceed the size-limit of NMR (~35kDa), exhibiting prohibitive line-
broadening, and thus are not seen on the HSQC spectrum. 
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4.3.2 Timecourse HSQCs of α-synuclein and KDGIVNGVKA 
 
HSQC spectra of 200µM WT aSyn, with and without 200µM KDGIVNGVKA peptide, were 
collected every day for a period of two weeks. In between measurements the samples were 
incubated at 37°C with agitation to allow the formation of fibrils. During this timeframe excessive 
line-broadening caused by the formation of large aggregates results in the loss of many peaks. Some 
visible signals did remain, primarily belonging to residues within the CTD and thus that lie outside 
the core of the aggregated species – oligomers or maybe protofibrils – and therefore have 
independent dynamic properties (see Figure 4-3). The observed changes in the HSQC were near-
identical between the samples of aSyn alone versus that incubated with the inhibitor. This fact is 
supportive of the hypothesis following the titrations of KDGIVNGVKA against aSyn that 
KDGIVNGVKA does not bind to monomeric aSyn and may instead be binding to a species that lies 
beyond the size-limit of NMR and is thus unobservable. 
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Figure 4-3 - HSQCs of WT aSyn before incubation and after incubation with and without KDGIVNGVKA for 7 days. The 
incubation of WT aSyn for 7 days at 37°C results in a significant loss of peaks. This is the case for the samples with and 
without an equimolar concentration of KDGIVNGVKA peptide. The fact that this takes place for both samples suggests that 
the KDGIVNGVKA peptide does not bind to monomeric aSyn and does not impede the formation of aggregates of sufficient 
size as to be rendered invisible by NMR. Those peaks that remain are exclusively located with the CTD of aSyn, which are 
highly dynamic and likely have relaxation properties independent of the rest of the molecule. 
 
4.3.3 WaterLOGSY peptide-binding experiment 
 
In order to investigate the hypothesis that KDGIVNGVKA is binding to higher-order aSyn 
species a more peptide-centric approach was utilized. Rather than trying to follow changes in 
protein signals the aim was to spot changes in the peptide and a loss of peptide signal upon binding. 
In light of this, WaterLOGSY experiments, in conjunction with 1D proton experiments, were used. 
Samples were prepared of protein plus peptide – alongside appropriate controls (peptide alone, 
protein alone) – and 1D proton and WaterLOGSY spectra were collected every day for one week. 
As seen in Figure 4-2 there was no evidence of binding between monomeric aSyn and KDGIVNGVKA 
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(the equivalent of day 0), but there were observable changes in signal intensity at later timepoints. 
This can be seen in Figure 4-4 which shows the raw 1D and WaterLOGSY spectra at day 0 and day 
6, and the peptide signal intensity is reduced in the sample of KDGIVNGVKA plus aSyn relative to 
the sample of KDGIVNGVKA alone. This was plotted in Figure 4-4 C&F where the difference in area 
under the peaks between the peptide alone and peptide plus protein samples is shown. These show 
a clear increase in difference over time. The apparent time-dependence suggests that aSyn has 
begun to form larger aggregates, and it supports the data from Figure 4-2 and Figure 4-3 and the 
hypothesis that KDGIVNGVKA does not interact with monomeric aSyn but that it may do so with 
oligomeric or fibrillar aSyn. 
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Figure 4-4 - 1D and WaterLOGSY timecourse experiments indicating the binding of KDGIVNGVKA to WT aSyn. Raw 1D spectra of 1mM KDGIVNGVKA alone and 1mM KDGIVNGVKA plus 50µM 
WT aSyn that have been incubated for 0 (A) and 6 days (B) respectively at 37°C.  There is a loss of intensity of some key peptide signals in the spectra of peptide plus protein compared to in the 
spectra of peptide alone. These differences are greater at the later timepoints, and are plotted on a bar chart (C). Raw WaterLOGSY spectra of 1mM KDGIVNGVKA alone and 1mM KDGIVNGVKA 
plus 50µM WT aSyn that have been incubated for 0 (D) and 6 (E) days respectively at 37°C. Similarly to in the 1D spectra there is a loss of intensity of some peptide signals in the spectra of the 
sample that contains WT aSyn versus that of the peptide alone. These losses of peptide signal, which increase over time, are likely due to the binding of KDGIVNGVKA to WT aSyn aggregates. 
The population of these aggregates will increase over time, and their size exceeds the size-limit of NMR rendering them “invisible”. The binding of KDGIVNGVKA to these species would, in turn, 
render them invisible and result in a loss-of-signal.
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Figure 4-5 - 1D proton NMR spectra of "fresh" and "aged" KDGIVNGVKA. Further samples were prepared using a different 
batch of peptide at 500µM in PBS pH 7.4 to ensure the changes over time were reproducible. Freshly prepared samples 
appear to contain two populations of peptide. After 7 days of incubation at 37°C with agitation the “aged” peptide appears 
to consist entirely of the modified peptide. 
 
It was also clear from the 1D and WaterLOGSY spectra of KDGIVNGVKA alone and of 
KDGIVNGVKA in the presence of aSyn that the peptide was changing over the timeframe of the 
experiments. These modifications and their potential relevance to aSyn interaction was 
investigated further by NMR and MS. 
4.3.4 Probing changes in KDGIVNGVKA over time 
 
 To probe the changes seen during the timecourse of the WaterLOGSY peptide-binding 
experiments in more detail further NMR experiments on the peptide alone were carried out. To 
ensure that this was a batch independent phenomenon an alternative batch of KDGIVNGVKA was 
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used. A 500µM sample of KDGIVNGVKA alone was prepared in PBS pH 7.4. This sample was termed 
“fresh” and a 1D proton spectrum was collected. This sample was reanalysed 1 week later after 
being incubated at 37°C with. This was termed the “aged” peptide. The spectra of both are shown 
overlaid in Figure 4-5. The same changes that observed during the course of the WaterLOGSY 
experiments are apparent; the most obvious changes are in the amide region (6.5 – 8.5ppm) of 
spectrum. There is notably a peak present in the fresh sample at 6.8ppm that is not seen in the aged 
sample. This is likely the peak corresponding to the amide group in the sole asparagine residue of 
KDGIVNGVKA, which may become deamidated over time. This process occurs more rapidly at 
elevated temperatures (e.g. during incubation at 37°C) and when the residue is followed by a 
flexible residue – like glycine (121). A set of natural abundance 1H-13C HSQCs on the fresh and the 
aged peptide samples were also conducted (Figure 4-6). 13C is naturally present as 1% of the total 
carbon on Earth, making these experiments possible with unlabelled peptide so long as a high 
peptide concentration was used (1mM).  
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Figure 4-6 - Natural abundance 1H-13C HSQC spectrum of fresh and aged KDGIVNGVKA. The black spectrum is fresh 
peptide whilst the red is the aged form. Note the shift in the asparagine Cα peak, which would suggest that the residue is 
deamidating over time. Concomitant shifts are also seen in the CH2 peaks for asparagine. 
 
The spectra revealed clear shifts in the position of the Cα and Cβ peaks likely corresponding 
to the asparagine residue (Figure 4-6). This was compelling evidence in favour of deamidation, but 
given the close proximity between the Asn and Asp peaks MS was used for confirmation. The 
deamidation of Asn results in a mass shift of 1Da, which is detectable by MS (122).  
 Fresh and aged KDGIVNGVKA, prepared under identical conditions to those used in the 
NMR experiments, was analysed by MS through direct infusion revealing a primary ion with the m/z 
value 521.3078 (Figure 4-7). The theoretical value is 521.3062, so the measured accuracy was to 
within 3ppm. In the fresh peptide sample the predominant peak has a value of 521.3078, with less 
abundant peaks at 521.8045 and 522.3008 which reflect those ions containing 13C. In the aged 
sample the distribution of these peaks is different, with the predominant peak being the middle 
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peak (521.8045). This suggests that partial deamidation of the sample has occurred, and the first 
13C peak of the unmodified peptide now overlaps with that of the deamidated peptide. By looking 
at the ratio in the relative abundances of each peak in the two samples it was possible to determine 
the proportion of the peptide that had been deamidated; this was about 51%. With HCD MS-MS 
the location of this deamidation was determined (see Figure 4-8). Unlike in Figure 4-7 in which m/z 
values of the whole peptide were recorded, using HCD MS-MS ion fragments of the peptide were 
generated. As can be seen in Figure 4-8, the distribution of peaks mimics that seen for the whole 
peptide until Asn is removed. The loss of the preceding peak indicates that Asn is responsible for 
the dual population (with a difference in mass of 1Da). This corresponds to the mass change induced 
by deamidation and confirms that Asn6 in the ten-residue peptide is the site of deamidation.  
 This confirms that partial deamidation of the Asn residue is taking place within a similar 
timeframe to the aggregation of aSyn in vitro. This holds relevance from the point of view of 
therapeutic development, as this may modulate the affinity of interaction between aSyn aggregates 
and KDGIVNGVKA, and may also affect the concentration of peptide that needs to be utilized in 
order to obtain maximum inhibition.  
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Figure 4-7 - Mass spectra of fresh and aged KDGIVNGVKA. Samples of fresh and aged KDGIVNGVKA were prepared at 1pmol/µL and infused at 5µL/min on the ESI source of an Orbitrap Fusion. 
Mass difference of 1Da is indicative of deamidation. In the aged sample the deamidated peptide peak overlaps with the 13C peak.  
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Figure 4-8 - HCD MS-MS spectra showing evidence for deamidation at position N6 in KDGIVNGVKA. The top spectrum shows the spectrum of fresh KDGIVNGVKA, whilst the bottom shows that 
of KDGIVNGVKA that has been allowed to ‘age’ and thus deamidate. The Y6 and Y5 ions have preceding peaks, as shown by red arrows, whilst Y4 does not. This is indicative of the deamidation 
taking place at the Asn residue at position 6. 
 62 
 
It is worth highlighting that Asn and Asp are both present in the peptide and both are 
capable of undergoing modification under similar conditions, with Asp forming iso-Asp (Figure 4-9) 
(123). It is possible to infer iso-Asp formation using the AspN protease, which specifically cleaves 
the peptide bond N-terminal to Asp residues but is incapable of doing so with iso-Asp (124).  
To investigate whether the formation of iso-Asp was also taking place further MS 
experiments were carried out on fresh and aged KDGIVAGVKA (Figure 4-10). KDGIVAGVKA was 
chosen due to its lack of Asn, which would otherwise complicate the analysis as it deamidates. The 
proportion of the total peptide containing iso-Asp rather than regular Asp is increased in the sample 
of aged peptide. This is indicated by the ratio of the peptides with the m/z values 414.7 and 499.8, 
which correspond to the +2 ions of DGIVNGVKA-Amid and Ac-KDGIVNGVKA-Amid respectively. 
After incubation with the AspN protease the ratio only increased marginally in the aged sample, 
even after 24 hours, whilst there was a much greater degree of cleavage in the fresh sample. This 
is demonstrated in Figure 4-10 B where the ratio of the 414.7 ion to the 499.8 increases much more 
substantially over time for the fresh KDGIVNGVKA peptide compared to the aged sample.  
In summary, both deamidation of Asn and isomerization of Asp both take place within 
KDGIVNGVKA during the experimental timeframe. It seems that deamidation of Asn is a more 
prevalent modification in KDGIVNGKVA than iso-Asp formation. This is indicated by the shift in the 
Asn peak in the natural abundance HSQCs, whilst Asp remains static (Figure 4-6). Clearly any 
modifications to this residue don’t occur in a sufficient proportion of the peptide population in the 
sample to be reflected in the NMR spectrum. The binding of KDGIVNGKVA to aSyn appears to 
increase over time, as suggested by the 1D and WaterLOGSY NMR experiments (Figure 4-4), but it 
remains to be seen whether deamidation is a help or a hindrance. Further experiments utilizing 
alanine variants of the KDGIVNGVKA peptide at the sites of the Asp and Asn residues will clarify the 
effect the modifications have in respect to binding. 
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Figure 4-9 - Schematic showing the mechanism of isoaspartate formation from asparagine and aspartic acid sidechains 
via a succinimide intermediate. 
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Figure 4-10 - Use of MS to determine isoaspartyl formation. The peptide KDGIVAGVKA was used so that changes as a 
result of asparagine modification were not seen. The AspN enzyme cleaves after Asp residues (A) but not iso-Asp, thus the 
ratio of KDGIVAGVKA:DGIVAGVKA indirectly reports on the level of isoaspartate formation. Ac-KDGIVAGVKA-Amid has a 
+1 ion (998.5993) and a +2 ion (499.8033), as does DGIVAGVKA-Amid (+1 = 828.4938, +2 = 414.7505). The relative 
abundances of the +2 ions of both are plotted in the table. The ratio of these values have been plotted at different 
timepoints (B). This data infers an increase in the level of isoaspartate in the sample of aged KDGIVAGVKA compared to 
the fresh sample.  
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4.3.5 ThT & TEM analysis of α-synuclein incubated with KDGIVNGVKA 
 
In their publication, Cheruvara et al showed that incubating WT aSyn with equimolar 
amounts of KDGIVNGVKA resulted in an absolute abrogation of fibril formation; this was visible by 
AFM images and from their ThT data (108). In order to validate their work and check that the 
peptide was functional WT aSyn was incubated at 37°C with agitation for one week, with and 
without an equimolar concentration of KDGIVNGVKA. 
Due to the observations in Figure 4-5 and Figure 4-6 that changes – deamidation – were 
taking place in KDGIVNGVKA ThT and TEM experiments were performed to compare the effects of 
fresh and aged forms of KDGIVNGVKA on fibril formation. Additionally, due to the fact that the 
peptide was intended to target the 45-54 region of aSyn its effects were also tested on the six PD-
linked mutants.  
 
4.3.5.1 Wild-type 
 
WT aSyn alone forms long, straight fibrils as can be seen by TEM (Figure 4-11 A). Incubation 
with either fresh or aged KDGIVNGVKA appears to result in the formation of much shorter fibrils 
rather than the total abrogation reported by Cheruvara et al (Figure 4-11 B&C) (108). Generally, 
those formed in the presence of equimolar amounts of KDGIVNGVKA appeared as shorter versions 
of the “normal” fibrils averaging 50-100nm in length (Figure 4-11 D&E). These shorter fibrils don’t 
form the large, dense “nests” of fibrils common with the protein alone. Those formed in the 
presence of the aged peptide appear to be similarly affected. The differences in length between 
fibrils formed by WT aSyn alone and the two peptide conditions were found to be statistically 
significant (Figure 4-11 E). There are three plausible explanations for this data:  
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 The deamidation of the Asn residue of KDGIVNGVKA has no significant impact on 
its inhibitory activity and binding to aSyn, and thus similar effects are seen in the 
presence of both the fresh and aged peptide. 
 The deamidated peptide is inactive and lacks the capability to bind to aSyn or 
impede its aggregation, yet a sufficient proportion of the unmodified “fresh” 
peptide remains and this plays an active role in inhibiting protein aggregation. 
 Alternatively, the deamidated KDGIVNGVKA is the active inhibitory species that 
binds to aSyn. As KDGIVNGVKA deamidates over the timeframe of the experiment, 
both the fresh and aged samples contain a sufficient proportion of deamidated 
peptide to mediate the observed impact on aSyn aggregation. 
The ThT data (Figure 4-11 F) shows that fluorescence increases over time in all three 
conditions as more β-rich species are formed. The samples of WT alone and WT plus fresh 
KDGIVNGVKA appear to be quite similar in their ThT profile, whilst those with the aged 
KDGIVNGVKA exhibit lower overall fluorescence. This is supported in the statistical analysis of the 
ThT data (Table 4-1). Using ANOVA with the Bonferroni means comparison test it was evident that 
the samples with aged KDGIVNGVKA are significantly different from the samples of WT aSyn alone 
and WT aSyn with fresh KDGIVNGVKA at day 1 and all later timepoints. These differences may be 
the result of two possibilities: that incubation with aged KDGIVNGVKA results in fewer overall fibrils; 
or that the incubation with aged KDGIVNGVKA results in the fibrils exhibiting an alternative 
morphology that is less able to bind ThT. The TEM images would suggest that there is not a reduced 
number of fibrils, and it is likely that the shortened fibrils formed in the presence of aged 
KDGIVNGVKA are less able to bind ThT.  
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Figure 4-11 – TEM fibril lengths analysis and corresponding ThT endpoint data of WT aSyn incubated with/without fresh 
or aged KDGIVNGVKA. 100µM WT aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM aged 
KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size of the 
fibrils formed (D) was performed and revealed that the incubation of WT aSyn with fresh or aged KDGIVNGVKA drastically 
reduces the average fibril size to <100nm. The fibril lengths data is also shown in box-and-whisker plot format (E). The 
upper and lower limits of the boxes indicate the 25th and 75th percentiles of the data, whilst the horizontal line and small 
square indicate the median and mean respectively. The “whiskers” indicate the 5th and 95th percentile range of the data. 
The number of length measurements taken for each condition were as follows: WT alone (114), plus fresh KDGIVNGVKA 
(281), and plus aged KDGIVNGVKA (200). Statistical significance was assessed by ANOVA with the Bonferroni post hoc 
test. * denotes significant differences to the 0.05 level with all other samples, † denotes significantly different to the 0.05 
level from the fresh KDGIVNGVKA sample, and ‡ denotes significantly different to the 0.05 level from the aged 
KDGIVNGVKA sample. Corresponding ThT measurements (F) were performed – in triplicate – on sample aliquots taken at 
day 0, 1, 3, and 7. Three experimental plates were prepared, but due to saturation only data from one is shown. 
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Table 4-1 - Table showing the statistical significance of the differences in the ThT data between WT aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate on 100µM WT aSyn 
alone, or with an equimolar concentration of fresh or aged KDGIVNGVKA peptide. The statistical significance was assessed 
by ANOVA with the Bonferroni test. Significant differences were those with p-values <0.05.  
 
4.3.5.2 A30P 
 
A30P aSyn will also form characteristic long amyloid fibrils by itself. These are long, straight 
and have a propensity to form huge clusters (Figure 4-12 A). In the presence of fresh or aged 
KDGIVNGVKA some short fibrils were present, but preferably formed less defined and more 
heterogeneous species (Figure 4-12 B&C). These were largely <150nm (Figure 4-12 D&E) and were 
more representative of oligomers or protofibrils. The differences between the lengths of the species 
formed in the two samples containing KDGIVNGVKA and the fibrils formed by A30P alone were 
found to be statistically significant (Figure 4-12 E). Judging by the ThT endpoint readings for these 
samples, however, there is little difference in ThT-binding and resultant fluorescence compared to 
A30P alone and this is reflected in the ANOVA statistical analysis carried out on the data (Figure 
4-12 F & Table 4-2). Interestingly, the level of ThT-fluorescence appears to go down over time in all 
three conditions. This may reflect the emergence of a morphology early-on in the aggregation 
process common to all three conditions and to which ThT does not bind well. It is quite clear from 
the TEM data presented here that both fresh and aged KDGIVNGVKA have a potent impact on the 
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aggregation of A30P aSyn, apparently abrogating the protein’s ability to form amyloid fibrils, and 
that this is not obvious when inspecting ThT-fluorescence data alone.  
 
Figure 4-12 – TEM fibril lengths analysis and corresponding ThT endpoint data of A30P aSyn incubated with/without 
fresh or aged KDGIVNGVKA. 100µM A30P aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed (D) and summarized as box-and-whisker plots (E). The upper and lower limits of the boxes indicate 
the 25th and 75th percentiles of the data, whilst the horizontal line and small square indicate the median and mean 
respectively. The “whiskers” indicate the 5th and 95th percentile range of the data. The number of length measurements 
taken for each condition were as follows: A30P alone (39), plus fresh KDGIVNGVKA (38), and plus aged KDGIVNGVKA (36). 
Statistical significance was assessed by ANOVA with the Bonferroni post hoc test. * denotes significant differences to the 
0.05 level with all other samples, † denotes significantly different to the 0.05 level from the fresh KDGIVNGVKA sample, 
and ‡ denotes significantly different to the 0.05 level from the aged KDGIVNGVKA sample. Corresponding ThT 
measurements (F) were performed – in triplicate – on sample aliquots taken at day 0, 1, 3, and 7. Three experimental 
plates were prepared, but due to saturation only data from one is shown. 
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Table 4-2 - Table showing the statistical significance of the differences in the ThT data between A30P aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate on 100µM A30P aSyn 
alone, or with an equimolar concentration of either fresh or aged KDGIVNGVKA peptide. The statistical significance was 
assessed by ANOVA with the Bonferroni test. Significant differences were those with p-values <0.05.  
 
4.3.5.3 E46K 
 
E46K alone forms amyloid fibrils that are shorter than those formed by WT, and they also 
seem to have a weaker propensity to form the huge networks seen for WT and some of the other 
mutant aSyn forms (Figure 4-13 A). In the presence of the fresh KDGIVNGVKA the ability of E46K to 
form fibrils appears undiminished (Figure 4-13 B), however in the presence of the aged peptide it 
does seem that the fibrils are fewer and shorter in length when observed by TEM (Figure 4-13 C). 
The mean fibril length in the sample containing aged KDGIVNGVKA is approximately 100nm, whilst 
both E46K alone and in the presence of fresh KDGIVNGVKA form fibrils with a mean length of 300nm 
(Figure 4-13 E). These differences were statistically significant, as assessed by ANOVA with the 
Bonferroni post hoc test. This is especially interesting given that at day 1 and day 3 the ThT-
fluorescence for the samples with aged KDGIVNGVKA is vastly greater than that for the samples of 
E46K alone or with the fresh peptide (Figure 4-13 F). This is reflected in the ANOVA statistical 
analysis shown in Table 4-3. By day 7 the statistically significant differences are no longer present. 
This suggests that E46K in the presence of the aged KDGIVNGVKA peptide aggregates via a different 
aggregation pathway to E46K alone or E46K plus fresh KDGIVNGKVA. This alternative aggregation 
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pathway initially results in the formation of highly ThT-reactive species but has shorter amyloid 
fibrils with lower ThT reactivity, more in line with the other sample conditions, as its endpoint. 
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Figure 4-13 – TEM fibril lengths analysis and corresponding ThT endpoint data of E46K aSyn incubated with/without 
fresh or aged KDGIVNGVKA.  100µM E46K aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed (D) was performed and is also shown in box-and-whisker format (E). The upper and lower limits of the 
boxes indicate the 25th and 75th percentiles of the data, whilst the horizontal line and small square indicate the median 
and mean respectively. The “whiskers” indicate the 5th and 95th percentile range of the data. The number of length 
measurements taken for each condition were as follows: E46K alone (63), plus fresh KDGIVNGVKA (26), and plus aged 
KDGIVNGVKA (66). Statistical significance was assessed by ANOVA with the Bonferroni post hoc test. * denotes significant 
differences to the 0.05 level with all other samples, † denotes significantly different to the 0.05 level from the fresh 
KDGIVNGVKA sample, and ‡ denotes significantly different to the 0.05 level from the aged KDGIVNGVKA sample. 
Corresponding ThT measurements (F) were performed – in triplicate – on sample aliquots taken at day 0, 1, 3, and 7. Three 
experimental plates were prepared, but due to saturation only data from one is shown.  
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Table 4-3 - Table showing the statistical significance of the differences in the ThT data between E46K aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate on 100µM E46K aSyn 
alone, or with an equimolar concentration of either fresh or aged KDGIVNGVKA peptide. Statistical significance was 
assessed by ANOVA with the Bonferroni test. Significant differences were those with a p-value of <0.05. 
 
4.3.5.4 H50Q 
 
H50Q alone forms relatively long fibrils (>150nm) (Figure 4-14 A&D), whilst in the presence 
of the fresh peptide it forms dense networks of very short fibrils (Figure 4-14 B). In the presence of 
aged KDGIVNGKVA fibrils are also seen and are of a similar length to those formed in the presence 
of fresh KDGIVNGVKA (Figure 4-14 C-E), but they appear more sparsely distributed and more 
heterogeneous. The ThT endpoint measurements (Figure 4-14 F) show that under all three 
conditions ThT fluorescence increases over time, and indicating an increase in cross-β character to 
which ThT will bind. Despite the differences in the samples as observed by TEM there are no 
statistically significant differences in the ThT data when compared by ANOVA, with the exception 
of the two samples containing KDGIVNGVKA at day 1 (Table 4-4). This may suggest that H50Q plus 
fresh KDGIVNGVKA initially embarks on a slightly different aggregation pathway to the other 
conditions, or that it reduces the initial rate of aggregation.  
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Figure 4-14 – TEM fibril lengths analysis and corresponding ThT endpoint data of H50Q aSyn incubated with/without 
fresh or aged KDGIVNGVKA. 100µM H50Q aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed was carried out (D). Both fresh and aged KDGIVNGVKA appear to result in shorter fibrils. The fibril 
lengths data is also shown in box-and-whisker plot format (E). The upper and lower limits of the boxes indicate the 25th 
and 75th percentiles of the data, whilst the horizontal line and small square indicate the median and mean respectively. 
The “whiskers” indicate the 5th and 95th percentile range of the data. The number of length measurements taken for each 
condition were as follows: H50Q alone (46), plus fresh KDGIVNGVKA (72), and plus aged KDGIVNGVKA (68). Statistical 
significance was assessed by ANOVA with the Bonferroni post hoc test. * denotes significant differences to the 0.05 level 
with all other samples, † denotes significantly different to the 0.05 level from the fresh KDGIVNGVKA sample, and ‡ denotes 
significantly different to the 0.05 level from the aged KDGIVNGVKA sample. Corresponding ThT measurements (F) were 
performed – in triplicate – on sample aliquots taken at day 0, 1, 3, and 7. Three experimental plates were prepared, but 
due to saturation only data from one is shown.  
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Table 4-4 - Table showing the statistical significance of the differences in the ThT data between H50Q aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate on 100µM H50Q aSyn 
alone, or with an equimolar concentration of either fresh or aged KDGIVNGKVA peptide. Statistical significance was 
assessed by ANOVA with the Bonferroni test. Significant differences were those with a p-value of <0.05. 
 
4.3.5.5 G51D 
 
G51D is reported in the literature as persisting in the oligomeric state for longer than WT 
aSyn and as being more toxic (125). This was in evidence on the TEM grids of G51D alone (Figure 
4-15 A) where only very few isolated patches of fibrils were seen. In the presence of the 
KDGIVNGVKA peptide – fresh or aged – fibrils were more prevalent (Figure 4-15 B&C). Similarly, 
approximately 50% of the fibrils in the sample of G51D alone were <100nm, whilst in the presence 
of the peptide there was generally a broader range in terms of fibril length seen (Figure 4-15 D&E). 
This suggests that the peptide pushes the G51D protein down a different aggregation pathway that 
favours the formation of amyloid fibrils. Therapeutically this may be beneficial rather than a bad 
thing as fibrils represent a more benign endpoint. All samples see an increase in ThT-fluorescence 
over time, indicating the formation of species with cross-β architecture (Figure 4-15 F). However, 
ANOVA reveals no statistically significant difference between the conditions (Table 4-5). The fact 
that there were comparatively few fibrils in the TEM sample of G51D alone, yet the ThT data is 
similar to the samples incubated in the presence of the peptide which formed many fibrils, could 
indicate that: the species formed by G51D alone have a different morphology that means they are 
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more ThT-reactive “pound-for-pound” than the species formed in the presence of the peptide, 
despite appearing fewer in number on the TEM grid; or that the fibrils formed by G51D alone did 
not adhere well to the TEM grid, and thus are underrepresented under the microscope. 
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Figure 4-15 – TEM fibril lengths analysis and corresponding ThT endpoint data of G51D aSyn incubated with/without 
fresh or aged KDGIVNGVKA. 100µM G51D aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed (D) was carried out and suggests that the incubation of G51D with KDGIVNGVKA may result in the 
formation of longer fibrils than typically formed by G51D alone. The fibril lengths data is also shown in box-and-whisker 
plot format (E). The upper and lower limits of the boxes indicate the 25th and 75th percentiles of the data, whilst the 
horizontal line and small square indicate the median and mean respectively. The “whiskers” indicate the 5th and 95th 
percentile range of the data. The number of length measurements taken for each condition were as follows: G51D alone 
(41), plus fresh KDGIVNGVKA (73), and plus aged KDGIVNGVKA (43). Statistical significance was assessed by ANOVA with 
the Bonferroni post hoc test. * denotes significant differences to the 0.05 level with all other samples, † denotes 
significantly different to the 0.05 level from the fresh KDGIVNGVKA sample, and ‡ denotes significantly different to the 
0.05 level from the aged KDGIVNGVKA sample. Corresponding ThT measurements (F) were performed – in triplicate – on 
sample aliquots taken at day 0, 1, 3, and 7. Three experimental plates were prepared, but due to saturation only data from 
one is shown. 
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Table 4-5- Table showing the statistical significance of the differences in the ThT data between G51D aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate with 100µM G51D aSyn 
alone, or with an equimolar concentration of either fresh or aged KDGIVNGKVA. Statistical significance was assessed by 
ANOVA with the Bonferroni test. Significant differences were those with p-values <0.05. 
 
4.3.5.6 A53T 
 
A53T aSyn is reported to aggregate more rapidly than the WT protein and alone it readily 
forms numerous long, straight fibrils (Figure 4-16 A) (126). These morphologically look very similar 
to those formed by the WT protein alone (Figure 4-11 A). In the presence of equimolar fresh or aged 
KDGIVNGVKA peptide the fibrils are drastically reduced in length (Figure 4-16 B&C). A lengths 
analysis of the fibrils on the grid (Figure 4-16 D&E) shows that species present in the samples 
incubated with peptide generally range from 50-250nm in length, whilst for A53T alone there is a 
much broader distribution with over 10% >1µm. These differences in length are statistically 
significant, as determined by ANOVA. The samples incubated with fresh KDGIVNGVKA also seem to 
be more prone to twisting. The ThT fluorescence (Figure 4-16 F) increases over time, as the protein 
begins to aggregate. The statistical significance of these measurements has been assessed by 
ANOVA (Table 4-6). After 7 days there were no significant differences between the samples despite 
the clear differences observable by TEM. Given the largely similar appearance of the fibrils in the 
three conditions it seems likely that the ‘end product’ – the fibrils – are similarly able to bind ThT, 
whether long or short. It also suggests that there is a similar overall amount of fibril formed in the 
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three samples. The statistically significant differences between A53T alone and the samples with 
KDGIVNGVKA at day 1 may be an indication that the A53T alone aggregates faster, and that 
KDGIVNGVKA slows it down. After this time point, the other two samples have caught up. 
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Figure 4-16 – TEM fibril lengths analysis and corresponding ThT endpoint data of A53T aSyn incubated with/without 
fresh or aged KDGIVNGVKA. 100µM A53T aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed (D) was performed and revealed that the incubation of A53T aSyn with fresh or aged KDGIVNGVKA 
reduces the size of most fibrils to below 200nm. The fibril lengths data is also shown in box-and-whisker plot format (E). 
The upper and lower limits of the boxes indicate the 25th and 75th percentiles of the data, whilst the horizontal line and 
small square indicate the median and mean respectively. The “whiskers” indicate the 5th and 95th percentile range of the 
data. The number of length measurements taken for each condition were as follows: A53T alone (62), plus fresh 
KDGIVNGVKA (68), and plus aged KDGIVNGVKA (52). Statistical significance was assessed by ANOVA with the Bonferroni 
post hoc test. * denotes significant differences to the 0.05 level with all other samples, † denotes significantly different to 
the 0.05 level from the fresh KDGIVNGVKA sample, and ‡ denotes significantly different to the 0.05 level from the aged 
KDGIVNGVKA sample. Corresponding ThT measurements (F) were performed – in triplicate – on sample aliquots taken at 
day 0, 1, 3, and 7. Three experimental plates were prepared, but due to saturation only data from one is shown. 
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Table 4-6 - Table showing the statistical significance of the differences in the ThT data between A53T alone, with fresh 
KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate with 100µM A53T aSyn, or 
with an equimolar concentration of fresh or aged KDGIVNGVKA peptide. Statistical significance was assessed by ANOVA 
with the Bonferroni test. Significant differences were those with p-values <0.05. 
 
4.3.5.7 A53E 
 
A53E is the most recently identified PD-linked point mutation in aSyn (77). It is thus the 
least characterized and little is known about its rate of aggregation and the fibrils that it forms. As 
can be seen by TEM, A53E by itself forms fibrils that are generally quite short and rarely exceed 
300nm (Figure 4-17 A&D). This stands in contrast to many of the long fibrils formed by WT and the 
other aSyn mutants. The general fibril-forming propensity of the protein appears reduced in the 
presence of fresh KDGIVNGKVA as fewer fibrils were seen on the grids. Incubation with the fresh 
peptide also encouraged the formation of shorter amyloid fibrils, with over 50% observed being 50-
100nm (Figure 4-17 B&D). The impact of aged KDGIVNGVKA on the length or number of fibrils was 
not quite so profound, and appeared quite similar to those formed by A53E alone (Figure 4-17 C). 
The ThT fluorescence of the samples increases over time, in line with the formation of β-rich species 
and fibrils (Figure 4-17 F). The statistical significance of the changes in ThT fluorescence was 
assessed by ANOVA, and significant differences were only measured at day 3 between the samples 
of A53E and the aged peptide compared to the samples of A53E alone or with the fresh peptide 
(Table 4-7). This may indicate that by the third day of incubation with the aged peptide that A53E 
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has proceeded down an aggregation pathway that is measurably different by ThT-assay and results 
in the differences seen by TEM – although by day 7 the differences in the ThT are no longer 
statistically significant. This would suggest that some oligomer or prefibrillar species in this 
alternative aggregation pathway binds to ThT more strongly than species formed in the other 
sample conditions and contains cross-β architecture. 
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Figure 4-17 – TEM fibril lengths analysis and corresponding ThT endpoint data of A53E aSyn incubated with/without 
fresh or aged KDGIVNGVKA.  100µM A53E aSyn alone (A), with 100µM fresh KDGIVNGVKA peptide (B), or with 100µM 
aged KDGIVNGVKA (C) was incubated at 37°C for 1 week with agitation and analysed by TEM. Lengths analysis of the size 
of the fibrils formed (D) was performed. A53E alone forms lots of fibrils generally shorter than 300nm. The incubation of 
A53E with the aged peptide does not substantially change the distribution of lengths compared to the protein alone, but 
fresh KDGIVNGVKA does heighten the proportion of fibrils that are 50-100nm in length. The fibril lengths data is also 
shown in box-and-whisker plot format (E). The upper and lower limits of the boxes indicate the 25th and 75th percentiles of 
the data, whilst the horizontal line and small square indicate the median and mean respectively. The “whiskers” indicate 
the 5th and 95th percentile range of the data. The number of length measurements taken for each condition were as follows: 
A53E alone (75), plus fresh KDGIVNGVKA (42), and plus aged KDGIVNGVKA (43). Statistical significance was assessed by 
ANOVA with the Bonferroni post hoc test. * denotes significant differences to the 0.05 level with all other samples, † 
denotes significantly different to the 0.05 level from the fresh KDGIVNGVKA sample, and ‡ denotes significantly different 
to the 0.05 level from the aged KDGIVNGVKA sample. Corresponding ThT measurements (F) were performed – in triplicate 
– on sample aliquots taken at day 0, 1, 3, and 7. Three experimental plates were prepared, but due to saturation only data 
from one is shown.  
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Table 4-7 - Table showing the statistical significance of the differences in the ThT data between A53E aSyn alone, with 
fresh KDGIVNGVKA, or with aged KDGIVNGVKA. ThT measurements were conducted in triplicate with 100µM A53E aSyn, 
or with an equimolar concentration of fresh or aged KDGIVNGVKA peptide. Statistical significance was assessed by ANOVA 
with the Bonferroni test. Significant differences were those with p-values <0.05. 
 
4.3.5.8 Summary of the effect of KDGIVNGVKA on α-synuclein fibril structure 
and aggregation propensity 
 
The results of the TEM and ThT experiments on WT aSyn and the PD-linked point mutations 
are summarized (Table 4-8). KDGIVNGVKA generally has an effect on all of the proteins in one shape 
or form, and these effects are fairly consistent regardless of whether the peptide is fresh or aged – 
with some exceptions. In most cases KDGIVNGVKA results in the formation of shortened amyloid 
fibrils with a similar morphology to those formed by the protein itself, but there are exceptions. The 
mean length of G51D and A53E fibrils did not change/increased in the presence of the peptide 
(Figure 4-15 E and Figure 4-17 E) compared to protein alone whilst A30P in the presence of the 
peptide formed species more reminiscent of oligomers than fibrils (Figure 4-12 B-C).  Comparisons 
of the ThT data are a little challenging due to error. Errors for data at the initial timepoints are low 
– indicating little in terms of systematic error – but at day 3/7 the errors for most samples are quite 
large. This is likely due to the aggregates physically impeding the passage of light in the samples; 
this is unavoidable. However ThT remains useful because samples that look similar by TEM can give 
quite different ThT measurements. This means that ThT can be used to provide indications 
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regarding the morphology or the quantity of fibrils. Ultimately, TEM and ThT must be used together 
to overcome the pitfalls of each and provide a holistic view of protein aggregation. The bearing the 
presence of fresh or aged KDGIVNGVKA has on the cell toxicity of aSyn has not been investigated 
here due to time constraints. However, this would be the next logical aspect to investigate.  
Table 4-8 - Table summarizing the results of the TEM and ThT experiments for WT and PD-linked aSyn mutants. Green 
= affirmative, red = negative. 
 
 
4.3.6 1D NMR & WaterLOGSY analysis of binding of KDGIVAGVKA and 
KAGIVNGVKA to α-synuclein 
 
Alanine variants of the KDGIVNGVKA peptide, KDGIVAGVKA and KAGIVNGVKA, were used in 
repeats of the 1D and WaterLOGSY binding analysis experiments conducted in 4.3.3. These 
experiments were conducted in an effort to elucidate the role (if any) the Asp and Asn residues in 
KDGIVNGVKA have on binding to aSyn. This is particularly pertinent given the known modifications 
occurring at these sites in KDGIVNGVKA, as demonstrated in Figure 4-7 and Figure 4-8. 
The 1D NMR experiments revealed a reduction in the intensity of the KAGIVNGVKA peaks in 
the samples of peptide plus aSyn in comparison to those controls of peptide alone (Figure 4-18 A-
C). The difference in the intensity of these peaks increased over the course of the seven days of the 
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experiment. This was not observed in the case of the KDGIVAGVKA peptide, suggesting an inability 
of this peptide to bind to aSyn (Figure 4-19 A-C). These findings were also seen in the WaterLOGSY 
experiments on the two peptides (Figure 4-18 D-F & Figure 4-19 D-F).  
This data supports the hypothesis in the case of the KDGIVNGVKA and KAGIVNGVKA peptides 
and that the peptide binds to aggregated forms of aSyn that form over the course of time. It also 
suggests that the Asn residue is of importance in the context of binding. In KDGIVAGVKA peptide 
lacking Asn, no decrease in the intensity of the peptide peaks was visible in the sample of peptide 
plus protein compared to the sample of peptide alone. A drop in the intensity of the peptide signals 
in samples of peptide plus protein compared to samples of peptide alone suggest that the peptide 
is interacting with large NMR-invisible species. The differences in the 1D with the KAGIVNGVKA are 
larger than those seen for the original KDGIVNGVKA peptide, which may suggest that it may be a 
better binder, although this is not seen in the WaterLOGSY data (Figure 4-18). It should be noted, 
however, that better binding does not necessarily equate to it being a better inhibitor of aSyn 
aggregation.  
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Figure 4-18 – 1D and WaterLOGSY spectra of KAGIVNGVKA peptide with and without WT aSyn at day 0 and day 6, and plots of differences in area under the peaks between spectra of 
KAGIVNGVKA alone and KAGIVNGVKA with WT aSyn. 1D spectra at day 0 (A) and day 6 (B) of 1mM KAGIVNGVKA alone (black) and with 50µM WT aSyn (red).The differences in the calculated 
area under the peaks of the spectra of peptide alone and in the presence of WT aSyn (C) are increased at day 6 than at day 0. WaterLOGSY spectra at day 0 (D) and day 6 (E) of these same 
samples are shown. The differences in area under the peak of these spectra are shown (F). These differences are also much increased at day 6 compared to day 0. These increases suggest a 
reduction in the peptide signals in those samples that contain WT aSyn compared to those of the peptide alone. The reduction in the peptide signal intensity is evidence in favour of a direct 
interaction between KAGIVNGVKA and large aSyn species (e.g. oligomers) that are “NMR-invisible”. 
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Figure 4-19 - 1D and WaterLOGSY spectra of KDGIVAGVKA peptide with and without WT aSyn at day 0 and day 6, and plots of differences in area under the peaks between spectra of 
KDGIVAGVKA alone and KDGIVAGVKA plus WT aSyn. 1D spectra at day 0 (A) and day 6 (B) of 1mM KDGIVAGVKA alone (black) and with 50µM WT aSyn (red).The differences in the calculated 
area under the peaks of the spectra of peptide alone and in the presence of WT aSyn (C) are reduced at day 6 than at day 0. WaterLOGSY spectra at day 0 (D) and day 6 (E) of these same samples 
are shown. The differences in area under the peak of these spectra are shown (F). These differences are also reduced at day 6 compared to day 0. The fact that the peptide signals in the sample 
of KDGIVAGVKA alone are not lower than those in the sample of KDGIVAGVKA plus WT aSyn would suggest that there is no binding to WT aSyn.  
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4.3.7 ThT and TEM analysis of α-synuclein incubated with 
KDGIVAGVKA or KAGIVNGVKA 
 
This is a repeat of the work carried out in 4.3.5.1 using the alanine variants of the peptide 
instead, KDGIVAGVKA and KAGIVNGVKA (Figure 4-20). It is clear from the TEM grids that neither 
fresh KDGIVAGVKA nor fresh KAGIVNGVKA do not abrogate the ability of aSyn to form amyloid 
fibrils (Figure 4-20 A&B). This is supported in the ThT data (Figure 4-20 C); both fresh peptide 
samples have the highest ThT-fluorescence at day 7, indicating the formation of amyloid fibrils (as 
seen in the TEM). However, it should be noted that the fluorescence of the samples incubated with 
the aged forms of these peptides have a comparable fluorescence to that of WT aSyn alone. There 
were also some fibrils visible by TEM, but not as prevalent as on the grids of WT aSyn alone. This 
may indicate either fewer fibrils, or that the fibrils have a lower affinity for ThT, or a combination 
of both of these factors. The fibrils formed in the presence of the aged KDGIVAGVKA also appear 
quite short in comparison to the fibrils formed by WT aSyn alone. Given the lack of Asn in this 
peptide and that the aged peptide has a different effect to the fresh form, it may be an indication 
that the formation of iso-Asp in this peptide is having more of an impact on fibril formation. 
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Figure 4-20 - TEM images and ThT endpoint reads of fresh and aged KDGIVAGVKA and KAGIVNGVKA with WT aSyn. 
TEM images of 100µM WT aSyn with 100µM fresh or aged KDGIVAGVKA (A) and 100µM fresh or aged KAGIVNGVKA (B) 
were incubated at 37°C for 1week. Aliquots taken at different timepoints were used for ThT endpoint reads (C). All 
measurements were carried out in triplicate on the plate. n=1. 
 91 
 
 
4.3.8 WaterLOGSY NMR analysis of binding of alanine-scanning 
peptide variants to α-synuclein 
 
Given the seeming abolition of binding to aSyn with the KDGIVAGVKA peptide, but not the 
KAGIVNGVKA peptide, further alanine-scanning variants of the peptide were prepared in an effort 
to identify those residues most essential for binding. These peptides were KDGAVNGVKA (A4), 
KDGIANGVKA (A5), KDGIVNAVKA (A7), and KDGIVNGAKA (A8). WaterLOGSY experiments identical 
to those conducted for the previous peptides were performed on these peptides. The results are 
not directly comparable due to an NMR system upgrade, however it is clear from the results of 
these experiments that the A7 and A8 peptides exhibit the same behaviour as seen for both 
KDGIVNGVKA and KAGIVNGVKA, in that the difference in peak intensity between the samples of 
peptide alone and peptide plus protein increases over time (Figure 4-21). This is indicative of their 
binding to aSyn aggregates. However, this was not seen for the A4 or A5 peptides. In conjunction 
with the data from the KDGIVAGVKA peptide this would suggest that the residues 4-6 
(KDGIVNGVKA) are essential for binding to aSyn.  
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Figure 4-21 - Plot showing the difference in WaterLOGSY peak intensity over time for alanine-scanning variants of 
KDGIVNGVKA. WaterLOGSY spectra were collected for each of 1mM KDGAVNGVKA (A4), KDGIANGVKA (A5), KDGIVNAVKA 
(A7), and KDGIVNGAKA (A8) alone and with 50µM WT aSyn. The difference in the area under the peptide peaks was 
calculated from the aromatic region (6-9ppm) of WaterLOGSY spectra collected at the initial timepoint (day 0) and a week 
later (day 6), following the incubation of the samples at 37°C with agitation. Negative differences are not shown. The 
positive differences seen for the A7 and A8 peptides are indicative of binding. 
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4.4 Discussion 
 
From the results of the experiments carried out in this chapter it seems that the ten-residue 
peptide KDGIVNGVKA is indeed binding to alpha-synuclein. The lack of peak shifts in the HSQC 
spectrum upon the addition of the peptide to aSyn suggest that it is not binding to the monomeric 
protein (Figure 4-2). The loss of peaks over time in the HSQC spectrum, in both the presence and 
absence of the KDGIVNGVKA peptide, suggests that the peptide does not prevent the aggregation 
of aSyn to the point where it reaches a size exceeding the size-limit of NMR (Figure 4-3). It is clearly 
apparent from TEM data that the peptide does impact aSyn aggregation, and it results in the 
formation of dramatically shortened fibrils (Figure 4-11). This may be through some form of 
‘capping’ mechanism that prevents fibril elongation, and would explain the lack of observable peak 
shifts in the HSQC titration data. In an effort to probe this 1D and WaterLOGSY NMR experiments 
were used with the aim of focusing on the peptide itself, rather than trying to directly observe 
changes in the protein signals. Through this strategy depletions in the peptide signal were observed 
over a time period corresponding to that of aSyn aggregation; this was only seen for those samples 
containing both aSyn and KDGIVNGVKA, but not those of peptide alone (Figure 4-4). This provides 
an indication that as aSyn begins to aggregate to the point where it is no longer NMR-visible that 
the peptide binds to these species and its own signal is also lost. This hypothesis is supported by 
TEM data which shows that aSyn incubated in the presence of the peptide still forms fibrils, but of 
a much shorter length as if their elongation has been perturbed (Figure 4-11).  
 Interestingly, whilst probing this interaction through NMR it became evident that the 
KDGIVNGVKA peptide was subjected to modification over the timeframe of the experiment (Figure 
4-5). Through the use of natural abundance HSQC experiments and MS this was determined to be 
a deamidation modification taking place at the Asn residue (Figure 4-6, Figure 4-7, and Figure 4-8). 
The precise impact of this modification on the binding of the peptide to aSyn is unclear. It cannot 
be ruled out from the results generated in this chapter that the deamidation has a) no impact; b) 
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improves the binding to aSyn; or c) impedes binding to aSyn. However, repeating the experiments 
with alanine-scanning variants of KDGIVNGVKA it became clear that the indications of binding seen 
in the 1D and WaterLOGSY data for KDGIVNGVKA were not seen if any of the three-residue stretch 
IVN were modified (Figure 4-21). This suggests that the IVN motif is necessary for binding, and this 
may imply that the deamidation of the Asn would be counter-productive with regards to binding. 
 The apparently successful identification of the region on the peptide responsible for binding 
is a step in the right direction, however the region of aSyn to which it binds could not be elucidated. 
The KDGIVNGVKA peptide was initially developed with the aim of targeting the 45-54 region of aSyn 
(108). However, it should also be noted that despite this the peptide seemed to remain effective 
against most of the PD-linked mutants, despite all-bar-one of these mutations occurring in this 
region (Table 4-8). Additionally, the initial experiment was aimed at targeting the monomeric form 
of aSyn, and yet the evidence here points to KDGIVNGVKA binding to aggregated forms of aSyn. 
There may be several possible explanations for these apparent dichotomies. It’s possible that within 
the cells (in which the peptide library was initially screened) that aSyn began to aggregate and the 
peptides were better able to bind to this than the monomeric protein. The library screening 
technique described by Cheruvara et al also bears resemblance to the well-known yeast two-hybrid 
assay (108). This is an assay that is notorious for generating false positives (127). It is possible that 
the KDGIVNGVKA is one such false positive; but unusually, despite being a false positive in terms of 
monomeric aSyn, is able to bind to aggregated aSyn. 
 Studying this system has proved enormously challenging for a host of reasons. Chief 
amongst these is the nature of aSyn as a dynamic system. This dynamism makes it impossible to 
study aSyn by X-ray crystallography, and the utility of NMR rapidly fades as aSyn begins to aggregate 
and line-broadening becomes prohibitive. These circumstances led to the use of NMR in attempt to 
observe changes in the peptide induced by binding, rather than by looking directly at aSyn. This was 
complicated by the discovery that the peptide was changing over time, which made it difficult to 
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compare data at different time-points. Additionally, the 1kDa 10-residue peptide is in an unusual 
half-way house between being a very small protein and a substantially large small-molecule. This 
makes the utilization of many of the NMR experiments designed to probe ligand binding (including 
WaterLOGSYs) more challenging. The characteristic sign-inversions seen in WaterLOGSY 
experiments using small-molecules are not seen with a 1kDa peptide, and thus changes in peak 
intensity were measured here instead. This is not ideal, however it was the best strategy available 
and has provided insight into the binding between aSyn and KDGIVNGVKA. Other strategies for 
studying the peptide-protein interactions here, such as ITC and FRET, were ruled out due to the 
heat changes resulting from aSyn aggregation and the need for bulky fluorescent tags respectively. 
 The utility of using peptides to prevent the aggregation of amyloidogenic proteins, like 
aSyn, is open to debate. Peptides have a number of advantages over smaller molecules, particularly 
that they are generally more specific and thus less prone to off-target effects. However, they also 
have a number of disadvantages that have historically ruled them out of being considered ‘serious’ 
therapeutic molecules (97). These are namely that they are prone to proteolytic cleavage, 
modification (e.g. deamidation), and difficulties may be encountered in getting them to the desired 
target. Some of these issues have started to be overcome, however. For example, to protect them 
from cleavage/degradation peptides may be altered with modifications, such as acetylation or 
amidation. Additionally, some of the issues surrounding targeting/penetrance can be overcome 
through the addition of specific localization sequences or by packaging the peptide into lipid vesicles 
(97,128). Targeting the brain is especially difficult given the BBB. This may possibly be overcome by 
allowing the peptide to ‘piggyback’ across with another molecule for which there is a specific 
transporter at the BBB (e.g. glutathione) (129).  
There are several other pitfalls that may be associated with the use of KDGIVNGVKA as a 
therapeutic for PD. Firstly, assuming that it was beneficial to inhibit the aggregation of aSyn as a 
treatment for targeting PD, it would likely require very early diagnosis. KDGIVNGVKA does not 
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exhibit any capacity for disaggregation of pre-exisiting fibrils, and is only preventative. Therefore, it 
would necessitate the identification of biomarkers that could be used to target those individuals 
going to develop PD before the manifestation of the hallmark clinical symptoms. Secondly, whether 
the inhibition of aSyn fibril elongation is beneficial is an open question. It is now widely considered 
that oligomers, rather than the fibrils themselves, that are species responsible for mediating toxicity 
(130). If this is the case then it may be that disrupting the kinetics of fibril formation could result in 
an increase in the supply of toxic oligomers, and thus the peptide may enhance neurodegeneration 
rather than abate it. 
It is clear much future work is required if this peptide is going to progress further. Obvious 
steps include the systematic study of the alanine-scanning variants of KDGIVNGVKA and compare 
and contrast the TEM/ThT data; this is currently being undertaken by collaborators at the University 
of Bath. Also useful would be to carry out in vivo studies of the effects of the peptide on a PD-model 
organism. Models of PD in C.elegans may be an option. These systems are relatively easy and cheap 
to maintain, and they can exhibit visible signs of PD (e.g. rigidity and impaired movement) (131). 
The administration of the peptide would also be possible by packaging it into lipid vesicles. 
Depending upon the outcome of such experiments further downstream work could be considered. 
Despite these numerous hurdles, this is a promising area of research that should be pursued in the 
future. 
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5 NMR metabolomics study of peptide mode-of-action 
5.1 Introduction 
 
5.1.1 What is metabolomics?  
 
Metabolomics is a nascent field of study and one of the newest members of the ‘omics family, 
which also includes genomics, proteomics, and transcriptomics. The ‘omics fields each aim to 
characterize a different layer of biological activity, with each having its own advantages and 
associated pitfalls. It is a holy grail of modern biology/biochemistry to integrate all of the data 
output by these studies to compile a holistic ‘phenome’. The metabolome – the profile of the 
metabolites (small molecules) in a cell or entity at a given time – represents the most direct 
observation of the state of the cell/tissue/sample at a given point in time.  
Metabolomics studies are generally conducted using either NMR or MS, again with each 
having their own advantages and limitations (132). NMR metabolomics is useful because it provides 
a highly-reproducible picture of small molecules within the sample; there is no separation step 
beforehand. It is also non-destructive meaning that samples may be re-analysed. However, in 
comparison to MS it is insensitive and requires a larger sample volume. Additionally, MS 
instrumentation is much more widely available and is very likely present in most research 
laboratories and clinical labs. NMR equipment – and by extension expertise in NMR metabolomics 
– is far less common, and this can prove to be a significant hurdle to a metabolomics study. 
5.1.2 Why conduct NMR metabolomics experiments? 
 
NMR metabolomics experiments are an extremely powerful way of reporting on the actual 
effects of different conditions or variables on a system. This is because the vast majority of 
metabolites contain 1H and thus possess an intrinsic NMR signature without the need for chemical 
modification. NMR is also a solution-based technique and thus samples can typically be studied 
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directly.   Disease impacts the metabolic profile of cells and this is probeable by NMR metabolomics. 
This can be exploited for the identification of novel biomarkers and the development of new 
therapeutics (133). For example, NMR metabolomics has been used to investigate the differential 
effects of incubation of monomers, oligomers and fibrils of aSyn and Aβ on SH-SY5Y neuroblastoma 
cells (109). This work saw significant differences in levels of metabolites associated with 
neurotoxicity and inflammation, including taurine, creatine, and glutamine. This presented a model 
system to probe the effects of KDGIVNGVKA on aSyn aggregation in more detail, as NMR 
metabolomics could be used to monitor the relative levels of these same metabolites in cells 
challenged to aSyn in the presence and absence of the peptide. 
5.1.3 Outline of statistical methods used in NMR metabolomics 
 
NMR metabolomics, like the other ‘omics disciplines, generates huge quantities of data that 
are difficult to directly interpret and therefore statistical analysis is essential. Some of the more 
commonly used methods and techniques to interpret NMR metabolomics data are outlined here. 
5.1.3.1 Normalization and scaling of data 
 
Normalization is a procedure applied across data, in this case across different NMR spectra, 
in order to account for unwanted biases (e.g. differences in the number of cells or dilution effects) 
(134–136). This then enables the comparison of these spectra for downstream statistical analysis. 
For example, if peaks associated with one metabolite differ across two samples it needs to be 
known that is not simply the result of one sample being derived from a larger or smaller number of 
cells. Normalization achieves this and means that samples can be assessed in terms of variables of 
interest. The metabolomics data analysis in this chapter was conducted through the MetaboAnalyst 
web server, which allows for the use of multiple different types of normalization, including: 
normalization by sum, normalization by median, and quantile normalization (137,138). 
Normalization by sum means that all of the features across each spectrum are added together and 
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used to produce a normalization factor. This basic type of normalization assumes that the total 
concentration of metabolites in each sample is consistent, and it also means that highly abundant 
metabolites contribute more than less abundant metabolites. This means that the normalization 
factor is very sensitive to changes in the concentration of highly abundant metabolites, which could 
be disadvantageous. Normalization by median on the other hand operates by calculating the fold 
change in the intensity of every bucket/metabolite in one spectrum against a target spectrum. The 
median fold-change is then used to generate a normalization factor, which is unaffected by changes 
in just a few metabolites. Quantile normalization operates by calculating a normalization factor 
based upon spectra presenting exactly the same distribution of peak intensities (134,136).  
Scaling of data is a related process but is applied to peaks within an individual spectrum to 
allow their comparison (135,136). In a spectrum there will be metabolites with a high abundance 
and there will be those at a lower abundance. Big differences in metabolites of low abundance may 
be of greater importance than smaller differences in metabolites with a higher abundance, but the 
methods used to display the data, such as principal component analysis (PCA) and principal least 
squares discriminant analysis (PLS-DA), do so in such a way to show the maximum variance. Thus, 
they would favour those metabolites that are highly abundant over those at lower abundance. 
Scaling is the method by which this is overcome and makes the differences between high 
abundance and low abundance metabolites within a spectrum more comparable. There are 
multiple types of scaling, and MetaboAnalyst allows for: mean centering, auto-scaling, Pareto 
scaling, and range scaling (139). The auto-scaling, Pareto scaling methods and range scaling 
methods also incorporate mean centering. Mean centering is the subtraction of the mean of all the 
peaks from each peak, enabling variables to be reported as higher than (positive) or lower than 
(negative) the mean. This does little to prevent one or two highly abundant metabolites from 
completely dominating the dataset, and so scaling is required (136). In auto-scaling the data is mean 
centered, and then subsequently the standard deviation of all the peaks is subtracted from all of 
the peaks (136). In Pareto scaling the peaks are mean centered, and then subsequently the peaks 
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are divided by the square-root of the standard deviation of the mean centered data (136). This is a 
trade-off between just applying mean centering, which maintains bias in favour of highly abundant 
metabolites, and auto-scaling which can go so far in providing a level playing-field between highly 
abundant and less abundant metabolites that it can bias in favour of noise and irrelevant features 
(136).  Range scaling is another alternative, in which the mean centered data is divided by the range 
(the difference between the largest and smallest values). Whilst it can be a useful method it should 
be treated with caution as it can give undue influence to extremes in the data (136).  
5.1.3.2 Univariate analysis 
 
Univariate methods of statistical analysis, such as T-tests and  one-way ANOVA, only 
consider one variable at a time (140). Univariate analysis is useful because it is easy to interpret, 
although it does not explore correlations between variables (metabolites) and requires adjustment 
to counteract compounding errors associated with performing multiple tests (for each metabolite 
peak). For more complicated datasets multivariate analyses may be preferable as they can enhance 
understanding of the effects in multiple metabolites and avoid the need for conservative 
adjustments to account for compounded error. Physical characteristics and how they relate to 
disease (height, age, body-mass index, etc.) are a good example. A univariate analysis can only 
consider one characteristic at a time whilst a multivariate analysis has the power to explore which 
characteristics (if any) are most indicative of a disease state. 
5.1.3.2.1 Welch’s T-test 
 
The Welch’s T-test is a univariate statistical method for determining whether samples 
adhere to the normal distribution (a bell or Gaussian distribution of values) (Figure 5-1A). Under the 
null hypothesis – an assumption that there is no divergence from this normal distribution – 
measurements should all fall within the normal distribution (Figure 5-1B). Failure to do this suggests 
that there is a deviation between the two conditions or that the sample collected in on the extreme 
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of the normal distribution (Figure 5-1C). The T-test calculates how “common” the measured data 
would be assuming it adhered to the normal distribution. This is where the p-value is introduced, 
and is why when the p-value is below a set threshold (e.g. 0.05) the null hypothesis is rejected. 
 
Figure 5-1 - The normal distribution and whether to accept or reject the null hypothesis. The normal distribution is shown 
(A) with the proportion of the data shown according to the distance from the mean in terms of standard deviation. The 
null hypothesis assumes that the populations adhere to the normal distribution and that they have the same means (B). If 
this is not the case then the null hypothesis is rejected (C). 
5.1.3.2.2 Analysis of variance 
 
The one-way ANOVA is a univariate statistical technique akin to the T-test that is useful 
when comparing multiple groups. The one-way ANOVA is used when only one independent variable 
is considered, however two-way ANOVAs that consider two independent variables are also 
available. These were not used in this study given the number of variables to consider. The use of 
multiple independent univariate tests when comparing multiple groups is considered sub-optimal 
as it increases the likelihood of a type I error (141). This occurs when the null hypothesis is rejected, 
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but it is true (a false positive). This can be accounted for in the one-way ANOVA using the Benjamin-
Hochberg false-discovery rate (FDR) correction (142). The one-way ANOVA will, however, only 
report that there is a significant difference between groups; it does not give any information as to 
which groups these are. Consequently, there is a need for post-hoc tests to provide this information. 
In MetaboAnalyst Fisher’s least significant difference (LSD) method was used as the post hoc test in 
this study (137,138).  
5.1.3.3 Multivariate analysis 
 
Multivariate methods of analysis, such as PCA and PLS-DA, are mathematical procedures 
that differ from univariate methods in that these take into account multiple different variables in 
the data at the same time (140). This is useful in the context of biological experiments because the 
results are often multi-factorial. For example, the rate of growth of bacteria may be affected by cell 
line, richness of growth medium, the temperature, aeration etc; this is a multivariate system for 
which a multivariate analysis must be conducted to allow proper interpretation. 
5.1.3.3.1 Principal components analysis 
 
PCA is a multivariate data transformation technique that strives to condense the 
dimensionality of variance within a sample by condensing multiple variables into so-called principal 
components (143). In a dataset there are some variables that are responsible for more variance 
than others, and some that may correlate/covariate. The principal components are new variables 
containing combinations of the original variables (as identified by the algorithm), and the first 
principal component presents the largest possible amount of “explained” variance in the data (143). 
The second principal component then explains the next largest, and so on. In doing this, the most 
important information is retained and the dataset can be explained in terms of a few principal 
components instead of a larger number of variables. 
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PCA is an unsupervised technique, meaning that it is given no prior information about the 
sample groups. For example, if bacterial growth was monitored under different conditions the PCA 
would not “know” that groups may be the different cell lines. It will simply project the data to show 
the maximum amount of variance possible. Principal components can be projected as a scores plot 
(Figure 5-2A). The “scores” refer to the degree to which the different principal components 
contribute to the variance of each of the samples. The principal components are then used as axes, 
and the data can be plotted in these terms. The loadings plot is similar to the scores plot in that its 
axes can be any of the principal components, but instead of plotting the different samples the 
factors contributing to the variance in the principal components are plotted instead – in this case it 
is the metabolite signals (Figure 5-2B). Also useful in the interpretation of PCA data is the biplot 
which is a combination of the scores plot and loadings plot (Figure 5-2C). Mean-centred data 
enables the axes to bisect 0, and thus points on these points further from 0 are more varied than 
those closer to 0 on any axis. 
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Figure 5-2 - Methods of representing PCA data. A scores plot (A) is shown, and the samples from two conditions have 
been plotted according to their variance in terms of the two principal components. A loadings plot (B) shows which 
characteristics – in this case metabolites – contribute the most to the variance in the two principal components. Here, 
taurine and creatine contribute strongly to the variance in the first principal component, whilst alanine and glutamine are 
most important in the second principal component. The biplot (C) combines the scores plot (A) and the loadings plot (B) to 
show the samples and those metabolites contributing to the most variance. 
  
5.1.3.3.2 Partial least squares-discriminant analysis 
 
PLS-DA  is a multivariate data transformation technique, or more formally a linear 
regression model (144). Like PCA, PLS-DA converts variables into new principal components and 
aims to increase separation between groups whilst minimizing the variance within groups. Unlike 
PCA, however, which is an unsupervised method, PLS-DA is a discriminant analysis or supervised 
method (145). This reflects that PLS-DA is given information about the class-labels whilst PCA is not. 
For example, if looking at bacterial growth under different conditions different cell lines PLS-DA will 
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perform a linear regression to establish the separation between these groups. An unsupervised PCA 
on the other hand would plot the data to show the greatest separation between samples, 
irrespective of their label. This supervised method can be useful to enhance separation, but can 
introduce bias and overfitting is easily achieved using this technique. This makes cross-validation of 
PLS-DA output essential before drawing any conclusions. The advantages and limitations of this 
method have been described in great detail elsewhere (146). 
Many of the plots used to display PLS-DA data are similar to those used for PCA (Figure 5-2). 
However, in addition to this variable importance in projection (VIP) plots are also used. VIP scores 
are calculated for each of the metabolites and are weighted sum of squares of the PLS loadings, 
taking into account the amount of explained Y-variation in each dimension. Essentially, the VIP plot 
shows those metabolites responsible for the most variance between the classes and their relative 
levels across them (e.g. creatine may be responsible for most variance and is elevated in condition 
1 in comparison to condition 2). 
5.1.3.4 Cross-validation 
 
Cross-validation is essential when analysing mathematical models, especially with 
supervised methods such as PLS-DA. These methods are often associated with overfitting, which 
means that the model is being fit to the noise. In the work conducted here the leave-one-out cross 
validation (LOOCV) method is utilized. The metrics Q2 and R2 may be used to assess the quality of 
the PLS-DA model as reported by the MetaboAnalyst server (138). Calculation of Q2 and R2 operates 
on the basis of a small subset of data being set-aside from the dataset and not used in the 
generation of a model. Following the generation of a model this small subset (the reference set) of 
data is then used to see how well the model fits. R2 and Q2 are percentages indicating how close 
the data are to the fitted regression, so a higher number indicates a closer fit. The R2 is the value 
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for the dataset as a whole, whilst the Q2 is the value when the model is applied to the reference set 
of data (147). 
5.1.4 Aims 
 
In the study by Phelan et al it was shown that the exposure of SH-SY5Y cells to aSyn (and Aβ) 
resulted in changes in the level of various metabolites (including taurine and creatine) that were 
associated with inflammation and neurotoxicity (109). These effects were distinct, however 
depending on whether the cells were exposed to monomeric, oligomeric or fibrillar protein. From 
this study a library of the metabolites in SH-SY5Y cells was available.  Using this library the aim was 
to use NMR metabolomics analysis to assist in investigating the effects of the KDGIVNGVKA peptide 
on aSyn toxicity. The hypothesis going into the study was that the incubation of KDGIVNGVKA 
peptide with aSyn reduced its toxicity, as seen by Cheruvara et al (108), and that this would be 
reflected in the metabolic profile of the cells when compared with those exposed to aggregated 
aSyn. On top of this NMR metabolomics would give detail into the mechanisms and pathways 
through which toxicity was mediated, and how the peptide mitigated this. NMR metabolomics 
studies necessitate precise control of experimental conditions and numerous control samples (see 
Table 5-1). In light of this it was possible to test multiple additional hypotheses. These included: 
 Exposure of cells to aSyn fibrils results in an increased level of metabolites associated 
with cell stress and death, when compared to monomeric aSyn.  
 That the exposure of cells to fresh or aged KDGIVNGVKA peptide alone results in no 
significant change in the metabolic profile of cells when compared to cells alone. 
 That exposure of cells to aSyn fibrils and independently incubated KDGIVNGVKA 
exhibits no difference in metabolic profile when compared to those exposed to aSyn 
fibrils alone, whilst differences are apparent when compared to aSyn fibrils formed 
in the presence of KDGIVNGVKA.  
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Table 5-1 - The different conditions to which the SH-SY5Y cells were exposed for NMR metabolomics experiments. 
Abbreviation Condition 
C PBS Blank 
P Fresh KDGIVNGVKA alone 
PA Aged KDGIVNGVKA alone 
M Monomeric WT aSyn alone 
MP Monomeric WT aSyn + Fresh KDGIVNGVKA (1:1) 
MPA Monomeric WT aSyn + Aged KDGIVNGVKA (1:1) 
F WT aSyn fibrils alone 
FPAT WT aSyn fibrils formed in the presence of KDGIVNGVKA peptide (1:1) 
FPAS WT aSyn fibrils + Aged KDGIVNGVKA (formed separately) 
FP WT aSyn fibrils + Fresh KDGIVNGVKA 
 
5.2 Methods 
5.2.1 Cell viability experiments 
 
Each condition (Table 5-1) was prepared to an equivalent monomer concentration of 55µM 
in PBS pH 7.4. Those peptide challenge conditions that did not require incubation over time (i.e. 
fresh) were snap frozen in LN2 before storage at -80°C. SH-SY5Y neuroblastoma cells were grown 
up in F-12 Ham’s media supplemented with 1x minimal essential medium (MEM), 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin (Pen-Strep). 5,000 cells were added to each well used 
in a 96-well plate and incubated at 37°C 5% CO2. After 24 hours 10µL of the challenge condition was 
added per well, with each condition having 6 repeats. PBS alone and 1% triton X-100 prepared in 
PBS pH 7.4 were used as “live” and “dead” cell controls, respectively.  The cells were left for 24 
hours before 10µL of CCK-8 reagent (Dojindo) was added to each well. After this, the absorbance at 
450nm was measured per hour for 4 hours on a FlexStation 3 (Molecular devices). Data was 
processed and analyzed using OriginLab. 
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5.2.2 Cell culture of NMR metabolomics samples 
 
Each condition (Table 5-1) was prepared as a 1.5mL ‘stock’ of 50µM protein and/or peptide 
in PBS pH 7.4. The PBS used in the experiment was all from a single batch prepared using a PBS 
tablet (Sigma). Those peptide challenge conditions that did not require incubation over time (i.e. 
fibrillation or ageing) were snap frozen in LN2 before storage at -80°C. Concomitantly, mycoplasma-
free SH-SY5Y neuroblastoma cells were cultured using Ham’s F12 nutrient mixture supplemented 
with 10% FBS, 1% Pen-Strep and 1x MEM non-essential amino acids (all Sigma) in a 37°C incubator 
with 5% CO2. Each peptide challenge condition was to be added to a T25 flask at 60 – 70% 
confluency at a final concentration of 5µM. Three clonal replicates (three flasks containing cells 
from the same batch) were required for each peptide challenge condition and thus the total number 
of T25’s required was 30. All cells were from the same batch and were of the same passage number 
(passage number = 21). As the samples had been prepared at 50µM in 1.5mL they were diluted in 
complete cell growth medium to 15mL to provide a final concentration of 5µM. The old cell medium 
was decanted from each flask and replaced with 5mL of the medium containing the peptide 
challenge conditions (three replicates x 5mL per flask = 15mL sample). The cells were incubated 
with the samples for a further 24 hours before harvesting. The “post-incubation” cell medium 
containing the protein/peptide was poured off and collected in 15mL Falcon tubes and frozen on 
dry-ice in case needed for later analysis. The cells were washed with PBS pH 7.4 to remove excess 
media and any dead cells. The cells were trypsinized using 1x trypsin-versene (Gibco). The trypsin 
was neutralized using complete cell medium and the cells transferred to pre-weighed Universal 
tubes. The cells were then spun down at 500g 4°C for 5mins. All supernatant was pipetted off and 
the mass of the tube was recorded (to 3 decimal places) to allow the determination of the total cell 
mass. The cell pellets were resuspended in 6mL of PBS and spun back down at 500g 4°C for 5mins. 
The PBS was pipetted off and the cell pellet carefully resuspended in 3mL of PBS. The 3mL of 
resuspended cells was split into 3x 1mL aliquots in Eppendorf tubes to serve as the three extraction 
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replicates. In total there were 90 Eppendorfs (10 conditions x three clonal replicates x three 
extraction replicates). The 1mL aliquots were spun down at 500g for 5mins at 4°C. The PBS 
supernatant was discarded and the pellets were snap frozen in LN2 and stored at -80°C for later 
extraction and analysis of polar metabolomics samples. 
5.2.3 Extraction of polar metabolites 
 
All steps were carried out on ice. The pellets were resuspended in 500µL of ice-cold 50% 
methanol, 50% double-distilled water (ddH2O). The samples were sonicated with an exponential 
micro-tip sonicator in an ice-batch at 23 kHz and an amplitude of 10µm for three 30s cycles with 
30s rest intervals. The samples were then vortexed for 30s before being centrifuged at 21,500g for 
5mins at 4°C. The supernatant was snap frozen in LN2 and lyophilized overnight. The pellets were 
snap frozen in LN2 and stored at -80°C for potential subsequent lipid extraction. 
5.2.4 Preparation of NMR metabolomics samples 
 
The lyophilized samples were resuspended in 200µL of 100mM sodium phosphate pH 7.4, 
with 100µM trimethylsilylpropanoic acid (TSP) (all prepared in 2H2O). The samples were vortexed 
and then centrifuged for 5mins at 21,500g at 4°C. Being careful not to dislodge any pelleted material 
the supernatant was loaded into clean 3mm (outer diameter) NMR tubes and placed in a 96-tube 
rack. 
5.2.5 NMR metabolomics data collection  
 
1D 1H NMR spectra were collected using pulse sequences based upon 1D NOE and Carr-
Purcell-Meiboom-Gill (CPMG) experiments. NMR spectra were acquired using a Bruker AVANCE 
IIIHD 700MHz spectrometer equipped with an automated SampleJet sample changer and a TCI 
gradient CryoProbe (Bruker). All spectra were collected at 298K with the temperature having been 
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calibrated using a 98% deuterated standard methanol sample and the methanol thermometer 
method of Amman et al (148). 1D 1H NOE spectra were collected with 32 scans, 4 dummy scans, an 
acquisition time of 2.726s, and a spectral width of 25.7491ppm. 1D 1H CPMG spectra were collected 
with 512 scans, 4 dummy scans, an acquisition time of 3.067s, and a sweep width of 17.1661ppm. 
TopSpin 3.5 pl 7 and IconNMR 4.6.7 (Bruker) were used for data acquisition and processing with 
standard processing routine comprising the line-broadening window function (0.3Hz), Fourier 
transformation, phasing, and referencing to TSP.   
5.2.6 NMR spectra quality control 
 
The quality of the NMR spectra were verified prior to any statistical analysis. This quality 
control entailed the analysis of the half-height line-width of the TSP peak, which should ideally be 
~1Hz, that the water suppression was successful and that the baseline peak was not distorted 
(149,150). Those samples that failed this initial quality control check were excluded and re-run on 
the spectrometer. Samples were also excluded if their signal:noise fell below the average total 
intensity of all spectra minus the standard deviation of the total intensity, which was 
58,106,308,602 AU.  
5.2.7 Annotation of NMR spectra and identification of metabolites 
 
AMIX (Bruker) was used to prepare bucket tables for submission to MetaboAnalyst (138), 
whilst TAME NMR (https://github.com/PGB-LIV/tameNMR) was used to optimize bucket 
size/positioning. Previous work by Phelan et al (MetaboLights ID: MTBLS455) meant that a 
preliminary metabolic profile of SH-SY5Y cells was available and that metabolites were already 
assigned for each bucket (109). 
5.2.8 Statistical analysis of NMR metabolomics data 
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All statistical analysis was carried out using the MetaboAnalyst server (138). Quantile 
normalization, mean-centering and Pareto scaling was applied (136). Welch’s T-test, ANOVA, PCA 
and PLS-DA analysis were all used to determine the separation between the groups. All statistical 
graphs and charts were produced by MetaboAnalyst. 
5.3 Results 
 
5.3.1 Cell viability experiment 
 
Cell viability experiments, complementary to the metabolomics study, were conducted as a 
more direct measure of the toxicity to cells and to ensure comparable cell numbers in the 
metabolomics study (backed up by the measured mass of cell pellets). The challenge conditions are 
listed in Table 5-1. The data showed consistent viability across all conditions as can be seen (Figure 
5-3). This is perhaps not entirely surprising as the cells were only challenged for 24 hours prior to 
measurement. This timeframe may be sufficient for differences to emerge in the metabolic profile 
of the cells but not sufficient to result in cell death. So long as the cells are metabolically active, 
formazan dye will be formed from the CCK-8 reagent and therefore the A450 will increase. 
Consequently this assay gives a binary assessment of whether the cells are alive or dead, and 
provides no information on the relative “health” of the cells. A one-way ANOVA was carried out to 
try and determine if any of the minor differences between the conditions were statistically relevant. 
Using the Bonferroni means comparison test no statistically significant differences were observed.  
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Figure 5-3 - Cell viability of cells exposed to the same conditions as used in the NMR metabolomics experiments. Cell 
viability was assessed using the CCK-8 reagent and measuring the absorbance at 450nm (A). Cell were challenged with 
identical conditions to those used in the NMR metabolomics experiments for 24 hours prior to measurement. Six wells 
were prepared for each condition. N=1.  Viability was consistent across all conditions and no statistically significant 
differences were determined by one-way ANOVA with the Bonferroni means comparison test. 
 
5.3.2 Initial spectral and statistical analysis 
 
In total there were ten different sample conditions (Table 5-1), and for each of these there 
were a further three clonal replicates and three extraction replicates generating a total of ninety 
samples. For each sample 1D 1H CPMG spectra were collected. These are widely used in NMR 
metabolomics as they can attenuate certain peaks according to their T2 and thus are used to remove 
the contribution from large molecules (e.g. proteins, polysaccharides) and improve the visibility of 
small molecules (151,152). Following on from the stringent quality control steps eighty of the 
original ninety collected spectra were useable (see Table 5-2).  
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Table 5-2 - Table showing the number of useable spectra per condition following quality control. 
Abbreviation Condition Number (after 
quality control) 
C PBS blank 8 
P Fresh KDGIVNGVKA alone 9 
PA Aged KDGIVNGVKA alone 8 
M Monomeric WT aSyn alone 8 
MP Monomeric WT aSyn + Fresh KDGIVNGVKA (1:1) 8 
MPA Monomeric WT aSyn + Aged KDGIVNGVKA (1:1) 9 
F WT aSyn fibrils alone 8 
FPAT WT aSyn fibrils formed in the presence of 
KDGIVNGVKA (1:1) 
7 
FPAS WT aSyn fibrils + Aged KDGIVNGVKA (formed 
separately) (1:1) 
6 
FP WT aSyn fibrils + Fresh KDGIVNGVKA (1:1) 7 
 
Representative CPMG spectra following quality control are shown (Figure 5-4). The spectra 
were bucketed using the pattern file and library by Phelan et al as a template (109). “Bucketing” 
refers to the process by which the spectrum is split up into lots of sections or “buckets” that may 
cover a single peak or a group of peaks that are associated with a metabolite. The buckets were 
slightly edited to reflect minor differences in buffer composition and spectrometer frequency 
causing slight peak shifts compared to those in the published study. Following curation the spectra 
were split up into 245 buckets, for which 78 metabolites were associated with individual peaks or 
groups of peaks (see Figure 5-5 and Appendix Table 10-1). 
 
 114 
 
 
Figure 5-4 – Ten representative 1D 1H CPMG spectra of samples from the dataset, having undergone quality control. 
Note, the large residual water peak at ~4.7ppm is purposely avoided during spectral analysis. Inset below are zoomed in 
images of the aliphatic and aromatic regions. 
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Figure 5-5 – 1H CPMG spectra overlaid with buckets. TameNMR was used to visualize the buckets and optimize their 
position/width. Here is shown the buckets 108-141. The buckets cover either single peaks, or groups of peaks that vary 
together. 
5.3.2.1 Peptide toxicity 
 
The first question addressed using this dataset was whether SH-SY5Y cells exposed to 
KDGIVNGVKA in its fresh (P) or aged (PA) forms exhibited metabolic changes compared to cells 
exposed to the PBS control (C). The study by Cheruvara et al did not suggest that the KDGIVNGVKA 
peptide was toxic, but it was important for this study to determine that the peptide alone in either 
its fresh or aged (deamidated) forms did not impact the cell metabolome (108).  
By inputting the spectra into MetaboAnalyst statistical analyses were carried out to assess 
whether any significant differences were apparent. By ANOVA no significant differences were seen 
in the levels of any metabolites between the control samples and those exposed to the peptides 
(Figure 5-6).  PCA was used to further inspect the data, as being an unsupervised multivariate 
technique it can consider multiple variables at once. Nevertheless, the groups did not separate 
especially well (Figure 10-1). This means that further analysis can continue on the assumption that 
the peptide itself is not directly affecting the metabolome of the cells. 
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Figure 5-6 - ANOVA of the effect of KDGIVNGVKA on SH-SY5Y cells. A one-way ANOVA (A) comparing the NMR peak 
intensities of SH-SY5Y cells challenged with fresh KDGIVNGVKA, aged KDGIVNGVKA, or a PBS control did not reveal any 
statistically significant differences to the FDR-adjusted 0.05 level. The dotted line reveals the raw (not FDR-adjusted) 
threshold.  
 
5.3.2.2 Fibril toxicity 
 
Prior to further studies the effect of aSyn fibrils (F) on the metabolome of SH-SY5Y cells, 
compared to that of monomeric aSyn (M) or a PBS control (C) was assessed. It is increasingly 
accepted that amyloid fibrils are not the toxic species responsible for neurodegeneration, and 
rather it is oligomers that are the truly toxic species (20). It is clear from previous studies that fibrils, 
oligomers and monomeric aSyn have differential effects on cells that is visible in their metabolic 
profile (109). It was necessary to investigate these changes here, especially given that the 
KDGIVNGVKA peptide inhibitor may alter the delicate equilibrium existing between these three 
states.  
The metabolic profile of SH-SY5Y cells exposed to three different conditions – PBS control, 
monomeric aSyn, and aSyn fibrils – were compared to address this question. An initial comparison 
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was made by one-way ANOVA (Figure 5-7 A). Eight buckets corresponding to five metabolites were 
found to be significantly different (to the FDR-adjusted 0.05 level) between the samples. These 
metabolites were: 3,4-dihydrobenzoic acid, homoserine, glutamine, taurine, and creatine. The 
normalized fluctuations in concentrations of each are shown, with all exhibiting a reduction in 
concentration compared to the control cells (Figure 5-7 B). To analyse these changes in greater 
detail the multivariate analytical techniques PCA and PLS-DA were used (Appendix Figure 10-2 and 
Figure 5-8).  
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Figure 5-7 - ANOVA of the differential effects of aSyn monomers and fibrils on SH-SY5Y cells. A one-way ANOVA (A) 
comparing the peak intensities of different metabolites in SH-SY5Y cells exposed to PBS alone, monomeric aSyn, and aSyn 
fibrils. Eight peaks corresponding to five different metabolites (dihydrobenzoic acid, homoserine, glutamine, taurine, and 
creatine) were found to be significantly different to the FDR-adjusted 0.05 significance level (red). The raw threshold is 
indicated by the dotted line. Box-and-whisker plots (B) are shown for the different metabolites and reflect the difference 
in concentration of each under the different conditions. Black lines and asterisks underneath each indicate significant 
differences between the conditions as determined by Fisher’s LSD means comparison (* = <0.05, ** = <0.01, *** = <0.001). 
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PLS-DA was carried out on the three conditions together, but pairwise comparisons were 
also made in a bid to identify key sources of variability. The PLS-DA of all three conditions was able 
to separate out the control samples from those exposed to aSyn, but struggled in distinguishing 
between those that had been exposed to monomeric aSyn or aSyn fibrils (Figure 5-8 A). The list of 
the forty metabolites contributing most to this variation are shown and those metabolites identified 
by ANOVA were also highlighted here, especially creatine (Figure 5-8 B). PLS-DA of just two samples 
at a time was better able to separate out the groups (Figure 5-8 C&E) and similarly highlighted 3,4-
dihydrobenzoic acid, homoserine, glutamine, taurine, and creatine as metabolites of interest 
(Figure 5-8 D&F).  
The findings here show that the exposure of the cells to the aSyn fibrils resulted in a 
reduction in the level of creatine. This is interesting given that creatine has reported 
neuroprotective properties, and may reflect that aSyn fibrils induce some level of bioenergetic 
stress (153,154). Taurine, which was also found at lower levels in those samples challenged with 
aSyn fibrils, is also neuroprotective and has been reported to lower neurotoxicity from Aβ (155). 
The reported gain in myoinositol (Figure 5-8 B,D,F) in the samples exposed to fibrils also fits with 
the available literature. An increase in myoinositol has been associated with AD and reported to 
precede amyloid pathology (156,157). Many of the metabolites observed to change here were also 
seen to change in the paper by Phelan et al, in which cells were challenged with aSyn or Aβ in 
different aggregation states (109). The fact that the same metabolites are reported here gives an 
indication that these differences are reproducible and serves as an extra layer of verification. 
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Figure 5-8 - PLS-DA of the differential effects of aSyn monomers and fibrils on SH-SY5Y cells. The conditions of PBS alone 
(C), aSyn monomer alone (M), and aSyn fibrils alone (F) were compared. Scores plots of C compared to F and M (A), C 
compared to M (C), and C compared to F (E) are shown. Corresponding VIP tables are shown in (B), (D), and (F) respectively. 
These list the 40 metabolites that vary most across the conditions. Cross-validation was carried out for each. The R2 and 
Q2 scores for each are as follows: C vs F vs M (R2 = 0.9058, Q2= 0.6013 with 4 components), C vs M (R2 = 0.9927, Q2= 0.7082 
with 5 components), and C vs F (R2 = 0.9952, Q2= 0.6327 with 5 components). F vs M was also carried out but is not shown 
here due to cross-validation suggesting that the results are the result of overfitting (R2 = 0.9743, Q2= 0.0236 with 5 
components). 
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5.3.2.3 The effect of KDGIVNGVKA on fibril toxicity 
 
 
Figure 5-9 - ANOVA of the differential effects of aSyn fibrils on SH-SY5Y cells in the presence and absence of 
KDGIVNGVKA. A one way ANOVA (A) in the peak intensities of different metabolites extracted from SH-SY5Y cells that had 
been exposed to PBS alone (C), fibrils alone (F), fibrils plus aged KDGIVNGVKA (formed together) (FPAT), and fibrils plus 
aged KDGIVNGVKA (formed separately) (FPAS). Multiple buckets were found to be significantly different across the 
conditions to the FDR-adjusted 0.05 cut-off (red). These buckets represent the metabolites creatine-phosphate, glumate, 
taurine, and trimethylamine-N-oxide. The dotted line represents the raw cut-off. Box-and-whisker plots are shown for the 
changes in concentration of creatine-phosphate (B), glutamate (C), taurine (D) and trimethylamine-N-oxide (E) in the four 
conditions. Black lines and asterisks underneath each indicate significant differences between the conditions as 
determined by Fisher’s LSD means comparison (* = <0.05, ** = <0.01, *** = <0.001). 
 
 The primary focus of the metabolomics study was whether the shortening of the amyloid 
fibrils as a result of the incubation of aSyn in the presence of the KDGIVNGVKA peptide significantly 
changed the metabolic profile of exposed SH-SY5Y cells relative to those exposed to fibrils alone. In 
the analyses conducted previously (4.3.5) the shortening of fibrils was seen in those samples of 
peptide and protein incubated together. However, it needed to be verified that any observed 
changes in the cellular metabolome were as a result of this shortening, and not as a result of the 
 123 
 
cells simply being exposed to aged KDGIVNGVKA and fibrils at the same time. Thus, the metabolic 
profile of SH-SY5Y cells was compared for those which had been exposed to PBS alone (C), WT aSyn 
fibrils alone (F), WT aSyn fibrils that had been formed in the presence of KDGIVNGVKA (FPAT), and 
WT aSyn fibrils to which aged KDGIVNGVKA (FPAS) had been added.  
 A one-way ANOVA revealed significant differences in multiple bucket groups (down to the 
FDR-adjusted 0.05 level) between the conditions (Figure 5-9 A). These buckets corresponded to the 
metabolites creatine-phosphate, glutamate, taurine, and trimethylamine-N-oxide (Figure 5-9 B-E). 
To try and observe more subtle effects in the data PCA and PLS-DA were used. Unsupervised PCA 
did not show good clustering of the data (Appendix Figure 10-3), whilst through the supervised 
technique PLS-DA to compare pairs of sample conditions it was possible to achieve good separation 
and identify those metabolites varying the most across the conditions (Figure 5-10). Creatine and 
taurine were highlighted again here, and it is interesting that their levels are generally higher in the 
control samples and the FPAT samples than in the others. This suggests that the metabolome of the 
SH-SY5Y cells exposed to the shortened fibrils formed by aSyn in the presence of the KDGIVNGVKA 
peptide is more similar to the metabolome of the cells exposed to the PBS control and thus the 
peptide is mitigating the effects of aSyn. This is further backed up by the fact that the PLS-DA was 
able to separate C and FPAS (Figure 5-10 A) and FPAS and FPAT well (Figure 5-10 E), but was less 
successful with C and FPAT (Figure 5-10 C). 
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Figure 5-10 - PLS-DA of the differential effects of aSyn fibrils on SH-SY5Y cells in the presence and absence of 
KDGIVNGVKA.  PLS-DA was carried out on the following sample conditions: PBS alone (C), aSyn fibrils alone (F), aSyn fibrils 
that had been formed in the presence of the KDGIVNGVKA peptide (FPAT), and aSyn fibrils to which aged KDGIVNGVKA 
peptide had been added (FPAS). Scores plots of C compared to FPAS (A), C compared to FPAT (C), and FPAS compared to 
FPAT (E) are shown. VIP plots show the 40 metabolites that vary most in these conditions (B, D, and F). Cross-validation 
was carried out for each. The R2 and Q2 values for each are as follows: C vs FPAS (R2 = 0.9696, Q2 = 0.8523 with 3 
components), C vs FPAT (R2 = 0.9779, Q2 = 0.5473 with 4 components)), and FPAS vs FPAT (R2 = 0.9960, Q2 = 0.6193 with 5 
components). 
 
5.4 Discussion 
 
In this chapter is described the results of the analysis of the data generated through NMR 
metabolomics experiments, conducted with the aim of shedding light on the mechanism(s) of 
action of the KDGIVNGVKA peptide inhibitor of aSyn aggregation. In their initial publication 
Cheruvara et al conducted cell viability assays suggesting that the KDGIVNGVKA peptide operated 
to reduce aSyn-mediated toxicity (108). Cell viability assays are relatively binary and so NMR 
metabolomics experiments were attempted here with the aim of trying to identify pathway-specific 
information and gain a greater understanding of how the peptide enacted its protective effects. 
Ten challenge conditions (see Table 5-2) were prepared based upon information gained in Chapter 
4, such as fresh and aged KDGIVNGVKA peptide, and fibrils formed in the presence of the peptide 
which should thus be shortened compared to standard aSyn fibrils. Cell viability experiments using 
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these sample challenge conditions showed no loss in viability over a 24-hour window, meaning that 
any apparent differences across the samples were as a result of metabolic changes induced by the 
conditions and not due to cell death (Figure 5-3).  
Previously our group has taken advantage of NMR metabolomics to observe differences in 
the metabolic profiles of SH-SY5Y cells that had been challenged with monomeric, oligomeric, or 
fibrillar aSyn (109). In this work it was seen that metabolites associated with oxidative stress and 
neurotoxicity exhibited changes. This study also meant that there was easy access to a pre-existing 
metabolite library and associated pattern file for SH-SY5Y cells. Changes in some of the metabolites 
seen in the paper by Phelan et al were similarly found here. In the conditions of F, FPAT, and FPAS 
differences in taurine, creatine, and trimethylamine-N-oxide were seen relative to the control 
(Figure 5-9). This is of interest as these metabolites have all been linked to neurodegeneration. 
Taurine has been reported to be neuroprotective, which is thought to be mediated through the 
activation of GABA receptors (155). Creatine has been seen to block the appearance of aSyn 
aggregates in MPTP models of PD and has been used in clinical trials (154,158). Trimethylamine-N-
oxide has been reported by Jamal et al to promote compactness in peptides of aSyn which may be 
less aggregation-prone, and thus may be neuroprotective (159). In F and FPAS these metabolites 
were seen at lower levels compared to the control, whilst in the FPAT samples they were at levels 
more in-line with those in the control samples (Figure 5-9). This may be indicative of the 
KDGIVNGVKA peptide having a protective role, as in the FPAT samples cells have been challenged 
with the shortened fibrils that form in the presence of the peptide. By comparing those samples 
challenged with the peptide alone versus the control samples (P, PA vs C) it was ruled out that these 
observed differences were the direct result of the peptide and were instead the result of its effects 
on aSyn itself (Figure 5-6 & Appendix Figure 10-1). 
 There are, however, numerous drawbacks to this study that should be mentioned. Firstly, 
the model is not perfect. The addition of aSyn to cells is not a truly physiologically-relevant system 
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and any differences in the cellular metabolome of these samples may reflect more of a difference 
in the internalization of aSyn rather than a change in toxicity. Thus, although the FPAT samples are 
apparently more like the control samples this may merely reflect that the aSyn species are less able 
to enter the cells to cause damage. This seems unlikely, however, given that the aSyn species 
present in the FPAT samples should be smaller than in the F and FPAS samples, and thus if anything 
are probably better internalized than the others.  Secondly, pathway-level detail of metabolites 
could not be obtained and this makes it challenging to draw concrete conclusions from the results 
of the experiment. It may have been the case that greater differences, and thus more information, 
could have been obtained had the cells been challenged with the sample conditions for a longer 
period of time. In this experiment the cells were challenged for just 24 hours, but 48 hours may 
have been more appropriate. Additionally, the data analysis was at times not straightforward. Part 
of this difficulty may have arisen as a result of the comparatively poor signal:noise seen for the 
samples as a result of the sample extraction procedure utilizing 50% methanol rather than 
acetonitrile, as used in the study by Phelan et al (109). The switch to methanol was carried out to 
allow the isolation of lipidic metabolites subsequent to the extraction of the polar molecules. This 
lipidomics analysis was ultimately not carried out due to time constraints. It’s possible that the use 
of acetonitrile would have led to improved signal:noise to the point that more interesting features 
in the data were observable. It is also possible that had the lipidomics work been undertaken that 
this would have complemented the polar metabolomics and revealed other interesting findings. 
Both of these are possibilities for any wishing to work on this project in the future. 
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6 The effect of pathogenic mutations and post-
translational modifications on α-synuclein 
aggregation and lipid-interactions 
 
6.1 Introduction 
 
6.1.1 Point mutations in α-synuclein 
 
As stated earlier in 1.7.1.2 there are six point mutations in the aSyn protein sequence which 
have been identified as causing hereditary forms of PD (Table 6-1). The different mutations, despite 
their close proximity (Figure 6-1), can have quite radically different effects on pathology (e.g. early-
onset vs late-onset). The effects of these mutations have been characterized to varying extents, and 
thus one of the aims of this chapter has been to carry out experiments on each under identical 
conditions and at the same time. This is to both tread new ground and to perhaps help resolve some 
of the controversies that currently exist in the literature regarding these mutants.   
 
Figure 6-1 - Micelle-bound aSyn with highlighted PD-linked mutation sites. Solution NMR structure of WT aSyn bound to 
a sodium dodecyl sulfate (SDS) micelle (PDB: 1XQ8) (30). The broken α-helix lies across the surface of the micelle and is 
made up of residues (3-37 and 45-92), meaning much of the NTD (1-60) and the NAC region (61-95) are involved. The 
residues highlighted in red mark the sites of the PD-linked point mutations in aSyn studied in this chapter (A30P, E46K, 
H50Q, G51D, A53T, and A53E). 
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Table 6-1 - List of PD-linked point mutations in aSyn and their features. Listed include the year of discovery, the apparent 
time at which PD is diagnosed, the reported effect (if any) on the ability of aSyn to bind to lipid membranes, and the effect 
of the mutations on the rate of aSyn’s aggregation. 
Mutation Discovered Time of onset (visibly) Effect on 
membrane binding 
Effect on 
aggregation 
A30P 1998 (75) Early-onset. Observed as 
early as 56 years of age 
(75). 
Perturbs 
membrane 
interactions. 
Exhibits disrupted 
N-terminal helix 
formation (160). 
Reported to 
accelerate 
aggregation 
compared to WT 
(78). 
E46K 2004 (76) Early-onset. Observed as 
early as 50 years of age 
(76). 
Reportedly results 
in stronger affinity 
for membranes and 
the extension of 
the helix-forming 
region of the N-
terminal (160,161). 
Reported to 
accelerate 
aggregation 
compared to WT 
(161). 
H50Q 2013 
(49,162) 
Late-onset (49,162).  No impact (163). Increased rate of 
aggregation 
compared to WT 
(163,164). 
G51D 2013 (50) Early-onset. Observed as 
early as 19 years of age 
(50,165). 
Exhibits impaired 
membrane 
association 
(79,125). 
Reduced rate of 
aggregation. 
Persists in an 
oligomeric state 
for a longer 
period 
(125,166). 
A53T 1997 (58) Early-onset (58). No impact (160). Accelerated rate 
of aggregation 
compared to WT 
(78,167). 
A53E 2014 (77) Early-onset. Onset at 36 
years-old has been 
reported (77). 
Not reported. Reduces rate of 
aggregation 
(168). 
 
 
6.1.2 Post-translational modifications and α-synuclein 
 
Post-translational modifications (PTMs) to proteins are a major component of biochemistry 
and molecular biology. They can be the result of controlled processes, or aberrant indicators of 
disease. These modifications can be essential for the functioning of a protein, or they may play a 
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role in the mediation of cell signalling pathways. With respect to aSyn multiple PTMs are known to 
play roles in its physiology and pathophysiology. These include phosphorylation, nitration, 
ubiquitination, and acetylation (53,55,169,170). This chapter is aimed at investigating the role of 
tyrosine nitration in aSyn aggregation and its effect on the lipid-binding properties of the protein. 
This PTM was of interest partially because of its poor characterization with respect to aSyn, and 
especially its effect on PD-linked mutants.   
6.1.2.1 Tyrosine nitration 
 
The nitration of L-tyrosine to form 3-nitro-L-tyrosine is one of many PTMs that can take 
place within the body (Figure 6-2). It is particularly associated with neurodegenerative disease 
because of the close link between neurodegeneration and oxidative stress (171,172); nitration itself 
is carried out by peroxynitrite (ONOO-) which is formed from the reaction of superoxide (O2•-) and 
nitric oxide (NO•), both of which are indicative of cellular oxidative/nitrative stress. It is of interest 
to me in this study because nitrated aSyn is present at elevated levels in Lewy bodies (53). It has 
also been reported that the nitration/oxidation of aSyn through exposure to peroxynitrite can lead 
to the cross-linking of tyrosine residues to form dityrosine, and that this results in the formation of 
stable higher-order aSyn species (173). Additionally, it has been shown that nitration can impede 
aSyn’s ability to associate with lipid membranes – presumably through nitration of Y39 which is the 
only tyrosine found within the lipid-binding region – but this has not been covered in any substantial 
detail for the PD-linked mutations described in 6.1.1 (174).   
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Figure 6-2 - Schematic showing the formation of 3-nitro-L-tyrosine.  3-nitro-L-tyrosine is formed from L-tyrosine by 
peroxynitrite (ONOO-), which is a powerful oxidizing agent formed under conditions of oxidative stress. 
6.1.3 Lipid-binding and α-synuclein 
 
As discussed in 1.5.1 and 1.5.2 aSyn binds to lipid-membranes via its NTD. In doing so the 
NTD forms an amphipathic helix that lies across the surface of the membrane (or membrane-
mimetic) (Figure 6-3) (30). The precise role of this interaction in the native function of aSyn remains 
elusive, but appears closely linked to the maintenance of the “reserve-pool” of synaptic vesicles, 
and also in the promotion of SNARE-complex formation that facilitates the docking and fusion of 
synaptic vesicles to the presynaptic membrane (26,47). Synaptic vesicles are small, tightly-rounded 
and contain negatively-charged lipid headgroups, such as phosphatidylserine (175). This is thought 
to be why the NTD of aSyn contains such a high proportion of residues with positively-charged 
sidechains. More recently, Fusco et al have shown the involvement of two other regions in aSyn’s 
lipid-binding behaviour (36). They showed by NMR that residues 1-25 form a helix that serves as a 
lipid-anchor, whilst residues 26-97 interact with the membrane more transiently to serve as a lipid 
sensor. They also showed weak interactions from the highly dynamic CTD of aSyn. Together they 
report that the regions allow aSyn to bind to multiple synaptic vesicles and promote synaptic vesicle 
clustering (36,37).  
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Figure 6-3 - Schematic showing the binding of aSyn to synaptic vesicles. Cytosolic aSyn protein exists as a disordered 
monomer, but has an affinity for tigtly-curved lipid bilayers containing negatively-charged lipid headgroups; properties 
exhibited by synaptic vesicles. In the presence of the vesicles the N-terminal portion of the protein forms a helix that lies 
across the surface of the bilayer, whilst the CTD remains disordered and only weakly interacts with the membrane (36).  
 
The relationship between aSyn aggregation and lipid-interactions is unclear. It has been 
shown that the association of aSyn and lipid bilayers promote primary nucleation, which is the 
ultimate rate-limiting step in amyloid formation (176). This is likely due to the reduced 
dimensionality and conformational space available when the protein is attached to the membrane. 
However, a reduced affinity for lipid bilayers – caused by mutations or PTMs – would presumably 
result in an increased supply of cytosolic aSyn (177). This, too, could encourage or prevent protein 
aggregation. The influence of lipids on the aggregation of aSyn is dependent on a number of factors, 
including the size, curvature and composition of the lipid membranes in question, and on the total 
amount of aSyn in the cell and the proportion of this which is lipid-bound (178).   
6.1.4 Aims 
 
In the body of work encompassing this chapter the differential effects of the PD-linked 
mutants and tyrosine nitration on membrane-affinity and the rate of aggregation of aSyn are 
explored using a combination of CD spectroscopy, TEM, and ThT fluorescence. The pathological 
relevance of these modifications is well known, but has not been explored in a systematic manner 
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and thus many gaps exist in the literature (53,166,167). Large quantities of each of the PD-linked 
mutants were expressed and purified for use in these studies, and tyrosine nitration was performed 
using peroxynitrite produced in-house. This allowed for a comprehensive and systematic study of 
the properties of each of the mutants under identical conditions at the same time.  
6.2 Methods 
 
6.2.1 Preparation of peroxynitrite 
 
Peroxynitrite was prepared using the procedure first described by Hughes and Nicklin (179). 
To a 50mL ice-cold and stirring mixture of 50mM sodium nitrite and 50mM hydrogen peroxide 25mL 
of 1M HCl was added. Immediately thereafter, 25mL of 1.5M NaOH was added to the mixture to 
stabilize the formed peroxynitrite. 
6.2.2 Nitration of α-synuclein by peroxynitrite 
 
Lyophilized aSyn was reconstituted in nitration buffer (100mM potassium phosphate pH 
7.4, 25mM NaHCO3, 0.1mM diethylenetriaminepentaacetic acid (DEPA)) to facilitate the nitration 
of the protein by peroxynitrite. Freshly prepared peroxynitrite was added to the protein samples at 
approximately a 100-fold excess. Confirmation of the success of nitration was inferred by dot blot 
and by measuring the absorbance at 430nm.  The protein solution also takes on a yellow tinge. 
6.2.3 Confirmation of nitration by dot blot 
 
Nitrated WT and mutant (A30P, E46K, H50Q, G51D, A53T and A53E) forms of aSyn were 
prepared to a final concentration of 100µM as determined by A280 in nitration buffer. 5µL of each 
was pipetted as a small spot onto a strip of nitrocellulose membrane. The spots were allowed to 
air-dry and then a further 5µL of sample was pipetted on top. This was then also allowed to air-dry. 
The membrane was blocked through incubation for 1hr in 5% bovine serum albumin (BSA) in 
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phosphate buffered saline with Tween 20 (PBS/T) at room temperature (RT). The membrane was 
then incubated with an anti-3-nitrotyrosine primary antibody produced in mice (Sigma) at a 1 in 
2,000 dilution for 1hr at room temperature. The membrane was then washed for 3x 10mins in 
PBS/T. The membrane was then incubated with the goat anti-mouse secondary antibody 
conjugated to alkaline phosphatase at a 1 in 10,000 dilution for 30mins. The membranes were then 
washed with PBS/T for 3x 10mins. Dots were visualized using SIGMAFAST™ Fast Red TR/Naphthol 
AS-MX tablet kit according to the manufacturer’s instructions. 
6.2.4 Confirmation of nitration by measuring A430  
 
2µL of sample was loaded onto a NanoDrop 2000 spectrophotometer (Thermo Scientific) 
that had been pre-blanked with buffer. The absorbance of the sample at 430nm was recorded.  
6.2.5 Native-PAGE of nitrated and non-nitrated α-synuclein 
 
Nitrated and non-nitrated aSyn (WT, A30P, E46K, H50Q, G51D, A53T and A53E) was 
prepared as previously described, and buffer exchanged into ddH2O and lyophilized. This was then 
resuspended in PBS pH 7.4 to a final concentration of 100µM. Native PAGE gels, loading and running 
buffer were prepared as described here (180). 12µL of sample was loaded per well and the gels 
were run at 100V at 4°C for 4 hours. Bands were visualized using Coomassie blue. 
6.2.6 Cell viability experiments with nitrated and non-nitrated α-
synuclein 
 
Both nitrated and non-nitrated forms of aSyn (WT, A30P, E46K, H50Q, G51D, A53T and 
A53E) were prepared as previously described. 100µM samples were prepared in PBS pH 7.4 and. 
100µL aliquots were taken and snap frozen in LN2 at different time points: day 0, day 3 and day 7. 
SH-SY5Y neuroblastoma cells were grown up in F-12 Ham’s media supplemented with 1x MEM, 10% 
FBS and 1% Pen-Strep. 5,000 cells in 100µL were added to each well used in a 96-well plate. After 
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24 hours 5µL of protein aliquot was added per well, with each condition having 6 repeats. PBS alone 
and 1% triton X-100 prepared in PBS pH 7.4 were used as “live” and “dead” cell controls, 
respectively.  The cells were left for 24 hours before 10µL of CCK-8 reagent (Dojindo) was added to 
each well. After this, the absorbance at 450nm was measured per hour for 4 hours on a FlexStation 
3 (Molecular devices). Data was processed and analyzed using OriginLab. 
6.2.7 Preparation of small unilamellar vesicles 
 
Small unilamellar vesicles (SUVs) containing 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC)  were prepared using Coagulation Reagent I at a 5:3:2 
ratio of DOPE:DOPS:DOPC (Avanti Lipids, USA). The chloroform solvent was evaporated away under 
a stream of nitrogen and the lipid residue was resuspended in nitration buffer to 10mg/mL. The 
SUVs were formed through sonication on ice with a fine probe head using three cycles of 1 minute 
“on, 1 minute “off”. 
6.2.8 Circular dichroism analysis of secondary structure 
 
CD measurements were performed using a Jasco J-1100 spectrometer. The cell used was a 
Quartz SUPRASIL cell (Hellma) with a 0.2mm path length. Measurements were collected between 
260 and 180nm at a temperature of 25°C with 3 accumulations. The DIT was set to 1s, the scan 
speed to 50nm/min and the data pitch to 1nm. 60μL samples were pipetted between the plates of 
the cell with care taken to avoid large bubbles. Nitrated and non-nitrated forms of aSyn (WT, A30P, 
E46K, H50Q, G51D, A53T and A53E) were freshly prepared as previously described in nitration 
buffer. For the experiments with SDS micelles the protein was diluted in buffer to achieve a final 
concentration of 50µM. 10mM SDS micelles were prepared by dissolving SDS powder in 1mL of 
nitration buffer to prepare a 0.25M stock solution. Prior to use this stock was warmed to 40°C to 
ensure the SDS was fully solubilized and this was added directly to the protein sample, such that 
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the final concentration of SDS and protein was 10mM and 50µM respectively. For the experiments 
with the lipid SUVs the final protein concentration used was 10µM (0.14mg/mL). The SUVs 
(prepared as described in 6.2.7), were added to the sample such that the lipid concentration was 
1.4mg/mL. Data were processed using Microsoft Excel and OriginLab. The baseline contribution 
from the buffer or buffer plus SDS micelles/lipid SUVs was subtracted and the 260nm region 
adjusted to zero. Secondary structure content predictions were made using the BeStSel prediction 
server (181,182). The secondary structure content predictions were based upon the 190-250nm 
portion of the CD spectrum. The 180-190nm portion was not used for secondary structure 
deconvolution due to the high-tension (HT) often rising above 500V and leading to excessive noise 
in this region of the CD spectra. 
 
6.2.9 ThT analysis of the aggregation of Parkinson’s-linked α-
synuclein mutants 
 
Unless otherwise explicitly stated, samples of 500μL aSyn (WT, A30P, E46K, H50Q, G51D, 
A53T and A53E) were prepared in PBS pH 7.4 at a concentration of 100μM. Each of these tubes was 
incubated at 37°C with agitation for 1 week. Samples were taken and used for endpoint 
fluorescence measurements on a Flexstation 3 microplate reader (Molecular Devices). Samples 
were measured in triplicate and the final volume in each well was 50μL. The 50μL was made up 
using 25μL of sample and 25μL of buffer with 2μM ThT. λex = 440nm and λem = 490nm. Data was 
processed and analysed using OriginLab. Lag times were estimated from the time at which 
fluorescence began to climb as signal saturation prevented the use of sigmoidal fitting functions to 
determine the halfway point.  
6.2.10 TEM analysis of the aggregation of Parkinson’s-linked α-
synuclein mutants 
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5μL of each sample as used for the ThT assay was mounted onto a carbon-coated copper 
grid for 2mins. The grid was then gently blotted onto a piece of filter paper to remove excess liquid 
before applying 4% (w/v) uranyl acetate for 30s. Uranyl acetate was removed and the grid dried by 
blotting onto a piece of filter paper. Images were collected on a 120kV Tecnai G2 Spirit BioTWIN 
electron microscope (FEI) with a SIS Megaview III camera. Image and fibril length analysis was 
carried out using ImageJ and OriginLab (183). 
6.2.11 ThT analysis of the aggregation of nitrated α-synuclein 
 
Nitrated and non-nitrated WT aSyn were prepared as previously described and both were 
lyophilized. The lyophilized protein was resuspended in PBS pH 7.4 to a concentration of 345µM. 
The nitrated and non-nitrated protein were loaded into wells on a 96-well plate. Each well 
contained a final volume of 100µL with 2µM ThT. The plate was incubated at 37°C with agitation. 
λex = 440nm and λem = 490nm. The protein concentration was chosen at the time because I was 
trialling conditions for another experiment (small-angle X-ray scattering) that ultimately was not 
possible.  
6.3 Results 
 
6.3.1 TEM analysis of the aggregation of α-synuclein Parkinson’s-
linked mutants 
 
The ability to successfully express and purify each of these forms of aSyn has already been 
confirmed in section 3.3.1. The PD-linked aSyn mutants have been discovered over the course of 
the past 20 years, and thus this represents a hitherto unseen systematic study of the mutants under 
identical conditions. By TEM WT and each of the recombinantly-produced forms of aSyn associated 
with PD are seen to be fully capable of forming amyloid fibrils in vitro (Figure 6-4A-G). The 
distribution of the lengths of fibrils formed is shown in Figure 6-5. Broadly, the TEM data shows that 
the synucleins can be split into two groups: those that generally form long (>300nm), straight fibrils, 
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and those that are more inclined to form shorter and more heterogenous fibrils (Figure 6-5H). The 
latter group consists of G51D and A53E, whilst the former group is all of the others. Intriguingly, 
these are the most recently discovered of the PD-mutants and thus least characterized. G51D is 
thought to persist in an oligomeric state for longer (125), which may explain the presence of fewer 
fibrils, whilst A53E forms lots of fibrils, but many of these are sub-200nm. A30P is exceptional in 
that although it typically forms long, straight fibrils those >1000nm in length constitute nearly half 
of all those measured, with very few fibrils under 200nm seen at all (Figure 6-5 B).  
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Figure 6-4 - TEM images of WT aSyn and each of the PD-linked mutants. Each protein was prepared to 100µM in PBS pH 
7.4 and incubated at 37°C with agitation for 1 week. The samples (WT (A), A30P (B), E46K (C), H50Q (D), G51D (E), A53T 
(F) and A53E (G)) were negatively stained with 4% uranyl acetate. Scale bars are 200nm in length. 
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Figure 6-5 - Fibril lengths analysis of the fibrils formed by WT aSyn and each of the PD-linked mutants. Each protein was 
prepared to 100µM in PBS pH 7.4 and incubated at 37°C with agitation for 1 week. Images were collected of the fibrils 
mounted on carbon-coated copper grids and negatively-stained using 4% uranyl acetate. The fibril lengths distributions 
are shown for: WT (A), A30P (B), E46K (C), H50Q (D), G51D (E), A53T (F) and A53E (G). The lengths were measured using 
ImageJ (183). The mean fibril lengths for each are shown (H) and the statistical significance of the differences were 
determined by ANOVA with Bonferroni post-hoc analysis. Asterisks indicate the p-value <0.05. The number of 
measurements used for each lengths analysis is as follows: WT (114), A30P (39), E46K (63), H50Q (46), G51D (41), A53T 
(61), and A53E (75). 
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6.3.2 ThT analysis of the aggregation of α-synuclein Parkinson’s-
linked mutants 
 
To analyse the effect of the point mutations on the aggregation propensity of aSyn, ThT 
fluorescence assays were carried out. The assay was poorly reproducible, despite setting up wells 
in triplicate and running the experiment multiple times on several plates with different batches of 
protein and freshly prepared stocks of ThT. As a consequence of this poor reproducibility the errors 
are quite large and the n-number is different for some of the proteins (Figure 6-6). Some 
measurements were not included in the analysis due to their being clearly anomalous (either not 
aggregating at all or appearing saturated). Additionally, it was not possible to determine the lag 
times by fitting the curves to the Boltzmann function – as would be done under ideal circumstances 
– because the top of the curves for many of the measurements was not reached before the detector 
reached saturation. This is probably a result of the relatively high (100µM) protein concentration 
used, yet a high concentration of protein must be used to ensure that the protein is capable of 
aggregating within a reasonable timeframe. Thus, the lag time was estimated manually as the point 
at which the ThT fluorescence rose above the baseline for each sample. The data is summarized in 
Figure 6-6. It is noteworthy that A53T appears to have the shortest lag time of all the mutants, 
whilst A30P appeared to have the longest lag time. This is unsurprising given the previously 
reported rapid aggregation of A53T, but the A30P result is more unexpected (167). This is doubly 
interesting given its seeming propensity to form the longest fibrils (Figure 6-5 B). All of the other 
aSyn variants are within the same general range of ~20hours. 
 The results are extremely variable, and this is likely because the rate of aggregation can be 
dramatically affected by the presence of any seeds (oligomers). Given that these species exist in 
equilibrium with monomeric protein it is impossible to remove them, and thus obtaining truly 
homogenous stating samples is not feasible despite treatment with HFIP. It is worth highlighting 
that Figure 6-6B shows that despite the variation there are clear clusters for many of the variants. 
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This presumably reflects batch-to-batch variation in the number of  seeds/oligomers present at the 
start of the experiment or slight variations in concentration .The introduction of a set starting 
quantity of seeds was not desirable as this would eliminate any effort to probe the propensity of 
the aSyn variants to seed their own aggregation. 
 
 
Figure 6-6 – Aggregation lag times for WT and PD-linked aSyn variants, as measured by ThT fluorescence. A box-and-
whisker plot (A) shows the variation in the data. The upper and lower limits of the boxes indicate the 25th and 75th 
percentiles of the data, whilst the horizontal line and small square indicate the median and mean respectively. The 
“whiskers” indicate the 5th and 95th percentile range of the data. A column scatter plot (B) shows the individual lag time 
datapoints. The data is variable overall, but seems prone to clustering around particular timepoints. This may reflect batch-
to-batch variation or errors associated with a particular experiment. The samples consisted of 100µM protein in PBS pH 
7.4. The plates were incubated at 37°C for 1 week with agitation and the fluorescence measurements recorded every  five 
minutes (λex = 440nm, λem = 490nm). Wells were set up in triplicate, and the experiment was run on three occasions (n=3). 
The number of data points for each are as follows: WT ( 7), A30P (6), E46K ( 6), H50Q (3), G51D (3), A53T (9), and A53E 
(7). 
 
6.3.3 Circular dichroism analysis of the variation in lipid-affinity 
between α-synuclein mutants 
 
CD spectroscopy is a powerful “soft” biophysical technique used to probe protein 
secondary structure. As mentioned previously and shown in Figure 6-3, aSyn forms a helix in the 
presence of a membrane (or membrane mimetic), which enables the use of CD spectra to effectively 
report on the structural changes occurring upon membrane binding (30). Measurements were 
carried out on protein alone, protein plus SDS micelles, and protein plus SUVs (DOPE:DOPS:DOPE 
5:3:2). SDS micelles were used as a membrane-mimetic and because these had been used in solving 
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the NMR solution structure (PDB: 1XQ8) (30). The SUVs of DOPE:DOPS:DOPE were used as a mimic 
of synaptic vesicles as has been established elsewhere in the literature (36). The experimental 
conditions for the measurements using the SDS micelles and the SUVs were slightly different; this 
was a reflection of physical necessity. The critical micelle concentration (CMC) of SDS is 6-8mM at 
25°C, and thus in order to form the SDS micelles needed for this experiment the concentration of 
SDS must be above 8mM. The SUVs were utilized at a concentration of 1.4mg/mL in the presence 
of just 10µM (0.14mg/mL) protein. This was a compromise to minimize light scattering from the 
SUVs that would render the spectra noisy, whilst also providing a sufficient excess of lipid to protein. 
It is a consequence of the light scattering from the SUVs, and to a lesser extent the SDS micelles, 
that the normalized root mean square deviation (NRMSD) – a measure of the “goodness of fit” 
between the experimental data and the calculated spectrum – is greater for those samples. This 
means that there is greater error associated with those samples than for the samples of protein 
alone. Lower NRMSD values are therefore more desirable, however a perfect fit is unlikely to ever 
be reached and thus the calculated values for secondary structure content in CD are rarely 
completely accurate. Due to the possibility of noise and the fact that the secondary structure 
deconvolution software operates by looking for ‘key’ indicative features (e.g. negative peak at 
222nm for α-helices), the percentage secondary structure values should be taken with a pinch of 
salt and an awareness that the spectra can be over-interpreted by the software. This is especially 
true for β-sheet elements, which exhibit a large degree of heterogeneity from structure-to-
structure. BeStSel, the software used in this analysis, shows greater care with β-structural elements 
and takes this heterogeneity into account, however no approach is likely to be perfect 
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Figure 6-7 - CD spectra and estimations of secondary structural content of WT aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM WT aSyn alone, of 50µM WT aSyn with 10mM SDS, of 10µM 
WT aSyn, and of 10µM WT aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural content estimations 
(B) were carried out using BeStSel (181,182). As expected WT aSyn alone exhibits little helical content, but this rises 
significantly in the presence of SDS micelles or SUVs. This comes at the expense of the proportion in random coil (“other”) 
conformation. The normalized root mean square deviation (NRMSD) values are 0.03314, 0.00771, 0.04622, and 0.02811 
for the samples of 50µM WT alone, with SDS, 10µM WT aSyn alone and with SUVs respectively. 
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Representative CD data (for the WT protein) is shown (Figure 6-7). Note, the helicity 
increases (as expected) in the presence of both SDS micelles and lipid SUVs. This comes largely at 
the expense of the proportion of random coil. In both conditions the level of helicity is similar, 
suggesting comparable affinity (Figure 6-7 B). It is noteworthy that the spectrum of 10µM WT aSyn 
alone is more intense than that of 50µM WT aSyn alone (Figure 6-7 A). This is surprising given that 
the molar residue ellipticity normalizes the spectra on the basis of the protein concentration (as 
seen for all of the other samples/conditions), and so this case likely reflects an inaccurate 
concentration determination for this sample. However, it should be noted that this does not affect 
the estimation of the secondary structural content by BeStSel, as it is the spectral features rather 
than their intensity which are important.  
 
Figure 6-8 - Helical content of aSyn alone, in the presence of a membrane mimetic, and in the presence of SUVs. The 
amount of helix as a proportion of the total secondary structure of aSyn (WT and PD-linked mutants) was calculated from 
CD spectra using the secondary structure prediction server BeStSel (182). Helical content increases in the presence of SDS 
micelles, a membrane mimetic, and SUVs composed of 5:3:2 DOPE:DOPS:DOPC, used as a more physiological mimic of 
synaptic vesicles. Measurements of protein alone (black) and protein plus SDS micelles (red) were conducted with 50µM 
protein (and 10mM SDS). Measurements of protein alone (green) and protein plus SUVs (blue) were conducted with 10µM 
protein (and 1.4mg/mL SUVs) so as to minimize light scattering. 
 
 146 
 
This experiment was repeated for each of the PD-linked mutants, for which the full spectra 
and their corresponding secondary structure calculations are found in Appendix 10.3. The general 
trend of the CD data is that the samples of protein alone are mainly composed of “other” secondary 
structure elements, as defined by BeStSel (181,182). “Other” encompasses random coil/disordered 
protein, as well as very rare and uncommon elements such as poly-proline helices. Given that aSyn 
is considered to be an IDP this is likely to just be random coil content (44). The samples of protein 
alone also contain a significant level of β-content, mainly antiparallel strands but also β-turns and a 
small level of parallel strands. This may reflect the fact that aSyn exists in an equilibrium with early 
aggregates (e.g. oligomers), and thus there is likely always a low level of β-containing aggregates 
present. The samples in the presence of SDS micelles and lipid SUVs typically exhibited increased 
helical content, which can be inferred to mean the protein is associated with membranes (Figure 
6-8). The only exception to this was A53T which did not form helices in the presence of SUVs. 
Generally, the helicity of the samples is greater in the presence of the SDS micelles than with the 
lipid SUVs, although the WT protein is seemingly an exception to this. SDS micelles are quite small 
in diameter (~1.75nm), tightly curved, and strongly negatively charged (184). By contrast the 
DOPE:DOPS:DOPC SUVs are larger in diameter, SUVs are on the order of tens of nanometres to 
100nm, are less strongly charged, and not as tightly curved as the SDS micelles. It may be the case 
that this combination of features of SDS micelles make them particularly attractive to aSyn, 
especially given that the helix forming NTD region has a net-positive charge, but this data is less 
physiologically relevant compared to that with the SUVs. This increase in helicity comes largely at 
the expense of the other/random coil secondary structural content, but also somewhat at the 
expense of β-content. Whilst it has been established in the literature that membrane-binding can 
induce the aggregation of aSyn (and thus result in β-sheet formation) it has also been shown that 
helix formation can extend into the NAC region and can thus also be protective from aggregation 
(160,185). A53T is especially notable as exhibits the highest-level of helicity of all the samples in the 
presence of SDS, but has exceedingly low (<5%) helicity in the presence of the SUVs (Figure 6-8 and 
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Appendix Figure 10-8). However, in the presence of the SUVs 55% of A53T is either antiparallel or 
parallel β-strand, or β-turn. This may indicate that in the presence of the lipid SUVs A53T forms 
aggregates, whilst it binds to SDS-micelles and remains helical. Interestingly, in a publication by 
Bodner et al A53T was reported as having a similar lipid-affinity to WT, whilst E46K was reported as 
having enhanced lipid-affinty and A30P as having a lower affinity (160). Here, E46K and A30P exhibit 
similar helicity under all conditions. This may reflect a problem with the indirect nature of these 
experiments, however more direct means of probing aSyn-lipid interactions (e.g. surface plasmon 
resonance (SPR) and isothermal titration calorimetry (ITC)) proved unfeasible with this system.  
The degree of helicity, and the inferred lipid-affinity, of the aSyn variants is quite varied. It 
is possible that these differences may reflect difference in toxicity and disease pathology. Reduced 
affinity for membranes may increase the cytosolic supply of protein, whilst increased affinity may 
provide additional nucleation points for aggregation. Alternatively helix formation involving 
residues required for β-sheet formation can be inhibitory of aggregation (160). The physical basis 
of the differences in interaction between the mutants, however, are more difficult to explain. The 
PD-linked mutations are all in a similar region (the NTD), of which three result in a change in the 
charge. That may be enough in this critical membrane-associating region to cause significant 
alterations in their lipid-affinity. The only two mutants described as forming helices of differing 
lengths, A30P and E46K (160), here show similar helicity (Figure 6-8).  This may suggest that the 
mutations have an allosteric effect that affects lipid-binding in some other manner or perhaps that 
they alter binding to different types of lipid to different extents. 
 
6.3.4 Nitration of α-synuclein by peroxynitrite 
 
The success of the nitration of aSyn by peroxynitrite was confirmed through an increase in 
absorbance at 430nm compared to a control of WT aSyn that was not exposed to peroxynitrite 
(Figure 6-9A). 3-nitrotyrosine absorbs at 430nm and causes the sample to exhibit a characteristic 
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yellow colour. Independent confirmation was obtained by Dot blot through the use of an anti-
nitrotyrosine antibody derived from mice. With the exception of the negative control, all samples 
showed spots with the spot intensity appearing to match up well with the A430 values (Figure 6-9B). 
The slight variation may be due to either minor differences in protein concentration or non-uniform 
modification of tyrosine residues. Nevertheless, this demonstrates that nitrated aSyn can be 
prepared for downstream studies.  
 
Figure 6-9 - A plot of absorbance values and a Dot blot of WT aSyn, exposed to peroxynitrite, confirming nitrotyrosine 
formation. The bar chart (A) shows the A430 values for aSyn exposed to peroxynitrite and a negative control sample (WT 
aSyn not exposed to peroxynitrite). The A430 value corresponds to the absorbance of 3-nitrotyrosine. Dot blot of 5µL of 
each sample at 100µM (B). The primary antibody was an anti-nitrotyrosine antibody isolated from mice. An anti-mouse 
antibody conjugated to alkaline phosphatase was used as a secondary, and spots were visualized using a SIGMAFAST Fast 
Red kit. 
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6.3.5 Native-PAGE analysis of the effect of tyrosine nitration on the 
oligomerization state of WT α-synuclein 
 
A Native-PAGE of the nitrated and non-nitrated forms of WT aSyn was run to compare the 
oligomerization state of the proteins. In the non-nitrated sample the protein exists predominantly 
as a single strong band – the monomer – whilst there are also some other bands which are 
presumably less prevalent oligomeric species, such as dimers and tetramers, which would ordinarily 
be denatured, and thus not apparent, on an SDS-PAGE gel (Figure 6-10). The nitrated sample 
presents as a streak, which is indicative of a wide range of different protein sizes and conformations; 
this suggests that the protein is aggregating. However, given that the sample is able to enter the gel 
at all they are probably not fibrils and are more likely to be oligomers. This is supported by material 
in the literature suggesting that exposure to peroxynitrite results in the formation of cross-linked 
tyrosine and stable aggregates (173). 
The samples loaded onto the gel were freshly prepared and not incubated for any 
significant length of time prior to loading. The oligomer formation induced by tyrosine nitration 
appear to occur rapidly and spontaneously without much encouragement. Contrastingly, the 
aggregation of WT aSyn in vitro requires prolonged incubation (~1 week) at 37°C with agitation to 
form fibrils. 
 
Figure 6-10 - Native-PAGE gel of nitrated and non-nitrated WT aSyn. Approximately 8.5µg protein was loaded per well. 
Non-nitrated WT aSyn appeared predominantly monomeric, with some other minor species present; presumably dimers 
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and higher-order species. Nitrated WT aSyn appeared as a streak, indicating significant sample heterogeneity e.g. dimers, 
tetramers and higher-order oligomers. 
6.3.6 ThT and TEM analysis on the effect of tyrosine nitration on the 
rate of aggregation of WT α-synuclein 
 
ThT fluorescence experiments were used to probe the effect of tyrosine nitration in WT 
aSyn on its rate of aggregation. It is clear from Figure 6-11 that non-nitrated WT aSyn aggregates as 
expected, yet the nitrated form of the protein does not result in a gain of ThT fluorescence. This 
suggests that no fibrils are being formed, and that the oligomers implied by the Native-PAGE gel in 
Figure 6-10 are likely amorphous or unable to bind ThT. This corroborates data obtained by Hodara 
et al who also found that nitrated aSyn did not form fibrils by itself, but that it could be incorporated 
into pre-existing fibrils of unmodified protein (174). Lengths analysis of aggregates or fibrils was not 
possible due to the sheer paucity of any measurable species formed. 
It was the initial aim of this body of work to use nitrated WT aSyn (and H50Q and G51D) to 
carry out small-angle X-ray scattering (SAXS) experiments to monitor the aggregation process of 
aSyn as described by Herranz-Trillo et al (45). SAXS experiments would necessitate a high protein 
concentration (≥5mg/mL) in order to obtain the necessary signal:noise. Sadly, due to unforeseen 
circumstances it was not possible to carry out these planned experiments in collaboration with 
Bente Vestergaard at the University of Copenhagen. It is for this reason, however, that the protein 
concentration used in this ThT experiment was 345µM (5mg/mL) rather than 100µM as used 
elsewhere in this thesis.  
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Figure 6-11 - TEM and ThT analysis of the aggregation of nitrated WT aSyn. Negative-stain TEM images (A) of WT aSyn 
and of nitrated WT aSyn. The samples had both been incubated at 37°C with agitation in in PBS pH 7.4 at a concentration 
of 345µM (5mg/mL) for 1 week. WT aSyn forms huge numbers of fibrils at this concentration making it difficult to see 
individual fibrils. Nitrated WT aSyn does not really form fibrils, with there only being a few isolated strands. This is 
corroborated by the ThT fluorescence data (B) which shows a rapid increase in the fluorescence for the sample of the non-
nitrated protein whilst the nitrated WT aSyn remains flat, suggesting little or no fibril formation. 
6.3.7 Native-PAGE analysis of the effect of tyrosine nitration on the 
oligomerization state of the α-synuclein Parkinson’s-linked 
mutants 
 
Having confirmed the nitration of WT aSyn results in the rapid formation of oligomeric 
species, it was of interest to see if the same effect could be replicated for the PD-linked mutants 
(A30P, E46K, H50Q, G51D, A53T, and A53E).  By Native-PAGE a similar effect to that seen with the 
WT protein was also seen for the mutants (Figure 6-12). The nitrated proteins, unlike the non-
nitrated proteins, do not migrate as discrete bands but rather as smeary streaks suggesting a large 
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number of different species. This suggests that the nitrated samples are inclined to rapid 
oligomerization. This may lead to increased cytotoxicity. 
 
Figure 6-12 - Native-PAGE gel of nitrated and non-nitrated aSyn mutants. Approximately 8.5µg protein was loaded per 
well. Non-nitrated aSyn – for each mutant – appeared predominantly as a monomeric band although some, particularly 
E46K and A53E, were quite streaked suggesting a significant level of oligomer formation. However, as with the WT protein, 
the streaking was far more pronounced for the samples of nitrated protein. 
 
6.3.8 Effect of tyrosine nitration on α-synuclein toxicity 
 
Given that tyrosine nitration induces the rapid oligomerization of aSyn, and that oligomers 
are now widely considered to be the species associated with toxicity (20), cell viability assays were 
carried out on samples of nitrated and non-nitrated aSyn – WT and the PD-linked point mutants. 
SH-SY5Y neuroblastoma cells were challenged for 24 hours with a final concentration of 5µM 
nitrated and non-nitrated forms of aSyn that had been incubated for different lengths of time. The 
percent viability of the cells was calculated relative to Live (PBS alone) and Dead (1% Triton X-100) 
controls. The viability of the cells exposed to the proteins that had been freshly prepared (day 0) 
and that had been incubated for three days is shown (Figure 6-13 A&B). The general trend at the 
initial timepoint (day 0) is that the nitrated samples are more toxic than the non-nitrated samples 
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(Figure 6-13 A). This fits with the previous findings in Figure 6-12 that nitrated samples form 
oligomeric species and with information in the literature that oligomers are the main toxic species 
(20). Nitrated H50Q is particularly toxic at the first timepoint and this is a statistically significant 
difference from the other conditions (Figure 6-13 A&C). After the protein samples had been 
incubated for three days, however, the picture is less clear. After this period of time most non-
nitrated protein will have begun to form toxic oligomers, and indeed many of the non-nitrated 
samples exhibit similar or greater toxicity than their nitrated counterparts after three days (Figure 
6-13B). The exceptions to this are nitrated H50Q and G51D, which both reduce the viability of the 
cells to about 60%. This is reflected in the statistical analyses (Figure 6-13 D). It has been suggested 
that tyrosine nitration in aSyn can have allosteric effects (186), far removed from the modification 
sites, and this may result in H50Q and G51D adopting a conformation that is particularly toxic 
comparative to the other aSyn mutants. The immediacy of the toxicity of nitrated H50Q is surprising 
given the association of H50Q with late-onset PD, in contrast to G51D which is associated with early-
onset disease (166). An interesting question posed by this data is whether nitration pushes aSyn 
down alternative aggregation pathways to the non-nitrated protein, which results in the formation 
of more toxic species, or whether it simply accelerates the “normal” aggregation process and it is 
the presence of oligomers that is accountable for the observed results in Figure 6-13. Given that 
the non-nitrated samples do “catch-up” with the nitrated samples after incubation (with the sole 
exception of G51D) it would suggest that the latter is true, however the former option cannot be 
ruled out. 
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Figure 6-13 - Bar charts comparing the viability of cells exposed to nitrated and non-nitrated aSyn at different 
timepoints, and tables showing the statistical significance of these differences. Nitrated and non-nitrated forms of aSyn 
were prepared at 100µM and incubated with agitation at 37°C. Aliquots were taken at day 0 and day 3 and were added 
to wells of SH-SY5Y cells at a final concentration of 5µM. The absorbance of the formazan dye CCK-8 at 450nm was used 
to assess viability at day 0 (A) and day 3 (B), and all data were normalized relative to live and dead controls. Nitrated (N) 
samples were more toxic than non-nitrated (NN) samples at day 0, likely due to a higher prevalence of oligomers, but 
results were more mixed for the samples incubated for 3 days. This is likely due to the non-nitrated samples having had 
more time to form toxic oligomers. ANOVA with Bonferroni post-hoc analysis was carried out to assess the statistical 
significance of the differences at day 0 (C) and day 3 (D). Squares coloured green indicate p-value < 0.05, whilst red 
indicates p-value >0.05. Six wells were prepared for each condition. N=2. 
 
6.3.9 Effect of tyrosine nitration on the lipid-association of α-
synuclein 
 
It has been suggested that tyrosine nitration of aSyn can result in an impairment of the 
protein’s ability to associate with lipid membranes (186,187). Tyr39, as the only tyrosine residue 
within the helix-forming region of the protein, is thought to be key in this, and the reduced affinity 
is thought to be as a result of electrostatic repulsion due to the introduction of a negatively charged 
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NO2- group. Interestingly, the same study revealed that nitration of just the C-terminal tyrosine 
residues within aSyn also reduced membrane affinity, suggesting some form of allostery (186). 
Here, the aim was to see if this same effect was seen in the PD-linked mutants of aSyn as well as 
the WT protein, and if this is reflected for the physiologically relevant SUVs as well as the membrane 
mimetic SDS. 
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Figure 6-14 - CD spectra and estimations of secondary structural content for nitrated WT aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM WT aSyn alone or with SDS 
micelles, and 10µM WT aSyn alone or with lipid SUVs composed of DOPE:DOPS:DOPC (5:3:2) are shown. Secondary 
structure estimations from the CD spectra as calculated by the BeStSel server are shown (B) (181,182). The NMRSD values 
are as follows: 50µM WT aSyn alone (0.03314) or with SDS (0.00771), 10µM WT aSyn alone (0.04622) or with SUVs 
(0.02811), 50µM nitrated WT aSyn alone (0.01935) or with SDS (0.00719), and 10µM nitrated WT aSyn alone (0.04619) or 
with SUVs (0.08725). 
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Figure 6-15 - Helical content of nitrated aSyn alone, in the presence of a membrane mimetic, and in the presence of 
SUVs. The amount of helix as a proportion of the total secondary structure of aSyn (WT and PD-linked mutants) was 
calculated from CD spectra using the secondary structure prediction server BeStSel (182). Helical content increases in the 
presence of SDS micelles, a membrane mimetic, and SUVs composed of 5:3:2 DOPE:DOPS:DOPC, used as a more 
physiological mimic of synaptic vesicles. Measurements of protein alone (black) and protein plus SDS micelles (red) were 
conducted with 50µM protein (and 10mM SDS). Those of protein alone (green) and protein plus SUVs (blue) were 
conducted with 10µM protein (and 1.4mg/mL lipid) so as to minimize light scattering. 
  
 CD spectra were collected for nitrated protein alone, in the presence of SDS micelles, and 
in the presence of the SUVs (DOPE:DOPS:DOPC 5:3:2) designed to mimic synaptic vesicles. A 
representative dataset of CD spectra for nitrated WT (superimposed over the spectra of the non-
nitrated samples) is shown (Figure 6-14). The CD data, including the secondary structure 
estimations and associated NRMSDs, for each of the other nitrated aSyn variants is located in the 
Appendix 10.4. The helical content of nitrated protein alone, in the presence of SDS-micelles, and 
in the presence of the lipid SUVs, is given (Figure 6-15).  The nitrated forms of the aSyn variants 
alone exhibit little or no helicity, as expected. The data suggest that the majority of their secondary 
structure is instead random coil, but with also a large proportion of antiparallel β-structure. Despite 
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the Native-PAGE data (Figure 6-12) suggesting that the nitrated forms of aSyn are more oligomeric 
than the non-nitrated forms, there is little difference in the secondary structure profiles of nitrated 
and non-nitrated protein alone (see Appendix 10.4). The general trend, as seen with non-nitrated 
aSyn, is that in the presence of SDS micelles or lipid SUVs the helicity in the samples increases. 
Noteworthy examples include nitrated WT, which exhibits high helicity (>30%) in the presence of 
SDS, and nitrated H50Q which has the most helix (>15%) of any of the proteins in the presence of 
SUVs (Figure 6-15). It should be highlighted, however, that the proportion of helix formed is 
generally much lower in the nitrated samples as compared to the non-nitrated, which corroborates 
the findings of Sevcsik et al (186). This is probably due to the introduction of a negative charge on 
Tyr39 (located in the lipid-associating NTD of aSyn) and the consequent electrostatic repulsion with 
the negatively charged lipid headgroups.  
 It is difficult to draw hard-and-fast “rules” from this data, as there are clear exceptions. For 
example, nitrated G51D exhibits helicity in the presence of lipid SUVs but none with SDS micelles 
(Figure 6-15). These variations likely reflect intrinsic properties about the different proteins that 
result in their preference for membranes of different composition, size, charge, and curvature.  
6.4 Discussion 
 
The work presented in this chapter has focused on multiple different aspects on aSyn 
biochemistry, with the aim of shedding light on its physiology and pathophysiology. This includes its 
affinity for lipid membranes, its rate of aggregation, fibril length and morphology, and cell toxicity. 
These parameters have been investigated in previous studies, but these analyses frequently suffer from 
batch-to-batch variation and different conditions (pH, ionic strength, seed concentration) making it 
difficult to cross-compare and draw concrete conclusions. The work conducted in this chapter stands 
apart from these previous studies in that the experiments were conducted as far as possible under 
identical conditions in the same lab, with the aim of providing a more robust analysis. Additionally, the 
six PD-linked point mutations in aSyn and the effects of tyrosine nitration have also been investigated 
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here. The six mutations are associated with familial forms of PD yet can have quite distinct disease 
profiles, despite their relative proximity within the NTD (75–77,125,162,188). Tyrosine nitration, on the 
other hand, is a PTM of pathological relevance that has been identified within LBs (53). The elucidation 
of the effects of each of these modifications and mutations is important if the complex nature of PD 
and the synucleinopathies is to be disentangled.  
It is known that the PD-linked mutants exhibit differences in their affinity for lipid bilayers, their 
rate of aggregation, and their fibril morphologies (31,166). Differences in the lipid affinity were probed 
through CD spectroscopy, which reported on the level of helicity in the samples; an occurrence in aSyn 
upon binding to lipids (33). This ability to bind to lipid bilayers is thought to be part of aSyn’s native 
physiological function, which appears to be closely linked to the regulation/replenishment of the 
synaptic vehicle pool and in the formation of SNARE complexes that promote synaptic vehicle docking 
at the presynaptic terminal (39,47). It has long been considered that these differences may be relevant 
to the disease process, too. However, the findings on whether lipid-binding enhances or impedes 
protein aggregation have been contradictory (189,190). This question has been at the periphery of 
research into aSyn for some time, but has newfound prominence given the discovery by Shahmoradian 
et al that LBs contain far more in terms of lipid membranes than previously realized (191). The rate of 
protein aggregation is also of great interest, but is equally enigmatic given the recent doubt thrown 
onto the historic assumption that it is the fibrils that mediate cell toxicity (20). For example, A53T is 
widely considered to have the fastest rate of aggregation of the PD-linked mutants, and the recently 
discovered early-onset mutation G51D is known to have a much reduced aggregation rate (125,167). 
Interestingly, this suggests that G51D persists in an oligomeric state for longer, and these oligomers 
are now widely considered to be the main species responsible for mediating toxicity  (20). This may go 
some way to rationalizing why G51D results in an early-onset form of PD and highlights the need to 
understand the protein aggregation process in detail.  
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The work conducted within this chapter makes several important and novel contributions to 
the field. CD experiments revealed that tyrosine nitration – induced via peroxynitrite, a highly-reactive 
compound formed as a consequence of oxidative stress – impedes the ability of each of the PD-linked 
mutants of aSyn to associate with lipid membranes, a phenomenon previously only shown for the WT 
protein (Figure 6-8 & Figure 6-15). Additionally, nitrotyrosine formation also results in the formation 
of oligomeric or polymeric aSyn species for each of the PD-linked mutants, as inferred from Native-
PAGE (Figure 6-10 and Figure 6-12). These oligomeric species are resistant to downstream aggregation 
and amyloid formation (Figure 6-11). Cell toxicity assays of nitrated versus non-nitrated protein here 
suggest that, at least at early timepoints, nitrated aSyn is more toxic to cells than non-nitrated (Figure 
6-13). These cell toxicity assays are imperfect, however, as the cells are challenged with aSyn species 
applied externally and thus the assays are possibly also reflecting differences in internalization of the 
protein.  
Given the findings of Shahmoradian et al it is clear that a greater investigation of the effects of 
nitrotyrosine formation is needed in vivo (191). Impaired lipid-affinity as a direct result of tyrosine 
nitration may result in an increased cytosolic supply of aSyn. If the oligomers formed in the presence 
of peroxynitrite are truly resistant to amyloid formation this may be a beneficial modification. 
However, whilst nitrated aSyn alone may itself not form amyloid fibrils it may be able to attach to pre-
existing fibrils and participate in amyloid formation in this way. In this case, peroxynitrite and oxidizing 
conditions may result in a swelling of the cytosolic aSyn concentration and result in aggregation and 
increased cell toxicity. The links between neurodegenerative disease and oxidative stress are 
established and well-known, and thus it seems unlikely that nitrotyrosine formation is beneficial in 
the context of aSyn (192).  
In the course of this study it was also discovered through TEM that aSyn and its mutants can be 
broadly separated into three groups in terms of fibrils. G51D and A53E typically form numerous, short 
(~50nm) fibrils, whilst the others generally form fibrils >300nm (Figure 6-5). A30P rests in a group of 
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its own as it alone formed a majority of fibrils >1000nm in length. Different lengths/numbers of fibrils 
present a varying number of fibril ends to serve as elongation points and fibril surface which can 
facilitate secondary nucleation processes, thus altering aggregation kinetics. It is also possible that 
different morphologies may differentially facilitate seeding which may affect cell-cell transmission of 
aSyn pathology (100). Recent breakthroughs in cryo-EM have made it possible to solve the structures 
of amyloid fibrils, and even distinguish between polymorphic species in near-atomic detail (46). Such 
a detailed analysis of multiple species of aSyn fibril was beyond the scope of this project, but it would 
be interesting to see the effect of these different point mutations on the final fibril structure given 
that these residues are likely involved in the preNAC steric zipper in the ‘rod’ polymorph.  
There are a number of drawbacks and caveats that need to be considered regarding the work 
in this chapter. CD spectroscopy has been used as a measure of the affinity of aSyn and its variants 
for SDS-micelles and lipid SUVs. This is legitimate given that aSyn is known to form helices that lie 
across the surface of membranes, which is observable using CD. However, this is an indirect measure 
of lipid-binding and in an ideal world supplementary evidence from a more direct and complementary 
technique would be welcome. Efforts to obtain such supporting evidence using SPR were 
unsuccessful, as both aSyn and the SUVs proved too sticky to the chip to get interpretable data. ITC, 
on the other hand, was also not viable as numerous competing processes (aggregation, lipid 
association etc) would make interpretation of the data extremely difficult. Consequently, CD alone 
has been used to probe aSyn-lipid interactions. Also, the most information-rich portion of the far-UV 
(260-180nm) region of the CD spectrum is in the 180-190nm range. Unfortunately, this is the region 
that suffers most from light-scattering caused by the detergent micelles and SUVs. In light of this the 
secondary structure estimations using the BeStSel prediction server only took into account the 
spectrum to 190nm. The calculated spectra were fitted as close as possible to the experimental 
spectrum, but the individual spectra should be considered as well as the determined secondary 
structural values to ensure that the values make sense given the possibility of noise. 
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ThT measurements of aSyn aggregation were also inconsistent and suffered from batch-to-batch 
variation. Attempts to control this were made by using freshly-prepared ThT stock solutions and only 
using HFIP-treated aSyn prepared from the same batch. These steps did not fully ameliorate these 
consistency issues, and so the data presented here should be considered with caution. This is 
seemingly a widespread issue in the analysis of amyloid rates of aggregation and may be reflective of 
different starting quantities of seeds in the samples.  
Future work should aim at trying to tie together these different aspects of aSyn 
biochemistry in a more in vivo context and establishing their relationship with each other. 
The toxicity of the different mutants could be investigated in an animal model; C.elegans 
would be a good starting point given its comparative simplicity, the availability of PD models, 
and low cost. Antibodies and fluorescent tags could be used to assess the presence of 
oligomers and fibrils, investigate co-localization with membranes, and the extent to which 
nitrotyrosine is found in these systems. 
  
 163 
 
7 The association between α-synuclein, cyclophilin-D, 
and the mitochondria  
 
7.1 Introduction 
 
The work within this chapter was initially formatted and compiled for a publication, which 
was sent to Scientific Reports. Subsequently to receiving and addressing the reviewers’ comments 
it was decided that this work was to be put towards a patent application. This is currently underway, 
and thus the contents of this chapter are to remain under embargo. The NMR and ITC experiments 
in this chapter were conducted by Prof Lu-Yun Lian. Cyclophilin-D was expressed and purified by Dr 
Amy Wood and given to me on behalf of Prof Lu-Yun Lian. I expressed and purified all full-length 
aSyn (including 15N-labelled form), conducted the ThT assays, TEM, and the cell viability 
experiments.  
7.1.1 Cyclophilin name controversy  
 
There is controversy and inconsistency in the literature regarding the correct nomenclature 
of cyclophilins/peptidyl-prolyl isomerases and their corresponding gene names. All of the following 
experiments have been conducted on cyclophilin-D (CypD) (Uniprot ID: P30405), a peptidyl prolyl 
isomerase encoded by the gene PPIF.  
7.1.2 Neurodegenerative disease, mitochondrial dysfunction, and 
oxidative stress 
 
Neurodegenerative disease has been the subject of intense research for many years. 
However, many of the most basic questions surrounding this conglomerate of diseases remain 
unanswered. One such question is: why do the neurons die? A common element in 
neurodegenerative disease is mitochondrial dysfunction and oxidative stress (192,193). As stated 
in 1.7.1.1 there are a number of environmental factors implicated in PD-onset, including the 
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exposure to the compounds rotenone and paraquat which have been used as pesticides (73). These 
compounds operate by binding to the complexes of the electron transport chain within the 
mitochondria, resulting in an increase in the levels of reactive oxygen species (ROS) and impeding 
ATP synthesis (194). Indeed, rotenone exposure has been used to induce Parkinsonian symptoms 
in some mouse models of PD (74). Alongside this are the number of genes implicated in familial 
forms of PD, such as those encoding DJ-1 (redox sensor/protein deglycase), PINK1 (serine/threonine 
protein kinase), and parkin (E3 ubiquitin ligase), which seem to play roles in maintaining 
mitochondrial integrity (195–197). These different features overlap to start painting a picture of PD 
not just as a disease of the brain, but as a disease of the mitochondria. Greater understanding of 
this relationship between protein aggregation, oxidative stress and mitochondrial dysfunction is 
clearly needed in the 21st century if we are to design successful therapeutic agents. 
7.1.3 The mitochondria and α-synuclein 
 
Recently, there has been a growing body of evidence that aSyn can localize to the 
mitochondria and that this may be associated with disease (Figure 7-1) (198–202). For example, it 
has been shown that aSyn can interact with the phospholipid cardiolipin when it is exposed on the 
outer mitochondrial membrane, and that this leads to mitochondrial fragmentation and mitophagy 
(199). It has also been shown that oligomeric or post-translationally modified aSyn can bind to 
TOM20 and prevent the import of proteins into the mitochondria (203). This, too, results in 
impaired mitochondrial function and oxidative stress. Of special interest have been the reports that 
oligomers of aSyn can bind to the β-subunit of ATP synthase and induce the opening of the mPTP 
(198). Our group has generated data showing that aSyn is able to interact with CypD, a 
component/regulator of the mPTP. Given the key role of the mPTP and, by extension, CypD to both 
necrotic and apoptotic cell death this is an interaction that is quite clearly worth investigating 
further (204). 
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Figure 7-1 - Schematic showing the effects of aSyn localization to the mitochondria. The localization of aSyn to the 
mitochondria has been implicated in mitochondrial dysfunction. Notably, aSyn appears to impair mitochondrial function 
resulting in oxidative stress, associate with cardiolipin (red circle) which modulates its aggregation behaviour, bind TOM20 
(orange circle) to inhibit the translocation of proteins into the mitochondria, and aSyn oligomers promote the opening of 
the mPTP (green circle) and promote Ca2+ efflux, and by extension cell death (198,199,203,205). 
 
7.1.4 Cyclophilin-D and the mitochondrial permeability transition 
pore 
 
Human CypD is a mitochondrial protein that is synthesised as a 22kDa protein that is 
subsequently processed into a 17.8kDa protein following the removal of the mitochondrial 
localization sequence (Figure 7-2). It is a peptidyl-prolyl isomerase meaning that it catalyzes the 
interconversion between the cis and trans states of proline, and this functionality is thought to be 
involved in assisting the correct folding of proteins (206,207). The protein was found, through 
knockout studies in mice, to be a key regulator of the mPTP (110). 
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Figure 7-2 - Crystal structure of human WT CypD (PPIF). The crystal structure (PDB: 2Z6W) was solved to 0.96Å resolution 
to reveal a mixed α/β protein (A) (208). The structure shown is that of the processed 17.8kDa fragment, which has the 
mitochondrial localization sequence removed. The structure of the protein was solved with the potent inhibitor cyclosporin 
A (CsA) bound (B). The protein is shown in cyan, whilst the inhibitor of its activity, the 11-residue cyclic peptide CsA, is in 
shown in green.  
 
The mitochondrial permeability transition is a strange phenomenon of the mitochondria. It 
refers to a process by which the exposure of the mitochondria to high levels of Ca2+ results in 
swelling of the mitochondria and the sudden non-specific permeabilization of the inner 
mitochondrial membrane to molecules under 1.5kDa (209,210). This appears to be the result of the 
opening of a pore termed the mPTP. The opening of the mPTP results in the degeneration of the 
proton-motive force required to drive ATP synthesis, and instead ATP begins to be hydrolysed by 
the mitochondria. This leads to an energy crisis within the cell and necrotic cell death (204). The 
rupturing of the mitochondrial membranes may also occur, leading to the release of pro-apoptotic 
factors such as cytochrome c. However, apoptosis will generally only be initiated if the closure of 
the pore is achieved before necrotic cell death takes hold (211).  
The opening of the mPTP, and the damage associated with it, can be inhibited through the 
use of the cyclic peptide cyclosporine A (CsA) (Figure 7-2) (212). This peptide operates by binding 
CypD and preventing the opening of the mPTP (213). In this way the administration of CsA has been 
posed as a strategy to reduce damage to cardiac tissue during myocardial reperfusion (211).  
7.1.5 Aims 
 
 167 
 
Given the strong evidence in the literature of an overlap between CypD, mPTP opening, and 
aSyn aggregation the aim of this chapter was to shed more light on this area and elucidate what 
was happening with respect to aSyn at the mitochondria. The first step was to identify whether 
there was any form of interaction between aSyn and CypD, and if so to characterize it, primarily 
through the use of NMR spectroscopy and ITC. Following on from this the aim was to characterize 
the effect of the interaction on the aggregation of aSyn and the ramifications this had on its toxicity 
to cells. This was carried out primarily using TEM, ThT fluorescence assays, and cell viability 
experiments. 
7.2 Methods 
 
7.2.1 Peptides of α-synuclein 
 
ASynM peptide (residues 50-65, GVATVAEKTKEQVTN) and aSynC peptide (residues 119-
140, DPDNEAYEMPSEEGYQDYEPE140A) were synthesized by Gemini Biosciences at 98% purity. A 
control aSyn peptide (residues 74-95, VTAVAQKTVEGAGSIAAATGFV) was synthesized by Protein 
Peptide Research at 98% purity. 
7.2.2 Expression and purification of cyclophilin-D (WT, R55K, R82K) 
 
The 17.8kDa “mature” form of WT CypD, and the mutants R55K and R82K, were expressed and 
purified by Dr Amy Wood. The expression and purification procedure was as described previously 
(208). 
7.2.3 NMR experiments 
 
All NMR measurements were conducted on a Bruker Avance III 800MHz spectrometer 
equipped with a TCI CryoProbe (Bruker) at either 298K or 283K. All samples were prepared in 20mM 
phosphate pH 6.5, 20mM NaCl containing 5% D2O. The backbone resonances of CypD were assigned 
using 3D HNCA, HN(CO)CA, HNCO, HN(CA)CO, CBCA(CO)NH, and CBCANH experiments, whilst the 
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assignment of full-length WT aSyn was described in 3.2.7. Chemical shift perturbations were 
expressed as: 
∆𝛿 = {(∆𝐻)2 + (0.15∆𝑁)2}1/2 
Δδ values greater than 0.07 were considered significant. All data was processed in TopSpin (Bruker) 
and analysed in CCPN Analysis. 
7.2.3.1 NMR study of the interactions between cyclophilin-D and α-synuclein 
peptides 
 
ASyn peptides were prepared to a final concentration of 1mM and resonance assignments 
of the peptides were obtained using 2D TOCSY and NOESY experiments utilizing mixing times of 
60ms and 350ms respectively. To investigate the binding of aSynC to CypD, 13C/15N – labelled CypD 
was utilized. The 13C/15N CypD was used in conjunction with the aSynC peptide at a 20:1 
peptide:protein ratio and the binding site of aSynC on CypD was identified using 1H-15N HSQC 
experiments.  The assignment of the bound form of aSynC was enabled by collecting 13C/15N-filtered 
1D, 2D TOCSY and 2D NOESY experiments (350ms mixing time).  
7.2.3.2 NMR study of the interactions between cyclophilin-D and full-length 
α-synuclein (wild-type & A53T) 
 
The binding between WT CypD and WT or A53T aSyn was also probed. 1D proton and 1H-
15N HSQC experiments were collected at 283K on samples containing 1mM unlabelled WT CypD and 
100µM 15N-labelled WT or A53T aSyn. 
7.2.3.3 NMR study of the interactions between cyclophilin-D and full-length 
α-synuclein fibrils 
 
Experiments investigating the interaction between CypD and aSyn fibrils utilized 15N-
labelled full-length recombinant WT aSyn (prepared as described in 3.2.3) and were conducted at 
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288K.  2H/15N-labelled CypD was utilized to optimize the shift perturbations when in complex with 
the fibrils.  
7.2.4 ITC analysis of the interaction between α-synuclein peptides 
and cyclophilin-D 
 
ITC measurements were conducted on a MicroCal iTC200 instrument (Malvern Panalytical) 
at 25°C. All samples were prepared in 20mM phosphate pH 6.5, 20mM NaCl and this buffer was 
used to wash/equilibrate the cell. The experiments consisted of an initial injection of 0.5µL and then 
subsequently by fifteen 2.39µL injections, and a final injection of 1.89µL. Control experiments 
consisted of injecting buffer into buffer, and buffer into CypD. All experiments were carried out in 
duplicate, however for some titrations data from two runs was concatenated to achieve a saturating 
isotherm. The cell contained 50-100µM CypD whilst the syringe contained 500-2000µM aSyn 
peptides. All data was analysed using OriginLab. 
7.2.5 ThT fluorescence analysis of the effect of cyclophilin-D on α-
synuclein aggregation 
 
The following samples were prepared in PBS pH 7.4: 50µM WT aSyn fibrils alone, 150µM 
(WT, R55K, or R82K) CypD alone, 150µM WT CypD:CsA, 50µM WT aSyn plus 150µM (WT, R55K or 
R82K) CypD, and 50µM WT aSyn plus 150µM WT CypD:CsA. Samples of 50µM WT aSyn plus 25, 50, 
100, and 150µM WT CypD were also prepared. All samples contained ThT to a final concentration 
of 2µM. The samples were plated out in triplicate onto a 96-well black, clear-bottomed plate with 
100µL per well and incubated at 37°C with agitation for 7 days. Measurements were recorded using 
a Flexstation 3 microplate reader at wavelengths λex = 440nm and λem = 490nm. Data was processed 
and analysed using OriginLab. 
7.2.6 TEM analysis of the effect of cyclophilin-D on α-synuclein 
disaggregation 
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The samples were 50µM WT aSyn fibrils alone, 150µM (WT, R55K or R82K) CypD alone, and 
50µM WT aSyn plus 25, 50, 100 or 150µM WT CypD which had been incubated at 37°C for 7 days. 
5µL of sample was mounted on a carbon-coated copper grid for 2mins, before blotting off and 
negative staining using 4% uranyl acetate. Excess uranyl acetate was blotted off on filter paper and 
the grids left to dry. Grids were observed by TEM using a 120kV Tecnai G2 Spirit BioTWIN electron 
microscope (FEI) with a SIS Megaview III camera. Image and fibril length analysis was carried out 
using ImageJ and OriginLab. 
7.2.7 Cell viability experiments of SH-SY5Y cells exposed to α-
synuclein fibrils pre-treated with cyclophilin-D 
 
To test the toxicity of fibrils that had been pre-treated with CypD SH-SY5Y neuroblastoma 
cells were grown in T25 flasks in F-12 Ham’s growth medium supplemented with: 10% fetal bovine 
serum, 1% Pen-Strep, and 1x MEM essential amino acids. Cells were grown incubated at 37°C with 
5% CO2 until 90% confluency. At this point cell growth medium was decanted and the cells washed 
with PBS pH 7.4. The PBS was discarded and the cells trypsinized. Trypsinized cells were 
resuspended in the complete growth medium and plated out onto a 96-well clear-bottom plate, 
with 5000 cells/well in a volume of 100µL. The plate was incubated for 24 hours, after which 10µL 
of sample was added per well. Samples were as follows: live control (PBS alone), dead control (1% 
Triton X-100), 50µM WT aSyn fibrils alone, 150µM WT CypD alone, and 50µM WT aSyn fibrils plus 
150µM WT CypD. All samples had been pre-incubated quiescently at 37°C for 3 days prior to use. 
After the addition of samples the plate was incubated for a further 24 hours. 10µL of cell counting 
kit-8 (CCK-8) reagent (Dojindo) was added per well. The plate was incubated at 37°C for a further 4 
hours with absorbance measurements at 450nm being recorded every hour using a Flexstation 3 
microplate reader (Molecular Devices). The percentage cell viability was calculated by using the 
absorbance relative to the live and dead controls, which represented 100% and 0% viability 
respectively. For all sample conditions n=6.  
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7.3 Results 
 
7.3.1 The binding of α-synuclein by cyclophilin-D 
 
The question of whether there is an interaction between aSyn and CypD is of interest due 
to the reports in the literature of the linkages between aSyn, mPTP opening, and mitochondrial 
dysfunction (198,214). This question was probed by NMR due to our access to our previously 
obtained backbone assignments of both WT aSyn (see 3.2.7 and 3.3.2) and CypD (determined 
previously by Prof Lu-Yun Lian), and due to the technique’s utility in the study of IDPs and PPIs. To 
get a complete picture of the interaction HSQCs were collected for 15N-labelled WT aSyn in the 
presence of unlabelled CypD, and for 15N-labelled CypD in the presence of unlabelled aSyn.  
The addition of unlabelled CypD to the labelled aSyn resulted in peak shifts that were clearly 
evident on the HSQC spectrum (Figure 7-3A). Peak shifts corresponded largely to residues located 
within the C-terminus, but none of these shifts were >0.06 (Figure 7-3B). Peaks also exhibited 
substantial line-broadening, which is also commonly used to map sites of interaction and occurs as 
a result of intermediate exchange between the free and complexed states. Two main regions in 
aSyn were affected: H50, A53-A58, and E110, D119-Y125 (Figure 7-3B). Other peaks also exhibited 
line-broadening, but due to peak overlap their interpretation is extremely difficult. The majority of 
aSyn peaks remained visible after 48 hours, suggesting that the protein is not aggregating over this 
timeframe (Figure 7-3C). Interestingly, most of the line-broadening effects, like the chemical shift 
perturbations, were seen around the C-terminal portion of the protein suggesting that this is the 
site with which CypD interacts. 
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Figure 7-3 – HSQC spectra revealing the site on aSyn with which CypD interacts, and the corresponding chemical shift 
perturbations. 1H-15N HSQC spectra (A) show 100µM 15N-labelled WT aSyn alone (black) and in the presence of 1mM CypD 
(red) collected in 20mM phosphate pH 6.5, 20mM NaCl at 298K. Chemical shift perturbations are plotted for within 2 hours 
(B) and within 48 hours (C). Some chemical shifts are evident at both timepoints, predominantly in the C-terminal region 
of aSyn. Numerous gaps are apparent due to the loss of the peaks entirely as a result of line-broadening (indicated by 
double arrows). Both shift perturbations and line-broadening suggest PPIs. The data after 48 hours also suggests that the 
protein has not begun to aggregate. 
 
The addition of unlabelled aSyn to 15N-labelled CypD similarly resulted in chemical shift 
perturbations and substantial line-broadening of peaks also suggestive of binding (Figure 7-4A). It 
was thought from the results of the HSQCs of 15N-labelled aSyn that the main residues with which 
CypD interacted were in the C-terminus of aSyn. To confirm this HSQC experiments were conducted 
between 15N-labelled CypD and the aSynC peptide (residues 119-140) as well as the full-length aSyn 
protein (Figure 7-4B). Similar effects were seen here as with the full-length protein, confirming that 
CypD interacts with the C-terminal portion of aSyn. Those residues of CypD identified as being 
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involved are Gln63, Ser77, Phe83, Ala101, Asn102, Ala103, Gln111, Ser110, Phe112, Phe113, and 
Trp121. These residues are all located in or around the putative ligand-binding site of CypD (Figure 
7-4C). Given that the CTD of aSyn contains five proline residues and CypD catalyses the 
isomerization of these residues this is perhaps unsurprising. It may suggest that the interaction 
between the two proteins is in the capacity of CypD acting as a molecular chaperone, rather than 
as a key regulator of the mPTP. 
Identical experiments carried out using 15N-labelled CypD and an aSyn control peptide 
(residues 74-95) showed no signs of interaction, whilst with aSynM (residues 50-65) only showed 
very slightly shifted resonances and minimal line-broadening. To further probe the binding location 
within aSyn the A53T mutant was used. Similar peak shifts to those observed in Figure 7-3A with 
WT aSyn are also observed with A53T aSyn (Figure 7-5). If this were the binding site this mutation 
would be expected to perturb the aSyn-CypD interaction. Taken together this very strongly suggests 
that the region to which CypD binds is located away from the H50, A53-A58 region and is likely 
specific to the C-terminal region of the protein.  
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Figure 7-4 - HSQC spectra showing the binding site of aSyn on CypD. 1H-15N HSQC spectra (A) collected at 298K of 100µM 
15N-labelled CypD alone (black) and in the presence of 1mM aSyn (red). Underneath the spectra are zoomed-in images of 
peaks associated with chemical shift perturbation and line-broadening. 1H-15N HSQC spectra (B) collected at 283K of 50µM 
15N-labelled CypD alone (black) and in the presence of 1mM aSynC peptide. The lower temperature was utilized to minimize 
exchange and increase the affinity of the peptide for CypD. Underneath the spectra are zoomed-in images of those peaks 
that shift or broaden extensively following the addition of the aSynC peptide. The crystal structure of CypD (PDB:2BIT) 
(215) is shown (C) with those residues that exhibit substantial chemical shift perturbations or line-broadening coloured in 
yellow. These residues are located within or around the putative ligand-binding pocket of CypD. 
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Figure 7-5 - HSQC spectra showing the association between WT CypD and A53T aSyn. 1H-15N HSQC spectra of 100µM 
15N-labelled A53T aSyn alone (black) and in the presence of 1mM unlabelled WT CypD. The samples were prepared in 
20mM phosphate pH 6.5, 20mM NaCl and collected at 283K. Clear chemical shift pertubations are visible, indicating that 
WT CypD is capable of binding to A53T. This indicates that the binding site is likely located away from this region. 
 
To confirm that CypD was acting in its capacity as an isomerase more detailed NMR analyses 
were undertaken. The 1D spectrum of aSynC peptide alone shows both major and minor 
conformations, and this is particularly evident for the residues E137 and E139 (Figure 7-6B). Given 
the preponderance of proline residues in this region of aSyn this is likely due to cis-trans proline 
isomers. Integration of the major and minor peaks suggests that the trans conformation is about 
nine times more prevalent than the cis conformation. Filtered 1D experiments show that upon the 
addition of 50µM 13C/15N-labelled CypD there is substantial line-broadening of aSynC signals, 
especially those of the minor conformations of E137 and E139, and of E123, E130, Y133, D135, and 
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Y136 (Figure 7-6A). To confirm that CypD is having an impact on the cis-trans isomerization of the 
aSynC NOESY and 13C/15N-filtered NOESY spectra were collected on 1mM aSynC alone, and in the 
presence of 50µM 13C/15N-labelled CypD respectively (Figure 7-6 C&D). The addition of CypD to the 
aSynC peptide revealed the emergence of crosspeaks between the major and minor conformations 
of E137 and E139 that were not present in the spectrum of aSynC alone. This suggests that CypD is 
indeed fulfilling its role as a peptidyl-prolyl isomerase with respect to aSyn and that it is increasing 
the rate of isomerization between the cis and trans conformations. Given that the isomerization of 
CypD is potently inhibited by the cyclopeptide CsA we added it to a final concentration of 100µM in 
the sample containing 1mM aSynC and 50µM 13C/15N-labelled CypD to see if this resulted in the 
abolition of the new crosspeaks. This was indeed the case (Figure 7-6 E) and fully confirmed our 
hypothesis that CypD binds at the C-terminal region of aSyn via its isomerase domain whereby it 
proceeds to facilitate cis-trans isomerization of aSyn in its most proline-rich region. 
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Figure 7-6 - NMR analysis of the isomerization of aSynC peptide by CypD. The 13C/15N-filtered proton spectrum (A) of 
1mM aSynC in the presence of 50µM 13C/15N-labelled CypD, collected at 283K. The proton spectrum (B) of 1mM aSynC 
collected at 283K. The minor conformation peaks of E139 and E137 (E139m and E137m) are shown via zoomed-in peaks. 
These are likely the result of cis-trans peptidyl-prolyl isomers. Many of the aSynC peaks, especially those of E139m and 
E137m appear substantially broadened in (A) in comparison to in (B). This suggests an interaction between aSynC and 
CypD. A 13C/15N-filtered NOESY spectrum (C) of 1mM aSynC with 50µM of 13C/15N-labelled CypD shows crosspeaks between 
the major and minor conformation peaks of E137 and E139 which are not seen in the control NOESY spectrum (D) of 1mM 
aSynC alone collected at 283K. A NOESY spectrum (E) showing the abolition of these same crosspeaks following the 
addition of the potent CypD inhibitor, CsA, at 100µM. 
 
7.3.2 ITC analysis of the interaction between α-synuclein and 
cyclophilin-D 
 
In light of the NMR data showing that CypD binds to the C-terminal region of aSyn the next 
objective was to characterize the strength of this interaction by ITC. The experimental set-up 
consisted of CypD in the cell and aSynC/aSynM peptides in the syringe at high concentration. As 
expected following on from the NMR experiments, the injection of aSynC peptide resulted in heat 
pulses suggestive of tight binding to CypD (Figure 7-7A). This data was then fit to a single-site 
binding model, which output a Kd = 150µM. A repeat of this experiment with the aSynM peptide did 
not yield data suggestive of tight binding, which is supportive of the findings from the NMR 
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experiments (Figure 7-7B). The data from the aSynM could not be fit easily as any binding was 
considerably weaker and the calculated Kd >500µM. 
 
Figure 7-7 - ITC binding curves between CypD and the peptides aSynC and aSynM. The ITC data for CypD binding to aSynC 
(A) and aSynM (B) is shown. The top panel for each is the raw calorimetric data output. The bottom panels show the plots 
of integrated heat signal as a function of the molar ratio of ligand to protein. The data was fit to a one-site binding model 
to output the Kd, ΔH, and ΔS of the interaction. The Kd for aSynC was determined to be 150µM, whilst the Kd for aSynM 
could not be determined due to the binding being too weak. This made it impossible to output a reliable binding isotherm. 
 
7.3.3 ThT and TEM analysis of the effect of cyclophilin-D on α-
synuclein aggregation and disaggregation 
 
A recent publication by Baker et al showed that cyclophilin-40, a peptidyl-prolyl isomerase 
like CypD, is capable of dissolving amyloid fibrils formed by aSyn and tau (106). In light of this and 
our NMR data showing the binding of CypD to the CTD of aSyn, which lies outside the core amyloid 
fibril and remains disordered in the ssNMR and cryo-EM structures of aSyn fibrils, we investigated 
whether CypD had an impact on aSyn fibril formation or if it could even disaggregate pre-formed 
fibrils. A ThT fluorescence assay was carried out to assess the effect on aSyn aggregation using 
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50µM WT aSyn alone, 150µM WT CypD alone, 50µM WT aSyn plus 150µM WT, R55K or R82K CypD, 
and 50µM WT aSyn plus 150µM WT CypD:CsA. Each of these samples were incubated with agitation 
at 37°C for 7 days and endpoint ThT fluorescence measurements were recorded (Figure 7-8A). 
Control samples of relevant CypD alone and CypD:CsA were also collected and used for subtraction. 
The samples of aSyn that had been incubated with CypD exhibited ThT fluorescence that was 
significantly lower (P <0.001) than those of aSyn alone, whilst the addition of the potent CypD-
inhibitor, CsA, abolished this effect. This suggests that CypD is indeed preventing aSyn aggregation 
and fibril formation. Intriguingly this was observed for the R55K catalytically compromised mutant 
of CypD but not R82K. This may suggest that R82K as well as being catalytically-inactive is also 
unable to bind CypD, and that it is the binding rather than the isomerase activity that is responsible 
for the prevention of aggregation. It could thus also be inferred that CsA prevents aSyn binding.  
To explore whether this preventative effect was concentration dependent an additional 
ThT fluorescence assay was conducted, using CypD at concentrations ranging from 25µM to 150µM 
(Figure 7-9). It was evident from this data that at below a 1:1 CypD:aSyn ratio that aggregation was 
not prevented. However, at 1:1 and above there was no rise in ThT fluorescence, which is indicative 
of no fibril formation. 
The effects of CypD on pre-existing aSyn fibrils were assessed by TEM. Clear differences 
were observed (Figure 7-8B) and a lengths analysis of the fibrils formed by aSyn alone shows quite 
a broad distribution, with the average at ~450nm (Figure 7-8 C&D). However, when fibrils were 
incubated with WT CypD a vast number of much smaller fibrils is observed (Figure 7-8 B). This is 
reflected in the reduced size distribution of the fibrils, and the mean length is just ~50nm (Figure 
7-8 C&D). Interestingly, the data also suggests that this shortening of the fibrils is a result of the 
isomerase activity of CypD, as the same effect is not exhibited by the catalytically compromised 
mutants, R55K and R82K (Figure 7-8 B-D). 
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The ability of WT CypD to disaggregate pre-formed aSyn fibrils was tested at a range of 
concentrations (Figure 7-10). Samples of fibrils of WT aSyn alone (prepared to 50µM monomer 
equivalent) and in the presence of 25-150µM WT CypD were incubated at 37°C for 7 days. 
Representative TEM images of WT aSyn fibrils alone, and in the presence of 50µM and 100µM WT 
CypD are shown (Figure 7-10 A-C). An analysis of the lengths of the fibrils on the grids was 
performed (Figure 7-10 D). This revealed that the mean length of fibrils decreases very sharply upon 
the addition of CypD (from ~450nm to <200nm). The addition of CypD also results in a narrower 
distribution in the lengths of the fibrils. The mean length of aSyn fibrils drops consistently as the 
concentration of CypD present increases, up until 150µM CypD. This is likely due to the increased 
concentration of CypD resulting in itself aggregating, as a significant quantity of precipitated protein 
was observed in this sample. 
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Figure 7-8 - ThT fluorescence data and TEM images showing the effect of CypD on aSyn aggregation and 
disaggregation. ThT fluorescence endpoint reads (A) of 50µM WT aSyn, 50µM WT aSyn plus 150µM WT, R55K or R82K 
CypD, and of 50µM WT aSyn plus 150µM WT CypD:CsA are shown. All samples were incubated at 37°C for 7 days with 
agitation prior to measurement. Control samples of CypD(:CsA) alone were also collected, and these values were 
subtracted from the reads containing aSyn and CypD(:CsA). The ThT fluorescence of aSyn is reduced in those samples that 
were incubated with CypD, suggesting that CypD may prevent or impede aSyn aggregation. All ThT samples were plated 
in triplicate. N=2. The ability of CypD to disaggregate pre-formed aSyn fibrils was probed by TEM (B). Samples of 50µM 
aSyn fibrils, and of 50µM fibrils with 150µM CypD (WT, R55K or R82K) were incubated for 7 days at 37°C. The images 
suggest CypD may exhibit disaggregation behaviour as samples that had been incubated with WT CypD formed dense 
networks of much shorter fibrils compared to those in the sample of aSyn alone. The catalytically impaired CypD mutants, 
R55K and R82K, did not exhibit this same fibril shortening behaviour. Scale bars are 200nm. Fibril lengths analyses (C & D) 
show how the incubation of aSyn with WT CypD reduces the mean fibril length and that this is statistically significant. *** 
P <0.001 as determined by ANOVA with the Tukey range test. The number of measurements used for the lengths analysis 
are as follows: WT aSyn alone (103), with 150µM WT CypD (107), with 150µM R55K CypD (108), with 150µM R82K CypD 
(91). 
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Figure 7-9 - ThT fluorescence data showing the effect of varying CypD concentration on aSyn aggregation. Samples of 
50µM aSyn alone, and containing 25, 50, 100, and 150µM WT CypD were prepared in PBS pH 7.4. These samples were 
incubated for 7 days at 37°C with agitation prior to measurement. All samples were measured in triplicate. Relevant 
control samples were also prepared and subtracted. N=1. 
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Figure 7-10 - TEM images and fibril lengths analysis showing the effect of concentration on the ability of WT CypD to 
disaggregate aSyn fibrils. TEM images of 50µM WT aSyn alone (A), 50µM WT aSyn plus 50µM WT CypD (B), and 50µM 
WT aSyn plus 100µM WT CypD (C). The fibrils were formed by incubation of 100µM WT aSyn for 7 days with agitation at 
37°C. The fibrils alone or with WT CypD were incubated for a further 7 days without agitation at 37°C. All images were 
collected on carbon-coated copper grids and visualized by negatively-staining with 4% uranyl acetate. A box-and-whisker 
plot showing the fibril lengths data of WT aSyn alone and with 25-150µM WT CypD (D). The upper and lower limits of the 
boxes indicate the 25th and 75th percentiles of the data, whilst the horizontal line and small square indicate the median 
and mean respectively. The “whiskers” indicate the 5th and 95th percentile range of the data. The number of measurements 
used for the lengths analysis are as follows: WT aSyn alone (103), plus 25µM WT CypD (52), 50µM WT CypD (116), 100µM 
WT CypD (145), and 150µM WT CypD (156). 
 
7.3.4 NMR analysis of the disaggregation of α-synuclein fibrils by 
cyclophilin-D 
 
Following on from the TEM data suggesting that WT CypD was actively shortening aSyn 
fibrils we wanted to probe this process by NMR. As aSyn begins to aggregate and oligomerize its 
molecular weight rapidly exceeds the “size-limit” of NMR. This is generally ~35kDa without the use 
of non-uniform labelling or other techniques (216). Above this size-limit excessive line-broadening, 
caused by the slow tumbling rate of the molecules, causes the peaks to disappear. This could be 
seen in the HSQC of aSyn fibrils, whereby the only remaining residue peaks visible were generally 
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within the highly dynamic CTD which tumbles/relaxes independently of the rest of the fibril (Figure 
7-11A). However, over time in the presence of WT CypD many of these peaks reappeared and 
became more intense (Figure 7-11B-D). This suggests that the fibrils were being disaggregated by 
CypD and the monomer population of aSyn progressively restored. This would fit with the TEM data 
shown in Figure 7-8. The catalytic activity of CypD is passive in that the hydrolysis of neither ATP 
nor GTP is required to drive the process. This stands in contrast to the activity of some other 
chaperones (e.g. the Hsp70 disaggregase) that have been reported to disaggregate pre-existing 
aSyn fibrils, but in a process that is dependent on ATP hydrolysis (105). 
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Figure 7-11 - HSQCs showing the disaggregation of aSyn fibrils by CypD. 1H-15N HSQC spectra were taken of 100µM 15N-
labelled WT aSyn fibrils in the presence of 300µM WT CypD at 298K. All samples were prepared in 20mM phosphate pH 
6.5, 20mM NaCl. Spectra were collected at 0 hours (A), 8 hours (B), 12 hours (C), and 36 hours (D). As aSyn aggregates 
peaks are lost due to significant line-broadening. However, in the presence of WT CypD peaks are recovered over time. 
This restoration of peaks suggests that CypD is disaggregating the aSyn fibrils over time. 
  
7.3.5 Cell viability experiments of SH-SY5Y cells exposed to α-
synuclein fibrils pre-treated with cyclophilin-D 
 
Given that the incubation of aSyn fibrils with CypD results in their apparent shortening and 
disaggregation it became a question as to whether this resulted in a change of toxicity. Whilst fibrils 
are no longer considered to be the main toxic species any rise in the level of oligomers as a 
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consequence of fibril shortening/disaggregation could result in an increase in toxicity. Here, SH-
SY5Y neuroblastoma cells were exposed to WT aSyn fibrils alone, WT CypD alone, and WT aSyn 
fibrils that had been pre-incubated with WT CypD. All the samples had been incubated at 37°C for 
3 days prior to exposure to the cells, which were challenged for 24 hours. PBS pH 7.4 and 1% Triton 
X-100 were used as live and dead controls, respectively. As expected, neither the WT aSyn fibrils 
alone nor WT CypD alone were toxic to the cells, as indicated by the intensity at 450nm (Figure 
7-12). Additionally, the fibrils that had been pre-treated with CypD also exhibited no cell toxicity. 
This suggests that the action of CypD does not result in an increased population of oligomers, and 
thus a similar mechanism of action could be a viable strategy in targeting amyloid fibrils. 
 
Figure 7-12 - Cell viability assay of SH-SY5Y cells exposed to WT aSyn fibrils, WT CypD, and WT aSyn fibrils pre-treated 
with WT CypD using CCK-8. The cells were exposed to the following conditions for 24hours: PBS pH 7.4 alone (live control), 
5µM WT aSyn fibrils, 15µM WT CypD, 5µM WT aSyn fibrils pre-incubated with a three-fold molar excess of WT CypD, and 
1% Triton X-100 (dead control). The data shows that the pre-treatment of aSyn fibrils with CypD does not result in an 
increase in toxicity. Six wells were prepared per condition. N=1. 
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7.4 Discussion 
 
In this chapter is described a hitherto unknown and uncharacterized interaction between 
aSyn and the mitochondrial protein CypD. This work was initially conducted in response to reports 
that aSyn oligomers travelled to the mitochondria in neurodegenerative disease and initiated mPTP 
opening; a process regulated by CypD (112). The question of what triggers neuronal cell death is an 
open one and, given the known links between neurodegeneration, oxidative stress, and 
mitochondrial dysfunction, it seemed plausible that aSyn aggregates initiated Ca2+-mediated cell 
death via an interaction with CypD and subsequent mPTP opening (193). Lending a measure of 
credence to this hypothesis is the knowledge that many of the genes identified in familial cases of 
PD (e.g. parkin, PINK1) are also involved in mitochondrial quality control (69). The initial results of 
the experiments described in this chapter were extremely encouraging. HSQC titrations showed 
peak shifts and line-broadening in both aSyn and CypD when they were titrated against each other, 
which is strongly indicative of binding (Figure 7-3 & Figure 7-4). These shifts were in peaks 
associated with amino acids in the C-terminal portion of aSyn and those residues that make up the 
catalytic site of CypD. This data was backed-up by evidence from ITC experiments involving CypD 
and peptides of aSyn (Figure 7-7). It was seen that CypD and the aSynC peptide exhibited binding 
with a Kd = 150µM, whilst no binding was observed with the aSynM peptide. It has been shown 
previously that the CTD portion of aSyn transiently ‘wraps around’ to interact with the NTD and in 
this way protect the NAC domain from aggregation (38). In light of the NMR and ITC data obtained 
showing that CypD binds to the CTD of aSyn it was thought that this interaction would potentiate 
and encourage aSyn aggregation. In this vein ThT assays were conducted to follow aSyn aggregation 
over a period of 7 days, alone and in the presence of CypD. In stark contrast to initial expectations 
it was clear that CypD prevented the aggregation of aSyn in a concentration-dependent manner 
(Figure 7-8 & Figure 7-9). Not only was no ThT fluorescence apparent, but neither were any 
fibrils/aggregates seen by TEM. Interestingly, the addition of the potent CypD inhibitor, CsA, 
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abolished this effect as did the R82K mutation (Figure 7-8A). The catalytically-compromised mutant, 
R55K, exhibited the same effect as the WT CypD protein. This suggests that the prevention of aSyn 
aggregation is not as a result of the catalytic activity of CypD, but rather due to binding alone. It was 
around this time that Baker et al published a paper detailing how Cyp40 could unravel pre-existing 
amyloid fibrils of tau and aSyn (106). In light of this the effect of CypD on pre-formed aSyn fibrils 
was tested. ASyn alone forms fibrils with a quite broad distribution of lengths, with the mean 
~450nm. However, when incubated in the presence of CypD a vast number of shorter amyloid fibrils 
were seen, with the mean length being ~50nm (Figure 7-8 & Figure 7-10). This was not, however, 
seen in the presence of CsA or with the catalytically compromised mutants R55K and R82K. This 
indicates that, unlike the preventative activity, the ability of CypD to disaggregate pre-existing fibrils 
does rely on its catalytic peptidyl-prolyl isomerization activity. These TEM data were supported by 
NMR data in which 15N-labelled aSyn had been incubated with agitation so as to form fibrils. The 
15N-labelled fibrils were then incubated in the NMR tube in the presence of WT CypD and HSQC 
spectra were recorded every 12 hours for three days. HSQC spectra of aggregated aSyn tend to 
display only the peaks corresponding to the CTD of the protein, as the aggregates exceed the size-
limit of NMR and thus their NMR spectra are subjected to prohibitive line-broadening. The highly 
dynamic nature of the C-terminus of aSyn means that these peaks are often visible, however. Over 
the course of time the other peaks were restored and this is supportive of aSyn fibrils being broken 
up by CypD and an increase in the population of monomeric aSyn (Figure 7-11). It is also noteworthy 
that the NMR spectra of the aSynC peptide in the presence of CypD revealed numerous minor 
conformation peaks that were not present in the spectra of aSynC alone. These were likely the 
result of cis-trans proline isomerization catalysed by CypD, further supporting the TEM data.  
 Given the recent reports that oligomers, rather than fibrils, are the aSyn species most 
associated with toxicity it was also important to assess whether this disaggregation process 
catalysed by CypD resulted in a gain of toxicity (20). In my hands this was not the case, and SH-SY5Y 
cells challenged with aSyn fibrils treated with CypD did not exhibit a gain of toxicity compared to 
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the non-disaggregated fibrils (Figure 7-12). This makes the approach interesting from a therapeutic 
point-of-view and consequently the results of these experiments are being used as the basis of a 
patent application.  
 This approach is therapeutically interesting for a number of reasons. Firstly, it can act 
against pre-existing aggregates. This is extremely useful given that PD only becomes outwardly 
visible, and ergo diagnosable, in Braak stage 3 (61). Strategies that solely impede the aggregation 
process also by extension require supplementary research into biomarkers that may accurately 
predict PD onset. This means that this approach could potentially prevent the pathology getting 
worse, and hopefully go some way to reversing pre-existing problems. This statement should be 
tempered with the understanding that neuronal loss is irreversible and thus actual brain damage 
that has taken place during disease progression is likely to remain permanent. It may be possible to 
rescue neurons in the throes of Lewy pathology, though. Secondly, the ability of CypD to 
disaggregate aSyn fibrils is an ATP-independent process. This is quite remarkable given the stability 
of amyloid fibrils, and is in stark contrast to the ATP-driven disaggregation process observed by Gao 
et al using the Hsp70 disaggregase (105). It is my hypothesis that the disaggregation of aSyn by CypD 
instead works through CypD shifting the monomer-oligomer-fibril equilibrium back towards the 
monomeric state. This more passive approach could prove highly favourable given that bio-
energetic stress is a feature of neurodegenerative disease, and thus placing an additional energetic 
burden on diseased neurons could be counter-productive.  
 Despite these positives there are likely to be a number of other factors that need to be 
taken into consideration. If the preventative/disaggregase activity of CypD with respect to aSyn 
were to be harnessed therapeutically, in what form would this take? There is the possibility of 
administering CypD to patients, in which case there are questions as to how this would best reach 
the brain and enter the neurons. It would likely need to be packaged or modified in some way to 
allow its crossing of the blood-brain barrier and subsequent entry into neurons. If this were 
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successful how much CypD would be needed to mediate its disaggregase activity successfully? In 
the results reported in this chapter it was found that CypD reduced fibril length in a concentration-
dependent manner (Figure 7-10). This may mean that substantial quantities of CypD would be 
required to reach the brain. Surmounting these challenges may prove to be a herculean task. It 
should also be noted that CypD itself is a protein of key therapeutic interest and its role in the 
mitochondria and the permeability transition is incompletely understood. In light of this, any 
therapeutic administration of the protein or effort to modulate the activity of the protein should 
be approached with caution. 
 The reality is, as also necessitated by the patent application, that substantial in vivo work is 
required to take this project to the next level. This is to test the efficacy of the approach in a more 
physiological environment, to observe any unintended side-effects, and also to get a feeling for how 
any hurdles that may present themselves (e.g. delivery) may be circumvented. I believe that in the 
first instance it may be useful to assess the viability of the approach in cell models or in C.elegans 
before later moving onto more challenging systems (e.g. mice). This is an exciting chapter in the 
story of aSyn and it certainly warrants further investigation. 
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8 Concluding Statement and Future Directions 
 
Despite decades of intensive study the physiology and pathophysiology of aSyn remain 
poorly understood. This lack of understanding extends more broadly into the disease processes 
underlying neurodegeneration as a whole, and thus exists a total absence of non-symptomatic 
therapeutics. Research into tackling neurodegenerative diseases, especially AD, has been rocked by 
recent high-profile failures at late-stages of clinical trials and the resultant withdrawal of several 
pharmaceutical giants from the field as a whole. It is in this uncertain and myopic climate that the 
field of neurodegenerative research now rests. It is a time for the field to return back to basics, for 
researchers to learn to walk before they can run, and for previously established dogmatic truths to 
come under renewed scrutiny. This has recently been exemplified with respect to PD and the 
discovery, by Shahmoradian et al, that LBs are not as jam-packed with aSyn fibrils as previously 
thought, but also consist of vast quantities of organelles and lipid membranes (191). This finding 
alone in my view is paradigm-shifting. It forces a re-evaluation of the place of aSyn fibril formation 
at the centre of PD pathology and of the role that aSyn-lipid interactions play in the disease process. 
It also brings the role of mitochondrial dysfunction and oxidative stress more firmly back into the 
picture, as the mitochondria were found to ‘ring’ the LBs, and perhaps will encourage more effort 
into establishing the role of the other genes associated with familial PD (e.g. parkin, LRRK2) which 
are clearly of pathological relevance yet have been previously considered to be peripheral to the 
main story (60).  
 In light of all of this I feel that my PhD thesis represents a valuable contribution to the 
amyloid field. I have shown two approaches with future potential in being utilized as therapeutics. 
One of these is the KDGIVNGVKA peptide inhibitor of aSyn aggregation and the other is the use of 
CypD to both prevent aSyn aggregation and actively disaggregate pre-existing fibrils, for which a 
patent application is currently being compiled. Numerous challenges are likely to arise in the 
utilization of any peptide inhibitor of aSyn aggregation (stability, penetrance etc) and thus the 
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insight gained here – that it is the IVN motif that is necessary for aSyn binding – will be valuable in 
the development of any further peptide inhibitors without abrogating aSyn binding. The biophysics 
of the aSyn-CypD interactions have been well-characterized here, although greater insight into how 
precisely proline cis-trans isomerization mediates the observed effects would be welcome, as this 
could provide a link to using a similar strategy with other amyloids. Both of these approaches need 
further exploration in vivo, however. My efforts through NMR metabolomics and cell viability assays 
to assess their physiological effects provided encouraging results, suggesting that shortened fibrils 
and the disaggregation of fibrils do not increase cell toxicity, but are not alone sufficient to give 
insight as to how these approaches would fare in a more physiologically-relevant environment. This 
is the next step in carrying this work forward and is essential for the patent application process.  
The studies of aSyn-lipid interactions described in this thesis also have enhanced relevance 
in light of the recent advances in the literature. These lipid interactions are modulated by a variety 
of factors including charge and conformational state; nitration results in impaired lipid-interactions 
through seemingly a combination of electrostatic repulsion and tyrosine cross-linking to form non-
amyloidogenic oligomers/polymers. Slight changes in these variables, as exhibited by the different 
PD-linked aSyn mutants, result in differences in lipid affinity that may have profound downstream 
consequences. This is an aspect of aSyn pathology that remains a mystery and is of great interest; 
the question of why different point mutations in aSyn only one or two residues apart result in such 
great differences in the onset of PD. In this work I have attempted to answer this question by 
studying rates of aggregation, lipid affinity, fibril structure and morphology, and toxicity to cells. 
Differences were clearly evident across the different point mutants in both their nitrated/non-
nitrated forms and it seems likely that the answer is some combination of all of these features. 
However, the complete answer may only become evident with a greater understanding of the other 
processes at play in the development of PD. For example, recent work has shown the importance 
of prion-like seeding in spreading aSyn pathology. It is possible that different fibril structures will 
have different seeding capacities, and the formation of these different structures may be 
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dependent on a variety of factors including rate of aggregation, lipid-binding, and the local chemical 
environment. 
In conclusion, I am proud of the contribution I have made to the field as part of this PhD 
thesis and see it as a foundation on which future work can build. I am also optimistic for the future 
of the field. Despite large setbacks it seems that research and development is heading in the right 
direction, and hopefully this will lead to the emergence of new disease-modifying therapeutics.  
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10 Appendix 
 
10.1 Bucket table and identified metabolites  
 
Table 10-1 - List of buckets and the metabolites associated with them for NMR metabolomics of SH-SY5Y cell extracts. 
Left Right Number Label 
0.835 0.875 1 methyl 
0.875 0.883 2 isocaproate_1 
0.883 0.888 3 butyrate_2 
0.888 0.895 4 isocaproate_3 
0.895 0.903 5 butyrate_4 
0.903 0.913 6 Miscel_1 
0.913 0.933 7 butyrate_5 
0.933 0.949 8 Miscel_2 
0.949 0.97 9 Ile/alloIle_6 
0.97 0.986 10 alloIle_7 
0.992 0.986 11 Val_8 
0.992 0.998 12 Butanone_9 
0.998 1.004 13 Val_10 
1.004 1.025 14 Butanone/Ile_11 
1.025 1.043 15 Val_12 
1.043 1.049 16 2-oxybutyrate_13 
1.049 1.054 17 Val_14 
1.054 1.076 18 2-oxybutyrate_15 
1.076 1.106 19 Miscel_3 
1.106 1.113 20 misc_16 
1.113 1.132 21 Miscel_4 
1.132 1.158 22 misc_17 
1.158 1.173 23 Miscel_5 
1.173 1.189 24 ethanol_21 
1.189 1.19 25 3-aminoisobut_20 
1.19 1.196 26 misc-lipid_22 
1.196 1.203 27 ethanol_23 
1.203 1.222 28 misc-lipid_24 
1.222 1.228 29 fucose_25 
1.228 1.234 30 misc-lipid_26 
1.234 1.238 31 fucose_27 
1.238 1.241 32 Miscel_6 
1.241 1.245 33 misc-lipid_28 
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1.245 1.248 34 fucose_29 
1.248 1.257 35 misc-lipid/fuc_30 
1.257 1.276 36 Miscel_7 
1.276 1.283 37 3-hydroxyval_31 
1.283 1.306 38 caprate_32 
1.306 1.322 39 caprate_34 
1.322 1.327 40 lactate_35 
1.327 1.331 41 threonine_36 
1.331 1.34 42 lactate/thr_37 
1.34 1.395 43 Miscel_8 
1.395 1.415 44 3-phenprop_38 
1.415 1.448 45 Miscel_9 
1.448 1.47 46 isocaproate_39 
1.47 1.495 47 alanine_40 
1.495 1.518 48 isocaproate_41 
1.518 1.586 49 butyrate_42 
1.586 1.708 50 2-aminoadipat_43 
1.708 1.748 51 ethylmalonate_44 
1.748 1.761 52 misc_45 
1.761 1.786 53 Miscel_10 
1.786 1.804 54 4-hydroxybut_46 
1.804 1.909 55 2-aminoadipat_47 
1.909 1.931 56 acetate_48 
1.931 1.976 57 misc_49 
1.976 2.016 58 acetamide_50 
2.016 2.025 59 homoserine_51 
2.025 2.098 60 glutamate_52 
2.098 2.137 61 glu/gln_53 
2.137 2.142 62 homoser/gln_54 
2.142 2.171 63 o-acetylcholi_55 
2.171 2.183 64 GSSG/caprate_56 
2.183 2.196 65 cap/isoc_57 
2.194 2.202 66 iscocaproate_58 
2.202 2.212 67 butanone_59 
2.212 2.24 68 acetone_60 
2.24 2.247 69 4-hydroxybuty_61 
2.247 2.254 70 Miscel_11 
2.254 2.263 71 thymol_62 
2.263 2.278 72 Miscel_12 
2.278 2.31 73 3aminoadipate_63 
2.31 2.37 74 glu_64 
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2.37 2.374 75 Miscel_13 
2.374 2.382 76 misc_65 
2.382 2.399 77 pyruvate_66 
2.399 2.441 78 succinate_67 
2.441 2.468 79 gln_68 
2.468 2.474 80 misc_69 
2.474 2.48 81 gln_70 
2.48 2.497 82 misc_71 
2.497 2.52 83 5-aminolevuli_72 
2.52 2.53 84 citrate_73 
2.53 2.547 85 misc_74 
2.547 2.554 86 citrate_75 
2.554 2.584 87 GSSG_76 
2.584 2.615 88 3-aminoisobut_77 
2.615 2.643 89 misc_78 
2.643 2.655 90 citrate_79 
2.655 2.668 91 misc_80 
2.668 2.7 92 citrate_81 
2.7 2.717 93 misc_84 
2.717 2.724 94 misc_85 
2.724 2.73 95 Miscel_14 
2.73 2.738 96 dimethylamine_86 
2.738 2.756 97 Miscel_15 
2.756 2.768 98 sarcosine_87 
2.768 2.816 99 misc_88 
2.816 2.826 100 methylguanidin_89 
2.826 2.853 101 misc_90 
2.853 2.894 102 misc_91 
2.894 2.934 103 misc_92 
2.934 2.942 104 n-methylhydant_93 
2.942 2.947 105 misc_94 
2.947 2.992 106 GSSG_95 
2.992 3.006 107 ethylmalonate_96 
3.006 3.024 108 histamine_97 
3.024 3.037 109 creatine-phos_98 
3.037 3.044 110 creatine_99 
3.044 3.048 111 creatinine_100 
3.048 3.121 112 3-aminoisobut_101 
3.121 3.165 113 citrulline_102 
3.165 3.204 114 misc_103 
3.204 3.216 115 choline_104 
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3.216 3.229 116 o-p-cho/carn_105 
3.229 3.24 117 misc_107 
3.24 3.25 118 pi-Me-His_108 
3.25 3.253 119 taurine_109 
3.253 3.259 120 pi-Me-His/bet_110 
3.259 3.266 121 taurine_111 
3.266 3.273 122 Miscel_16 
3.273 3.277 123 TMNO_112 
3.277 3.281 124 taurine_113 
3.281 3.285 125 myoinisitol_114 
3.285 3.292 126 pi-Me-His_115 
3.292 3.302 127 _myoinisitol_116 
3.302 3.319 128 misc_117 
3.319 3.325 129 pi-Me-His/mis_118 
3.325 3.349 130 misc_119 
3.349 3.356 131 methanol_121 
3.356 3.362 132 misc_122 
3.362 3.387 133 carnitine_123 
3.387 3.41 134 Miscel_17 
3.41 3.416 135 taurine_124 
3.416 3.422 136 34dihydroxyben_125 
3.422 3.428 137 taurine_126 
3.428 3.431 138 carnitine_127 
3.431 3.439 139 taurine_128 
3.439 3.479 140 fucose_129 
3.479 3.482 141 3hydroxypheny_130 
3.481 3.524 142 arabinose_131 
3.524 3.551 143 myoinisitol_132 
3.551 3.56 144 lactose_133 
3.56 3.565 145 glycine_134 
3.565 3.576 146 lactose_135 
3.576 3.581 147 theophylline_136 
3.581 3.609 148 phosphocholine_137 
3.609 3.616 149 myoinisitol_138 
3.616 3.625 150 sarcosine_139 
3.625 3.631 151 myoinisitol_140 
3.631 3.638 152 gly-3-p-chol_141 
3.638 3.643 153 fucose_142 
3.643 3.647 154 myoinisitol_143 
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3.647 3.65 155 arabinose_144 
3.801 3.812 156 Lac_169/arab/fuc/lac 
3.812 3.845 157 arab/fuc/lac_168 
3.845 3.86 158 fuc/serine_170 
3.86 3.877 159 lac/G3PC_171 
3.877 3.893 160 lac/G3PC/arab_172 
3.893 3.904 161 G3PC_173 
3.904 3.907 162 betaine_174 
3.907 3.91 163 G3PC_175 
3.91 3.916 164 arabinose_176 
3.916 3.923 165 G3PC/arab_177 
3.923 3.929 166 G3PC_178 
3.929 3.938 167 creatine_179 
3.938 3.945 168 lac/G3PC_180 
3.945 3.96 169 lac/G3PC/arab_181 
3.96 3.97 170 pi-meth-his_182 
3.97 3.978 171 PMHis/galol_183 
3.978 3.99 172 gal/Ser/hip_184 
3.99 3.997 173 Ser/hip_185 
3.997 4.056 174 arabinose_186 
4.056 4.076 175 myoinisitol_187 
4.076 4.133 176 lactate_188 
4.133 4.146 177 misc_189 
4.146 4.19 178 ophosphochol_190 
4.19 4.274 179 Miscel_19 
4.274 4.303 180 threonine_191 
4.303 4.338 181 gly-3-p-chol_192 
4.338 4.343 182 tartrate_193 
4.343 4.352 183 gly-3-p-chol_194 
5.222 5.25 184 Lactose_195 
5.25 5.396 185 Miscel_21 
5.396 5.432 186 misc-sugar_196 
5.432 5.934 187 Miscel_22 
5.934 5.955 188 GTP_197 
5.955 5.965 189 Miscel_23 
5.965 5.979 190 misc_198 
5.979 5.99 191 misc_199 
5.99 5.999 192 misc_200 
5.999 6.01 193 misc_201 
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6.01 6.033 194 Miscel_24 
6.033 6.043 195 misc_202 
6.043 6.053 196 misc_203 
6.053 6.084 197 Miscel_25 
6.084 6.107 198 adenosine_204 
6.107 6.142 199 Miscel_26 
6.142 6.162 200 ADP/ATP_205 
6.162 6.519 201 Miscel_27 
6.519 6.526 202 singlet_206 
6.526 7.301 203 Miscel_28 
7.301 7.317 204 pi-meth-his_207 
7.317 7.328 205 misc_208 
7.328 7.479 206 Miscel_29 
7.479 7.493 207 benzoate_209 
7.493 7.535 208 Miscel_30 
7.535 7.597 209 benzoate_210 
7.597 7.769 210 Miscel_31 
7.769 7.782 211 pi-meth-his_211 
7.782 7.797 212 misc_212 
7.797 7.846 213 Miscel_32 
7.846 7.858 214 hippurate_213 
7.858 7.887 215 benzoate_214 
7.887 7.947 216 Miscel_33 
7.947 7.963 217 misc_215 
7.963 7.972 218 misc_216 
7.972 7.988 219 misc_217 
7.988 8.001 220 theophylline_218 
8 8.01 221 methylxanthine_219 
8.01 8.02 222 misc_220 
8.138 8.15 223 misc_221 
8.15 8.161 224 GTP_222 
8.161 8.176 225 Miscel_34 
8.176 8.186 226 oxypurinol_223 
8.186 8.192 227 Miscel_35 
8.192 8.204 228 hypoxanthine_224 
8.204 8.212 229 Miscel_36 
8.212 8.222 230 anserine_225 
8.222 8.269 231 Miscel_37 
8.269 8.282 232 ADP/ATP/aden_226 
8.282 8.346 233 Miscel_38 
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8.346 8.357 234 adenosine_227 
8.357 8.428 235 Miscel_39 
8.428 8.438 236 misc_228 
8.438 8.454 237 Miscel_40 
8.454 8.465 238 formate_229 
8.465 8.539 239 Miscel_41 
8.539 8.546 240 ATP_230 
8.546 8.556 241 ADP_231 
8.556 8.582 242 Miscel_42 
8.582 8.592 243 misc_232 
8.592 8.612 244 Miscel_43 
8.612 8.62 245 misc_233 
 
10.2 Principal component analysis of metabolomics data 
 
10.2.1 Peptide toxicity 
 
 
Figure 10-1 - PCA of the effect of KDGIVNGVKA on SH-SY5Y cells. A PCA scores plot (A) shows that the samples exposed 
to fresh (green) and aged (red) KDGIVNGVKA are more variable than the control samples (red). The biplot (B) shows that 
this variance is largely the result of fluctuations in the elevels of caproate, creatine, lactose and glycerol-3-phosphocholine. 
10.2.2 Fibril toxicity 
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Figure 10-2 - PCA of the differential effects of aSyn monomers and fibrils on SH-SY5Y cells. The Scores plot (A) showing 
the variance across different sample conditions: PBS control (red), monomeric aSyn alone (blue), and aSyn fibrils alone 
(green). The biplot (B) reveals that two of the biggest sources of variance across PC1 are lactose and arabinose, whilst in 
PC2 the main sources of variance are caproate, creatine and an unknown metabolite. 
 
10.2.3 Effect of KDGIVNGVKA on fibril toxicity 
 
 
Figure 10-3 - PCA of the differential effects of aSyn fibrils on SH-SY5Y cells in the presence or absence of KDGIVNGVKA. 
A Scores plot (A) showing the variance across different sample conditions: PBS alone (red), aSyn fibrils alone (green), fibrils 
plus independently aged KDGIVNGVKA (blue), and fibrils formed in the presence of KDGIVNGVKA (cyan). A biplot (B) reveals 
that major contributors to variance in PC1 are lactose and tartrate, and creatine, caprate and taurine in PC2. 
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10.3 Circular dichroism spectra and secondary structure estimations 
of α-synuclein in the presence of detergent micelles and small 
unilamellar vesicles 
 
 
Figure 10-4 - CD spectra and estimations of secondary structural content of A30P aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM A30P aSyn alone, of 50µM A30P aSyn with 10mM SDS, of 
10µM A30P aSyn alone, and of 10µM A30P aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). As expected A30P aSyn alone exhibits little helical 
content, but this rises in the presence of SUVs and more substantially in the presence of SDS micelles. The NRMSD values 
were 0.02091, 0.00785, 0.04081, and 0.08318 for the samples of 50µM A30P aSyn alone and with SDS, and of 10µM A30P 
aSyn alone and with SUVs respectively. 
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Figure 10-5 - CD spectra and estimations of secondary structural content of E46K aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM E46K aSyn alone, of 50µM E46K aSyn with 10mM SDS, of 
10µM E46K aSyn alone, and of 10µM E46K aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). E46K aSyn alone exhibits little helical content, but this 
rises extremely significantly in the presence of SDS micelles and to a much lesser extent in the samples containing SUVs. 
The NRMSD values are 0.01956, 0.00627, 0.05291, and 0.05385 for 50µM E46K aSyn alone and with SDS, and for 10µM 
E46K aSyn alone and with SUVs respectively. 
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Figure 10-6 - CD spectra and estimations of secondary structural content of H50Q aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM H50Q aSyn alone, of 50µM H50Q aSyn with 10mM SDS, of 
10µM H50Q aSyn alone, and of 10µM H50Q aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). H50Q aSyn alone exhibits little helical content, but this 
rises substantially in the presence of SDS micelles or SUVs (44% and 39% respectively). This comes at the expense of the 
proportion in random coil (“other”) and antiparallel conformations. The NRMSD values are 0.02143, 0.00673, 0.02621, 
and 0.00963 for 50µM H50Q aSyn alone and with SDS, and for 10µM H50Q aSyn alone and with SUVs respectively. 
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Figure 10-7 - CD spectra and estimations of secondary structural content of G51D aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM G51D aSyn alone, of 50µM G51D aSyn with 10mM SDS, of 
10µM G51D aSyn alone, and of 10µM G51D aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). G51D aSyn alone exhibits little helical content, but this 
rises in the presence of SDS micelles. There is a small increase in helicity in the presence of the SUVs, but instead a greater 
proportion of the protein exists in β-strand-like conformations. The NRMSD values are 0.02777, 0.01461, 0.03158, and 
0.0721 for 50µM G51D aSyn alone and with SDS, and for 10µM G51D aSyn alone and with SUVs respectively. 
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Figure 10-8 - CD spectra and estimations of secondary structural content of A53T aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM A53T aSyn alone, of 50µM A53T aSyn with 10mM SDS, of 
10µM A53T aSyn alone, and of 10µM A53T aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). A53T aSyn alone exhibits little helical content, but this 
increases enormously in the presence of SDS micelles. Intriguingly, the helicity in the presence of SUVs remains below 5%, 
whilst the level of parallel β-strand has increased to 15%. This may suggest the beginnings of protein aggregation. The 
NRMSD values are 0.01841, 0.00427, 0.05509, and 0.05994 for 50µM A53T aSyn alone and with SDS, and for 10µM A53T 
aSyn alone and with SUVs respectively. 
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Figure 10-9 - CD spectra and estimations of secondary structural content of A53E aSyn alone, in the presence of SDS 
micelles, and in the presence of SUVs. CD spectra (A) of 50µM A53E aSyn alone, of 50µM A53E aSyn with 10mM SDS, of 
10µM A53E aSyn alone, and of 10µM A53E aSyn with 1.4mg/mL SUVs (DOPE:DOPS:DOPC 5:3:2). Secondary structural 
content estimations (B) were carried out using BeStSel (181,182). As expected A53E aSyn alone exhibits little helical 
content, but this is substantially increased in the presence of SDS micelles or SUVs. Interestingly, in the presence of SUVs 
the level of helicity is lower than with SDS micelles, but some parallel β-strand characteristics have appeared and there 
remains 17% antiparallel signal. This may suggest protein aggregation. The NRMSD values are 0.0177, 0.00689, 0.04083, 
and 0.05726 for 50µM A53E aSyn alone and with SDS, and for 10µM A53E aSyn alone and with SUVs respectively. 
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10.4 Effect of tyrosine nitration on the lipid-association of α-
synuclein 
 
 
Figure 10-10 - CD spectra and estimations of secondary structural content for nitrated A30P aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM A30P aSyn alone, 50µM A30P 
aSyn with SDS micelles, 10µM A30P aSyn alone, and 10µM A30P aSyn with lipid SUVs composed of DOPE:DOPS:DOPC 
(5:3:2) are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel server are shown (B) 
(181,182). The NRMSD values are as follows: 50µM A30P aSyn alone (0.02091) and with SDS (0.00785), 10µM A30P alone 
(0.04081) and with SUVs (0.08318), 50µM nitrated A30P alone (0.03743) and with SDS (0.08103), and 10µM nitrated A30P 
alone (0.02923) and with SUVs (0.0538). 
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Figure 10-11- CD spectra and estimations of secondary structural content for nitrated E46K aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM E46K aSyn alone, 50µM E46K 
aSyn with SDS micelles, 10µM E46K alone, and 10µM E46K aSyn with lipid SUVs composed of DOPE:DOPS:DOPC (5:3:2) 
are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel server are shown (B) 
(181,182). The NRMSD values are as follows: 50µM E46K aSyn alone (0.01956), 50µM E46K aSyn with SDS (0.00627), 10µM 
E46K aSyn alone (0.05291), 10µM E46K with SUVs (0.05385), 50µM nitrated E46K aSyn alone (0.04146), 50µM nitrated 
E46K with SDS (0.11025), 10µM nitrated E46K aSyn alone (0.06251), and 10µM nitrated E46K aSyn with SUVs (0.0569). 
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Figure 10-12 - CD spectra and estimations of secondary structural content for nitrated H50Q aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM H50Q aSyn alone, 50µM 
H50Q aSyn with SDS micelles, 10µM H50Q aSyn alone, and 10µM H50Q aSyn with lipid SUVs composed of 
DOPE:DOPS:DOPC (5:3:2) are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel 
server are shown (B) (181,182). The NRMSD values are as follows: 50µM H50Q aSyn alone (0.02143), 50µM H50Q aSyn 
with SDS (0.00673), 10µM H50Q aSyn alone (0.02621), 10µM H50Q aSyn with SUVs (0.00963), 50µM nitrated H50Q aSyn 
alone (0.03003), 50µM nitrated H50Q aSyn with SDS (0.08117), 10µM nitrated H50Q aSyn alone (0.0232), and 10µM 
nitrated H50Q aSyn with SUVs (0.03809). 
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Figure 10-13 - CD spectra and estimations of secondary structural content for nitrated G51D aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM G51D aSyn alone, 50µM 
G51D aSyn with SDS micelles, 10µM G51D aSyn alone, and 10µM G51D aSyn with lipid SUVs composed of 
DOPE:DOPS:DOPC (5:3:2) are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel 
server are shown (B) (181,182). The NRMSD values are as follows: 50µM G51D aSyn alone (0.02227), 50µM G51D aSyn 
with SDS (0.01461), 10µM G51D aSyn alone (0.03158), 10µM G51D aSyn with SUVs (0.0721), 50µM nitrated G51D aSyn 
alone (0.0418), 50µM nitrated G51D aSyn with SDS (0.09259), 10µM nitrated G51D aSyn alone (0.03353), and 10µM 
nitrated G51D aSyn with SUVs (0.05897). 
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Figure 10-14 - CD spectra and estimations of secondary structural content for nitrated A53T aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM A53T aSyn alone, 50µM A53T 
aSyn with SDS micelles, 10µM A53T aSyn alone, and 10µM A53T aSyn with lipid SUVs composed of DOPE:DOPS:DOPC 
(5:3:2) are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel server are shown (B) 
(181,182). The NRMSD values are as follows: 50µM A53T aSyn alone (0.01841), 50µM A53T with SDS (0.00427), 10µM 
A53T aSyn alone (0.05509), 10µM A53T aSyn with SUVs (0.05994), 50µM nitrated A53T aSyn alone (0.02388), 50µM 
nitrated A53T aSyn with SDS (0.06388), 10µM nitrated A53T aSyn alone (0.03874), and 10µM A53T aSyn with SUVs 
(0.06684). 
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Figure 10-15 - CD spectra and estimations of secondary structural content for nitrated A53E aSyn in comparison to non-
nitrated protein. CD spectra (A) for nitrated (solid line) and non-nitrated (dashed-line) 50µM A53E aSyn alone, 50µM A53E 
with SDS micelles, 10µM A53E aSyn alone, and 10µM A53E aSyn with lipid SUVs composed of DOPE:DOPS:DOPC (5:3:2) 
are shown. Secondary structure estimations from the CD spectra as calculated by the BeStSel server are shown (B) 
(181,182). The NRMSD values are as follows: 50µM A53E aSyn alone (0.0177), 50µM A53E aSyn with SDS (0.00689), 10µM 
A53E aSyn alone (0.04083), 10µM A53E aSyn with SUVs (0.05726), 50µM nitrated A53E aSyn alone (0.03034), 50µM 
nitrated A53E aSyn with SDS (0.03895), 10µM nitrated A53E aSyn alone (0.03734), and 10µM A53E aSyn with SUVs 
(0.0641). 
